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SUMMARY
The introductory chapters (Chapters 1, 2) reviewed
nutritional problems, methods of nutritional support and 
methods of assessing disease activity in Crohn's disease.
Variable prevalences of macro- and micro-nutrient
deficiencies occur in patients with Crohn's disease. 
Previous studies have concentrated on the role of
intravenous nutrition for the correction of nutritional 
deficiencies.
A spectrum of methods for determining disease activity 
in Crohn's disease exists : a multinational collection of 
clinical scores; combination of clinical and laboratory
scores; and pure laboratory assessments. The most 
appropriate routine methods of assessment are clinical 
score combined with an objective laboratory test, such as 
the CRP. More sophisticated laboratory methods can be used 
in special circumstances.
The second section of the thesis summarised the aims and 
layout of the thesis.
Section III was concerned with special problems relating 
to disease activity, both in the assessment and in the 
alteration of disease activity brought about by
28
malnutrition and blood tranfusion. While previous studies 
have produced useful clinical indices, the ideal index 
remains in dispute. Most of the present clinical scores 
cannot be used for patients with stomas. Ten clinical 
scores and several laboratory tests were compared in 
patients with stable chronic disease and also in patients 
with active disease (Chapter 3). Separate groups of 
patients with stomas were also assessed by using a 
modified clinical index.
Interestingly there appeared to be different patterns 
of correlation between the clinical scores and the 
laboratory indices in both clinical situations. In acute 
patients most of the laboratory indices had poor 
correlation with the clinical indices with the exception 
of the CRP. In the stable group of patients, most of the 
laboratory indices correlated with the clinical indices. 
The CRP appeared to be the most reliable laboratory 
parameter for all clinical situations. The modified CDI, 
which was used for patient with stomas, showed 
significant correlations with other clinical indices and 
was used in subsequent studies.
Acute phase proteins, in particular CRP, can be useful 
in assessing disease activity in Crohn's patients, as was 
found in Chapter 3 of this thesis. However the effect of
29
malnutrition on the acute phase response has been ignored, 
and if present, could dramatically alter the assessments 
of disease activity. From the results of a study described 
in Chapter 4, which compared the acute phase response in 
well nourished and malnourished patients, I concluded that 
malnourished patients were able to mount similar acute 
phase responses compared with well nourished patients. 
Acute phase proteins, therefore, can be used in the 
assessment of disease activity even when the nutritional 
state of the patient is unknown.
^^Indium leucocyte scanning is a new and exciting 
development in the assessment of activity in Crohn's 
disease. Previous studies have used sophisticated 
techniques which are outwith the usual facilities of 
nuclear medicine department. Indium-oxine mixed leucoctye 
scanning was compared with other indices of disease 
activity (Chapter 5) . Indium scanning correctly located 
the extent of disease in only 58% of patients and there 
was poor correlation between the scan activity and the 
other indices of disease activity. These results were 
disappointing as I had hoped that routine Indium scanning 
would offer a more accurate method of assessing disease 
extent and activity.
Although blood transfusion is one of the oldest methods
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of artificial nutritional support, and is widely used in 
Crohn's disease, its immunomodulating effect on Crohn's 
disease has not been studied. This potential effect on 
disease activity and also relapse rates could have
important consequences in therapeutic trials in Crohn's
disease. The results from a large group of Crohn's
patients (treated both medically and surgically) did not 
show an advantage in the relapse rates following blood 
transfusion (Chapter 6) . Medical and surgical patients 
were analysed separately and appeared to have different 
responses to blood transfusion : the medical patients who 
did not receive a blood transfusion had better relapse 
rates; the surgical patients did better if they had 
received blood transfusions.
Section IV was an animal study (Chapter 7) comparing the 
new enteral liquid diets which were to be used in the 
enteral nutrition studies. Both of the diets, Elemental 
028 and Enteral 400 (Scientific Hospital Supplies,
Liverpool, UK), had similar nutritional efficacy and low 
faecal residue compared with the established enteral 
liquid diet, Vivonex HN, which has been used in other diet 
studies in Crohn's disease. Elemental 028 produced an 
increase in hepatic lipid, similar to Vivonex HN.
Section V, the clinical application of enteral nutrition 
in Crohn's disease, was composed of five studies (Chapters 
8 - 12). Chapter 8 assessed the role of elemental and
polymeric diets, using the new Elemental 028 and Enteral 
400 diets, as primary therapy for active Crohn's disease. 
The results showed that the polymeric diet, Enteral 400, 
was equally effective in inducing remission in active 
Crohn's disease, compared with Elemental 028. Polymeric 
diets could be used more frequently which would reduce the 
number of patients who are unable to tolerate elemental 
diets due to poor palatability and also reduce the costs.
Most of Section V involved the assessment of Home 
Enteral Nutrition (HEN) as a method of providing long-term 
nutritional support for malnourished patients with Crohn's 
disease, determining any practical problems and 
micronutrient deficiencies, and evaluating the usefulness 
of HEN in correcting growth retardation in adolescents 
with Crohn's disease. The studies showed that HEN is an 
effective and easy method of providing long-term enteral 
nutrition support and can correct growth retardation. 
Vitamin deficiencies are easily corrected by HEN due to 
the high vitamin content of the diets. Patients on HEN 
should be observed for potential magnesium deficiency, 
which occurred in 44% of patients. Overall the patients 
clinical disease and well-being improved during their
32
periods of HEN, and in particular their hospital admission 
rates fell.
SECTION I
INTRODUCTION
34
CHAPTER 1
REVIEW OF NUTRITIONAL PROBLEMS AND METHODS OF 
NUTRITIONAL SUPPORT IN CROHN'S DISEASE
INTRODUCTION
The awareness of nutritional problems in Crohn's disease 
has evolved slowly from brief comments in early case 
reports. In 1806 Drs. Charles Coombe and William Saunders 
recorded their clinical findings from their "singular case 
of stricture and thickening of the ileum" in which they 
observed that the patient was "more emaciated than any 
person witnessed" (Myren,1986). Dalziel (1913) in his 
series of nine cases recognised that malnutrition was a 
significant problem, as commented upon by Crohn et al. 
(1932) twenty years later.
More recent reports have documented the extent of 
malnutrition in patients with Crohn's disease. Significant 
weight loss to less than 90% of the ideal body weight 
(IBW) was found in 20-40% of out-patients with relatively 
mild disease (Harries et al., 1982; Lanfranchi et al.,
1982). The Cleveland Clinic study found up to 18% of 
patients had lost 20% of their body weight from the onset 
of their illness (Farmer et al., 1975). Many micronutrient 
deficiencies have been reported in patients with Crohn's 
disease (Harries & Heatley, 1983B).
The aetiology of malnutrition in Crohn's disease is
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multifactorial : reduced oral intake; inappropriate diets; 
malabsorption; active inflammation with enteric losses; 
and the effects of drugs, including cholestyramine and 
sulphasalazine. Undoubtedly the most important mechanism 
is reduced oral intake.
Malnutrition from any cause can lead to poor wound 
healing, increased susceptability to infection due to 
alteration of the immune system, and numerous vitamin and 
trace metal deficiencies which may result in alteration 
of neuromuscular activity (Dowd & Heatley, 1984) . However, 
only a few studies have examined prospectively the benefit 
of supplemented oral nutrition in malnourished patients 
with Crohn's disease (Harries et al., 1983A; Brignola et 
al., 1983; Imes et al., 1986). In the study by Harries et 
al. (1983A), the disease activity and immune function of 
28 patients were measured during a period of supplemented 
diet by using the liquid diet, Ensure plus (Abbott 
Laboratories, Maidenhead, UK), and compared to a control 
period during which they took only ordinary diet. 
Nutritional parameters, immune function tests and disease 
activity all improved during the period of supplemented 
diet. Brignola et al. (1983) used Precision (Wander, USA) 
and found less impressive gain in weight and reduced 
improvement in disease activity. Unfortunately very few 
patients in the study by Imes et al. (1986) were able to
tolerate the liquid diet Ensure, (Abbott Laboratories, 
Maidenhead, UK) to provide a satisfactory conclusion.In 
another study by Imes et al. (1988), individualised diet 
counselling managed to increase patients intakes to 
achieve the recommended intakes for all nutrients, and 
also produced an improvement in disease activity and 
reduction in drug therapy.
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INDICATIONS AND METHODS FOR NUTRITIONAL SUPPORT 
Correction of Malnutrition
Methods of nutritional support for patients with Crohn's 
disease are determined by the indications for feeding 
:correction of malnutrition; treatment of local 
complications; specific oral diets including lactose free 
and low residue; and primary therapy. Correction of 
malnutrition is the most frequent indication and can be 
achieved by supplements to the patients diet, enteral 
nutrition in hospital or at home, or by intravenous 
feeding. Oral supplements can be in the form of 
nutritionally complete liquid diets taken as sip feeds, or 
in the form of high calorie glucose mixtures added to the 
ordinary diet.
Specific Diets
In certain situations specific diets such as lactose- 
free or low residue can be of considerable benefit. 
However, it is important to remember that such diets are 
restrictive and may be nutritionally incomplete thereby 
further adding to the problem of malnutrition. The 
diagnosis of lactose intolerance should always be 
confirmed before embarking on a lactose-free diet which 
may lead to a negative calcium balance due to reduced 
intake of dairy produce. Kirschner et al. (1981) found
38
that 30% of adolescents with Crohn's disease had lactose 
intolerance and in some ethnic groups the incidence may be 
as high as 60-95% (Welsh, 1978).
Several patients after small bowel resection for Crohn's 
disease have fat malabsorption leading to steatorrhoea, 
which may be helped by a low fat diet. The reduced calorie 
intake can be increased by providing more carbohydrate or 
by adding medium chain triglyceride (MCT) supplements. For 
many years low fibre diets have been advocated for 
patients with Crohn's disease in an attempt to prevent 
obstructive symptoms, but in a trial by Levenstein et al. 
(1985), no benefit was found in using a low fibre diet 
compared with control diets. Fibre-rich diets, initially 
thought to be of some value, have been shown over several 
years to be no better than ordinary diets (Ritchie et al., 
1987).
Exclusion diets are very restrictive and require 
superhuman effort by patients, dietitians and doctors. 
Several groups have enthusiastically supported exclusion 
diets, advocating that the main benefit is the long-term 
remission rate (Alun Jones et al., 1985).
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Local Complications
Crohn's disease is frequently complicated by perianal 
disease and abscesses, high output fistulas and bile acid 
induced diarrhoea. Dietary manipulation can play a part in 
the management of these problems. Bowel rest by using 
either intravenous feeding or more frequently by enteral 
nutrition, especially elemental diets, can provoke marked 
symptomatic improvement (Voitk et al., 1973; Nelson et 
al., 1977; Russell & Hall, 1979).
Primary Therapy
Patients with Crohn's disease would benefit greatly if 
nutritional support, in addition to correcting 
malnutrition, also produced improvement in disease 
activity without additional drug therapy. This is the 
concept of "primary therapy" in Crohn's disease. This 
effect had been recognised in early studies looking at the 
role of nutritional support and had been attributed to 
"bowel rest" (Voitk et al.,1973; Fisher,1973; Rocchio et 
al., 1974; Reilly et al., 1976; Nelson et al.,1977;
Russell & Hall,1979). By providing intravenous nutrition 
or enteral nutrition using elemental diets, it was 
considered that the bowel rest provided by the reduced 
intestinal and pancreatico-biliary secretions, gut hormone 
excretion and bowel motility, would have a beneficial 
effect on disease activity. However, other important
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factors may be relevant: intraluminal antigenic food
particles (Alun-Jones et al., 1985); alteration in bowel 
microflora (Leijonmarck et al., 1988; and improvement in 
immune function following correction of malnutrition 
(Harries et al.,1984).
The dramatic increase in the use of nutritional support 
over the past ten years raises important questions about 
the ideal method of support. Several studies, although 
hampered by uncontrolled or retrospective design, have 
shown encouraging results with bowel rest and intravenous 
feeding (Fischer et al.,1973; Reilly et al.,1976; Muller 
et al.,1983; Ostro et al.,1985). Ostro et al . (1985)
suggested that disease remission could be achieved in up 
to 7 7% of patients who had been previously refractory to 
medical therapy. Another study found that surgery was 
avoided in 70% of patients who had failed to respond to 
medical treatment (Reilly et al., 1976).
However, two well designed studies found no difference 
between bowel rest by intravenous feeding compared with 
oral diet in patients with acute Crohn's colitis treated 
with high dose steroids (Dickinson et al.,1980; McIntyre 
et al.,1986). In a controlled trial involving 36 patients 
there were no differences in disease remission between 
the group treated by intravenous feeding or elemental diet
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(Alun-Jones et al., 1987). Greenberg et al. (1988A) 
randomised 17 patients with Crohn's disease unresponsive 
to medical therapy to receive intravenous feeding and nil 
by mouth, 19 similar patients received polymeric diet by 
nasogastric feeding and 15 patients partial intravenous
feeding with oral food. There were no significant 
differences between the three groups for clinical 
remission rates (71%, 58%, 60% respectively) or for long­
term remission at one year (42%, 55%, 56%).
It is not necessary to provide intravenous nutrition for 
primary therapy for active Crohn's disease unless the
enteral route cannot be used. Similarly for patients whose 
disease is complicated by fistulas there does not appear 
to be a specific benefit in using intravenous feeding and
bowel rest. In a review of previous studies involving a
total of 156 patients, only 35% achieved in-hospital 
fistula closure and only 17% long-term closure (Greenberg 
et al.,1988B).
Early reports of the use of .elemental diets in 
correcting nutritional deficiences in Crohn's disease 
patients found coincidental improvement in disease 
activity (Stephens & Randall, 1969; Voitk et al., 1973; 
Goode et al.,1976; Axelsson et al.,1977). This was 
considered to be a similar effect to that of primary
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therapy with intravenous feeding. Elemental diets are 
thought to exert their beneficial effect on disease 
activity by their hypoallergenicity resulting from their 
nitrogen source of free amino acids. Antigenic protein 
would therefore be unavailable to pass through the damaged 
bowel wall (O'Morain et al.,1984). Elemental diets have 
also been shown to reduce the protein loss from inflamed 
small bowel (Logan et al.,1981) and improve abnormal small 
bowel permeability in Crohn's patients (Sanderson et 
al.,1987a ). Controlled trials have shown elemental diets 
to be as effective as prednisolone (O'Morain et al.,1984), 
prednisolone with non-absorbable antibiotics (Saverymuttu 
et al.,1985) and ACTH/prednisolone/sulphasalazine in 
children (Sanderson et al., 1987).
All the patients included in these previous studies were 
established on their diets in hospital and then followed 
up as out-patients. In the diet groups all other food was 
excluded except clear fluids and tea without milk. It is 
impossible to check if the patients were adhering rigidly 
to their diets at home especially as elemental diets are 
unpalatable. This problem led several investigators to 
enquire whether more palatable whole protein (polymeric) 
diets could also achieve similar clinical results. 
Although the polymeric diets are not considerd to be 
hypoallergenic, their effect on patients with active
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Crohn's disease may arise from alternative mechanisms. 
There is some evidence that primary therapy for active 
Crohn's disease is not unique to elemental diets. Ginsberg 
& Albert (1988) have reported their experience with the 
whole protein diet, Ensure plus (Ross Laboratories, USA), 
in steroid dependent Crohn's patients. Two of four 
patients with small bowel disease and one of three 
patients with colitis went into remission. One patient 
from this study who had severe small bowel disease and who 
had been steroid dependent for 12 years became 
asymptomatic after 10 weeks on the diet and steroids were 
withdrawn.
The mechanisms by which elemental and polymeric diets 
work may be different. The cost of the treatment would be 
substantially reduced by using polymeric diets rather than 
elemental diets and by improving the palatability of the 
diets the patients' compliance would be increased.
HOME NUTRITIONAL SUPPORT
The management of patients with severe intestinal 
failure and fistulas secondary to Crohn's disease was 
revolutionised by home intravenous feeding regimes 
introduced in the early 1970's (Jeejeebhoy et al.,1976).
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Although highly effective, home intravenous feeding places 
an enormous burden on patients' lifestyle, has potential 
complications and high treatment costs. Fortunately, most 
patients requiring long-term feeding can be successfully 
managed by home enteral nutrition, a much easier method of 
feeding with fewer complications, and less expensive 
(Goode et al.,1976; Main et al.,1980; McIntyre et 
al.,1983; Bastow et al.,1985). Home enteral nutrition, 
using elemental diets, will improve disease activity, 
reduce resection requirements (Blair et al.,1986), and 
reverse both growth retardation and malnutrition (Blair et 
al.,1986; Belli et al.,1988). However reports to date have 
involved small numbers, mainly children, and have used 
elemental diets in the majority of cases.
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CHAPTER 2
REVIEW OF ASSESSMENT OF CROHN'S DISEASE ACTIVITY 
INTRODUCTION
Crohn, Ginsberg and Oppenheim (1932) recognised 
different patterns of disease, based on a spectrum of 
disease severity : " in the milder cases there may be
little or no emaciation and no anaemia." During the past 
55 years the emphasis has shifted from descriptive 
assessment of disease severity to quantitative assessment. 
Nowadays the use of the term " disease activity " implies 
a measure of the degree of bowel inflammation in Crohn's 
disease and is not necessarily interchangeable with 
"disease severity".
Truelove & Witts (1955) attempted to define severity in 
ulcerative colitis by using several clinical and 
laboratory indices to grade the illness from mild, 
moderate to severe.Their classification was the foundation 
for a cascade of multinational indices for Crohn's disease 
which have appeared over the past 20 years (Table 2.1).
The main stimulus for the multiple numerical indices was 
the appearance of controlled trials in Crohn's disease, 
starting with the azathioprine trial in 1971 (Willoughby 
et al.,1971). Many investigators considered that the 
response of therapeutic trials in Crohn's disease could
TABLE 2. 1
CLINICAL
CDI (1980) 
Present (1980)
OMGE (1984)
Wright (1987) 
Sandler (1988)
CROHN'S DISEASE INDICES
CLINICAL AND LABORATORY LABORATORY
Willoughby (1971)
De Dombal (19 74)
Talstad (1976)
CDAI (1976)
Whittington (1977)
O'Donoghue (1978)
Lloyd-Still (1979)
Al (1980)
New CDAI (1981)
Oxford (1984)
Factor Score (1984)
MOD Al (1985)
Cape Town (1986)
Brignola (1986)
Reibnegger (1986)
CAGS (1988)
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only be assessed by a uniform scoring system, in 
particular when large trials included many different 
centres and investigators.
CLINICAL SCORES
Willoughby Index
Willoughby et al. (1971) designed a disease activity
score for their controlled trial of azathioprine in 
Crohn's disease (Appendix 2.1). Each clinical feature was 
graded 0 - 3 ,  stool frequency graded 0-2, and one point 
was scored for low haemoglobin, low albumin and a high 
ESR. The theoretical disease activity maximum score was 
38, although in the trial the highest was 20. The disease 
activity score can be criticised by relying too heavily on 
subjective indices and complications. It is, however, an 
easy index to score and involves routine laboratory tests. 
The score was used as the basis for the O'Donoghue index 
(1978).
deDombal Index
deDombal et al. (1974) adapted Truelove and Witts's 
classification (1955) (Appendix 2.2). Disease severity was 
graded mild to severe depending on three local features, 
including bowel frequency, abdominal pain and rectal
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bleeding, and four systemic features : pulse rate,
temperature, haemoglobin and weight loss. This index was 
semi-quantitative and gave only three levels of disease 
activity. It was found to be difficult to allocate many 
patients into one of the three grades. Patients with 
colonic disease tended to be graded in a more severe 
category than patients with small bowel disease.
Talstad Index
Talstad & Gjone (1976) attempted to create a disease 
activity index which could be used for both ulcerative 
colitis and Crohn's disease. Initially patients were 
allocated disease categories (mild to severe) based on 
Truelove & Witts' classification (1955). Patients were 
subsequently assessed by 6 clinical symptoms and 12 
laboratory, radiological or sigmoidoscopic results 
(Appendix 2.3). The disease activity was expressed as "% 
disease activity" (of the theoretical maximum score of 
38). The results of % disease activity correlated with the 
ESR results. An estimate of disease activity was made 
:mild disease (<30% disease activity); moderate (30-70%); 
and severe (>70%) . Although this index was suitable for 
both Crohn's disease and ulcerative colitis patients it 
has not been adopted for regular use as it contains too 
many parameters which appear to have little relevance to
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disease activity (Maratka, 1981) . It is also impractical 
for use in routine, repeated assessments. One of Talstad's 
patients, who had toxic dilatation, had a % disease score 
< 70%, which placed him in the moderate group (Talstad & 
Gjone., 1976) .
Crohn's Disease Activity Index (CDAI)
A more quantitative method of assessing disease activity 
was introduced in 1970 for use in the American National 
Cooperative Crohn's Disease Study (Best et al., 1976).A 
panel of gastroenterologists identified 18 parameters 
which could be measured at outpatient clinics. The results 
were collected for 187 outpatient visits of 112 patients 
with Crohn's disease along with the physicians' global 
assessment. The contribution of each parameter to the 
physicians' global assessment was identified using 
multiple regression analyses. An index was derived 
(Appendix 2.4) and values of < 150 were considered, to
indicate quiescent disease, 150-450 active disease and > 
450 extremely active disease.
Three years later Best et al. (1979) revalidated the 
index using data from 1058 patient visits and concluded 
that the rederived coefficients were similar to the 
original ones. The CDAI has been used widely for many drug 
trials in Crohn's disease either in the original form
49
(Malchow et al., 1984) or in a slightly altered version 
(Rosen et al., 1982). The CDAI has been criticised for its 
cumbersome, complex form (Mee et al., 1978; Best Sc
Becktel, 1981), the necessity for the week-long diary
history, the heavy weighting of subjective parameters
(Cooke Sc Prior, 1984), and the use of a score < 150 to 
define remission (Hodgson, 1982). Six percent of patients 
defined as "poor" had a CDAI < 150 (Best et al., 1976).
The significance of "subjective" and "objective"
parameters in forming a Crohn's disease activity score is 
a recurring theme with every index. The subjective sense 
of well-being contributes 23% of the final CDAI. The CDAI 
has only two truely objective parameters, the weight of 
the patient and the haematocrit (Cooke Sc Prior, 1 9 8 4 )  .
Whittington Index
This index was created for a retrospective study of the 
management of Crohn's disease in children and adolescents 
(Whittington et al., 1977). One observer performed a 
retrospective case note review and determined :a) 
subjective evaluation of patients symptoms; b) physical 
examination,;c) haematocrit (normal > 35%), ESR (normal < 
20 mm/h), and serum albumin (normal range > 3.5 g/dl).
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From the data of the retrospective review disease activity 
rating scales were defined as : I, asymptomatic with
normal laboratory tests ; II, asymptomatic with abnormal 
laboratory tests; III, mild symptoms which did not 
interfere with activities or new physical findings, 
laboratory tests usually abnormal; IV, moderate symptoms, 
occasionally interfering with usual activities; V, severe, 
requiring symptomatic or antidiarrhoel drugs; VI, 
incapacitating symptoms. Subjective parameters play a 
major role in this index.
O'Donoghue Index
This index (O'Donoghue et al., 1978), created for a
withdrawal trial of azathioprine maintenance therapy, was 
based on the Willoughby index (Appendix 2.5). Some 
clinical parameters were altered : wound sepsis was
omitted and recent weight loss and abdominal mass included 
in this index. One extra laboratory parameter, the white 
blood count, was added.
Llovd-Still Index
Lloyd-Still & Green (1979) recognised that the CDAI 
ignored growth, which is an important indicator of illness 
in children. Furthermore children are rarely given 
antidiarrhoeal agents which appear as a parameter in the
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CDAI. Therefore the CDAI in the paediatric population 
tended to result in a lower score than in the adult 
population, for whom it was devised. Lloyd-Still & Green 
altered a scoring system which had been used for the 
assessment of children with cystic fibrosis (Appendix 
2.6) .
Crohn's Disease Index
Harvey & Bradshaw ( 1 9 8 0 )  eliminated all laboratory 
parameters and the requirement for a diary card from the 
the CDAI by producing a much simplified version of a one 
day scoring system (Appendix 2.7). This index correlated 
closely with the CDAI (Harvey Sc Bradshaw, 1 9 8 0 ;  Gomes et 
al., 1 9 8 6 )  and also the O'Donoghue index (Elliot et a l ., 
1 9 8 0 ) .  Gomes at al. ( 1 9 8 6 )  showed a significant
correlation between the CDI and colonoscopic macroscopic 
score, but not with the histological score. The main 
criticism of the CDI is the high subjective input ( 8 7 % of 
the index comprises 3 symptoms of stool frequency,
abdominal pain and well being). Brooke ( 1 9 8 0 )  criticised 
the CDI for its liquid stool score as post resection
patients may have diarrhoea with no other evidence of 
active disease. Further studies, using the CDI, have
reduced the weighting of the liquid stools.
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Activtv Index
Van Hees et al. (1980) were unhappy about the subjective 
factors with the CDAI, and devised a more objective
clinical score (Appendix 2.8). This score was created 
using a similar technique of stepwise multiple regression 
analysis to determine the contribution of 18 variables on 
the overall assessment. Nine variables were shown to have 
a good correlation. Index values less than 100 are
associated with inactive disease, 100-150 with slight 
activity and greater than 210 severe activity. However
patients who had undergone resection of greater than one
metre of small bowel or who had stomas were excluded.
The correlation of the Al with the CDAI was poor 
(rs=0.67), mainly because the Al is made up entirely of
objective variables of which the serum albumin contributes 
most to the Al. Poorer correlation has also been seen with 
other indices (deDombal et al., 1987 ). The Al is a
complex clinical index and is difficult to calculate.
Present Index
Present et al. (1980) described a novel method of 
attempting to allow for the heterogeneity of the clinical 
manifestations of Crohn's disease. For each patient
specific treatment goals were established. These goals
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fell into three categories : reduction of steroid dosage; 
healing of fistulas ; and improvement in other clinical 
signs and symptoms. The degree of change in each goal item 
was scored +3 for excellent improvement to -3 for severe 
deterioration. This method, although much harder to 
arrange and more time-consuming, may be more appropriate.
New CDAI
Realising the limitations of the CDAI in relation to the 
heavy subjective weighting, Prantera et al. (1981) devised 
an activity index, the New CDAI (NCDAI), using a 
computerised regression analysis. Sixteen clinical and 
haematological parameters were compared with three aspects 
of Crohn's disease : clinical activity, radiological
morphology and radiological extent. The NCDAI comprises 
three clinical and four haematological parameters 
(Appendix 2.9), and therefore is a more objective index. 
When validated with 90 subsequent patient visits the index 
proved to be highly correlated with the physicians' 
assessment. Prantera et al. (1982) later looked at the
correlation of the CDAI and their index (NCDAI) in 57
outpatients with Crohn's disease, and found that the
overall correlation was "moderate" (r = 0.61). However
there was a large discrepancy between the two indices in a 
large number of patients who had undergone surgery.
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Oxford Index
The International Organisation for the Study of 
Inflammatory Bowel Disease (IOIBD) concluded at their 
meeting in Oxford in November 1980 that the CDAI was too 
complex, and devised their own ten point index (Appendix 
2.10) (Myren et al., 1984). The advantages of this index
are the equal weighting of each variable which allows easy 
calculation, and the reduced number of subjective 
variables. There was good correlation with the OMGE index 
( r = 0.76 ) but poor correlation with the Activity Index 
( r = 0.33 ) (Myren et al., 1984).
OMGE Index
This index, devised by the Organisation Mondiale de 
Gastroenterologie (OMGE) Research Committee, is based on 
the CDI (Myren, 1984). This committee considered that the 
CDAI/CDI were dominated by bowel frequency and therefore 
their index has changed the scoring for stool frequency to 
a scale of 0-5, 0 being normal bowel habit, and 5 a bowel 
habit of 10 or more stools per day. Otherwise the OMGE 
index is identical to the CDI. This index has good 
correlation with the Oxford index ( r = 0.75 ), but poor 
correlation with the Activity Index ( Al ), r = 0.33.
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Factor Score
Cooke & Prior (1984) looked at the contribution of
haemoglobin, seromucoids and serum albumin to the 
assessment of disease activity, using the statistical 
method of "factor scores". 49 patients with Crohn's 
disease were investigated during periods when they had 
been severely ill and when they had completely recovered. 
A complex equation was generated, which was simplified to 
: factor score = [1/2 haemoglobin g/dl ] + [ albumin g/1 ]
- [ seromucoids g/1 x 4 } - [ constant 37 ] . Positive
values are associated with health and negative values with
illness.
Cape Town Index
This is a more complicated version of the Oxford index, 
allowing four degrees of severity for each of the 10 
items, thus obtaining a score of between 0-30 (Wright et 
al., 1986). The index provided heavier weighting to 
complications other than diarrhoea (Appendix 2.11). There 
was good correlation with the CDAI ( r = 0.76 ), CDI ( r = 
0.81 ) and poor with the Dutch Al ( r = 0.37 ). The
addition of the ESR to the Cape Town Index did not improve 
its overall correlation with the other indices.
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Modified Activity Index (MAI)
Pettit et al. (1985) found that the Dutch Al was not 
entirely applicable to their study of the value of acute 
phase proteins in determining sepsis in Crohn's disease 
patients. 50% of their patients were excluded from the 
clinical score as they had either undergone small bowel 
resection, had stomas or took drugs to control diarrhoea.
A simple alteration to the Dutch Al was instituted to 
allow for their study patients. As a result, the stool 
consistency was changed to for patients without stomas : 1 
= well formed ; 2 = soft or variable ; 3 = watery, and for 
patients with stomas 1 = semisolid solid effluent; 2 = 
watery effluent. The coefficient constant was changed from 
- 209 to - 261 to allow for different reference range for 
serum albumin. There was good correlation of the MAI score 
with the CRP (r = 0.63) and orosomucoid (r = 0.59).
Brignola Prognostic Index 
Previous indices had not provided prognostic information. 
Brignola et al. (1986) measured multiple laboratory 
indices of disease activity in 41 patients who were in 
remission ( CDAI < 150 ) , and were followed up for 18
months. Discrimanent analysis was performed on the indices 
and a prognostic index created : - 3.5 + [ ESR x 0.03 ] + 
[ alpha^- acid glycoprotein x 0.013 ] + [ alpha2~ globulin
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x 2 ].The discrimanent threshold for relapse was 0.35 and 
the index was highly accurate (88 %) for outcome at 18 
months.
3-CDAI
An index created along similar lines to the CDAI 
(Reibnegger et al., 1986). Multiple regression analysis 
was applied to 9 clinical and laboratory parameters, 
including the urinary excretion of neopterin, an immune 
marker mediated by human monocyte/macrophages induced by 
gamma interferon, derived from activated T cells. The 
derived index, the 3-CDAI, is : 5 x ( 50 - haematocrit ) + 
stool frequency + neopterin/10. There was good correlation 
with the CDAI ( r = 0.84 ) on subsequent follow-up visits. 
The authors state that their index is an improvement on 
the CDAI as it contains no subjective variables and is 
easy to calculate. However the measurement of urinary 
neopterin is not routinely available and is the major 
handicap with this index.
Wright Simple Index
Thirty three Crohn's disease patients were followed up 
for at least nine months in an attempt to identify 
clinical and laboratory parameters which would predict an 
acute relapse ( Wright et al., 1987 ). A simple index
(Appendix 2.12) was devised by the authors and compared 
with the CDAI, the Al and 10 laboratory parameters. 
Although the "simple index" correlated well with the CDAI 
(r = 0.72) and to a lesser degree with the Al (r = 0.42), 
the CDAI was the most sensitive of the three clinical 
indices as a predictor of an acute attack. The CDAI three 
months before an attack rose by an average of 203% 
compared with a rise of the simple index of only 36% and 
the Al of only 13%. Of the laboratory indices only the 
CRP, orosomucoids and alpha^-antitrypsin rose within the 
three months before an acute attack, and were no better as 
predictors of an acute attack compared with the clinical 
indices.
Sandler Index
The present clinical indices for Crohn's disease are 
unsuitable for epidemiological studies as they rely on 
laboratory tests and/or results from physical examination. 
The authors ( Sandler et al., 1988) devised an index based 
on the CDAI and on data collected from the Trial of 
Adjunctive Sulfasalazine in Crohn's Disease (Singleton et 
al., 1979), which could be used for large scale 
epidemiological surveys. Their index comprises : (3 x
average number of liquid stools per week) + (10 x sum of 
abdominal pain ratings) + (3 x sum of daily well-being
59
ratings). The results, in disease activity quartiles, were 
compared with the CDAI and produced excellent correlation 
(r = 0.87) .
Crohn's Activity Group Scale, CAGS
This complicated study (Pinchbeck et al., 1988) used 
discriminant function analysis to determine activity 
groups. 137 patients involved in a diet counselling study 
(Imes et al., 1988) were followed up for 12 months and the 
CDAI measured during visits. 31 laboratory tests were used 
as predictive variables. Patients were classified as 
having active or inactive disease on the basis of the CDAI 
results. A rather complicated equation was devised to 
calculate the activity group scales (Appendix 2.13).
Patients were followed longitudinally to determine the 
change in the group activity scales. Once a patient's CAGS 
suggested inactive disease there appeared to be a 82.1% 
chance that the patient would remain well over the next 
year. The authors claim that the main advantages of this 
method include objectivity and its predictive value. It 
may be of benefit in future drug trials by allowing pre­
randomisation of patients with low or high probability of 
future recurrences. The calculation is quite formidable.
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RADIOLOGICAL. ENDOSCOPIC, HISTOLOGICAL AND LABORATORY 
INDICES OF DISEASE ACTIVITY
Radiology
Radiological examination of the gastrointestinal tract 
was one of the main methods of assessing disease activity 
in the early studies of Crohn's patients (Crohn et al., 
1932). There is now evidence of an erratic and 
unpredictable correlation between radiological and 
clinical features (Goldberg et al. , 1 9 7 9 ) .  This method
also introduces radiation risk to the patient and is 
therefore unsuitable for repeated assessments. There is 
also poor inter-observer agreement. Radiological 
examination of the GI tract is now considered to be a 
cumbersome and ineffective method of assessing disease 
activity.
Colonoscopy
Unlike ulcerative colitis where the rectal mucosa is 
readily available for easy sigmoidoscopic access, areas 
affected by Crohn's disease are usually inaccessible to 
routine endoscopic techniques. Colonoscopy is safe in the 
majority of patients with Crohn's colitis and has been 
used to assess disease activity (Gomes et al., 1 9 8 6 ;  
Saverymuttu et al., 1 9 8 6 ) .  Modigliani Sc May ( 1 9 8 7 )  have 
shown that there is good reproducibility of colonoscopic
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findings in Crohn's disease and could be used in 
controlled trials.
Histology
Subtle histological abnormalities can arise in GI tract 
tissue taken from sites distant from macroscopic Crohn's 
disease : usually sophisticated histological techniques
are required ( Goodman et al., 1976; Dunne et al . , 1977).
The National Cooperative Crohn's Disease Study looked at 
the clinical usefulness of rectal biopsies in Crohn's 
disease (Hill et al., 1979). Biopsies from only 15% of the 
total patient group had histological changes 
characteristic of Crohn's disease and all but one of these 
were known to have colonic involvement. There was no 
correlation found between the rectal biopsy histological 
grade for disease activity and the CDAI (Hill et al., 
1979). Gomes et al. (1986) also found no correlation 
between colonoscopic biopsy grading for activity and 
several laboratory indices including CRP, ESR, platelet 
count and WBC.
LABORATORY INDICES 
Haemoglobin
The haemoglobin (or haematocrit) has been shown to be 
useful in detecting disease activity (Kaufman et al., 
1979) and appears in many clinical scores - CDAI (Best et 
al., 1976), Lloyd-Still Index (1979), Oxford index (Myren
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et al., 1984), Cooke & Prior (1984), and the Cape Town 
Index (Wright et al., 1985). The haemoglobin accounts for 
14% of the total CDAI score (Best et al ., 1976).
Nutritional status, blood loss, iron and vitamin 
supplements all affect the haemoglobin without necessarily 
reflecting the disease activity, which limits its 
usefulness in the assessment of disease activity (Van Hees 
et al., 1980).
Platelet Count
Thrombocytosis is often seen in Crohn's disease and may 
represent a non-specific response to inflammation. There 
is good correlation between the platelet count and other 
indices of disease activity (Talstad & GJone., 1973; 
Harries et al., 1983C) . Talstad Sc GJone (1973) found that 
thrombocytosis was more common in patients with large 
bowel disease than with small bowel disease.
Serum Albumin
Hypoalbuminaemia commonly occurs in Crohn's disease 
(Weeke et al., 1971; Beeken et al., 1972), and can arise
from various factors : nutritional deficiency,
malabsorption, gastrointestinal protein loss, and 
increased catabolism. There is evidence to suggest that 
albumin synthesis is increased but unable to compensate
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for excess enteric protein loss (Steinfeld et al ., 1 9 6 0 ) .
Surprisingly there is poor correlation between the serum 
albumin and gastrointestinal protein loss (Beeken et al., 
1 9 7 2 ;  Kaufman et al., 1 9 7 9 ;  Sategna-Guidetti et a l ., 1 9 8 2 ;  
Karbach et al., 1 9 8 5 ) ,  although this was not found in the 
study by van Tongeren et al. ( 1 9 7 6 ) .  Several authors
strongly advocate the use of serum albumin as a laboratory 
index for activity (Van Hees et al., 1 9 8 0 ;  Cooke Sc Prior,
1 9 8 4 )  although most clinical scores do not include it 
(Best et al., 1 9 7 6 ;  Andre et al., 1 9 8 1 ;  Brignola et al.,
1 9 8 6 ) .
Erythrocyte Sedimentation Rate (ESR)
Several studies have shown a good correlation between 
elevated ESR and disease activity (Talstad et al., 1973; 
Talstad & Gjone, 1976; Whittington et al., 1977; Mee et 
al., 1979; van Hees et al., 1980), and van Hees et al 
(1980) also included it in their index (Appendix 2.8).
However other studies have not confirmed the usefulness 
of the ESR (Werlin Sc Grand, 1 9 7 7 ;  Fagan et al., 1 9 8 2 ;  
Cooke Sc Prior, 1 9 8 4 ;  Wright et al., 1 9 8 6 ) .  Even Talstad Sc 
Gjone ( 1 9 7 6 ) ,  who had advocated the use of ESR as a useful 
parameter, found that it was normal in 10% of patients 
with severe disease. Whittington et al. ( 1 9 7 6 )  found it to
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be useful as a predictor of relapse in their paediatric 
patients. Harvey & Bradshaw (1980) in a reassessment of 
their clinical index advised that patients who have had 
previous bowel resections and who have high clinical 
scores with a normal ESR should not be regarded as having 
active disease. Brignola et al. (1986) found a highly 
significant difference in the elevation of ESR in patients 
who subsequently relapsed.
C-Reactive Protein
C-reactive protein (CRP), one of the acute phase 
reactants, has been shown to be useful in the management 
of many aspects of Crohn's disease. Firstly, a random 
measurement may help to distinguish between inflammatory 
bowel disease and functional bowel disease (Shine et al.,
1985). Secondly, CRP has been shown to correlate closely 
with disease activity (Mee et al., 1978; Campbell et al., 
1979; Prantera et a l . , 1981; Fagan et al., 1982; Andre et
al., 1985; Saverymuttu et al., 1986). Thirdly, an elevated 
CRP in combination with normal clinical disease activity 
scores can help in predicting relapses (Campbell et a l ., 
1979; Andre et al., 1983; Boirvant et a l ., 1988), although 
Brignola et al. (1986B) found it less sensitive than the 
ESR or alpha^-acid glycoprotein. Lastly, Pettit et al.
(1985) have shown that a CRP level > 33 mg/1 may indicate
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intra-abdominal sepsis.
There is not a close correlation of CRP with the other 
laboratory indices (Prantera et al., 1984), nor was there 
any correlation with the extent of the disease.
Orosomucoid ( Aloha^-Acid Glycoprotein)
On fractionation of the seromucoids, more than 90% is 
the glycoprotein orosomucoid (alpha^-acid glycoprotein), 
which has been shown to closely relate to disease activity 
(Andre et al., 1981; Cooke & Prior, 1984; Gomes et al.,
1986; Brignola et al., 1986). In fact Andre et al. (1981)
found that alpha^-acid glycoprotein compared with the 
other serum proteins and ESR correlated best with a 
clinical score. Cooke & Prior (1984) and Brignola et al 
(1986) incorporated alpha^ acid glycoprotein into their 
laboratory indices.
Other Acute Phase Proteins
Weeke et al. (1971) found that any other acute phase 
proteins, including alpha^-acid glycoprotein, alpha^- 
antichymotrypsin, haemopexin and haptoglobin were elevated 
in active disease. Other studies have confirmed that 
alpha^-antitrypsin can be elevated in active Crohn's 
disease and the alpha^-antitrypsin clearance can be used
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as a marker (see later in this chapter). Summers et al. 
(1979) found that a pronounced elevation of serum 
haptoglobin was often associated with fistulas and sepsis.
Protein Losing Enteropathy
Early investigators of the methodology of intestinal 
protein loss used a variety of different radiolabelled 
proteins : 1^1Iodine-albumin (Steinfeld et a l ., 1960);
^■^Iodine-polyvinylpyrrolidone (PVP) (Dawson et al., 
1961); and radio-iodinated human serum albumin (Jeejeebhoy 
& Coghill, 1961). All these studies found elevated 
gastrointestinal protein loss in patients with active 
Crohn's disease. Albumin synthesis was increased but 
unable to compensate for excessive protein loss (Steinfeld 
et al., 1960).
Although plasma proteins labelled with radioiodine are 
suitable for studying plasma protein kinetics, t h e y a r e  
not ideal for studying enteric protein loss as the free 
radioiodine can be concentrated in the salivary glands and 
then secreted, and can also be reabsorbed in the 
intestine.These problems can be overcome by using 
51Chromium which is not secreted nor absorbed by the 
intestine. Using ^1CrCl3 Beeken et al. (1972) found a
close correlation between intestinal protein loss and the 
extent and severity of Crohn's disease.
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Crossley Sc Elliott (1979) first used alpha^-antitrypsin 
as a method of detecting intestinal protein loss . Alphai- 
antitrypsin is a protease inhibitor synthesised in the 
liver and is not degraded by pancreatic enzymes.Random 
faecal alpha^-antitrypsin measurement was used at first 
(Crossley Sc Elliott, 1977) and subsequently a clearance 
method was introduced (Berbier et al., (1978). There is 
good correlation between alpha^-antitrypsin clearance and 
CrCl3 clearance (Florent et al., 1981; Sategna-Guidetti et 
al., 1982; Karbach et al., 1983). Most studies have not 
found a close correlation between alpha^-antitrypsin and 
disease activity scores (Sategna-Guidetti et a l . , 1982;
Karbach et al., 1983; Karbach et al., 1985). The clearance 
method requires a stool collection over several days, 
which is a disadvantage. Random faecal alpha^- antitrypsin 
concentration has been shown to correlate with disease 
activity (Thomas et al., 1981; Meyers et al., 19 85).
Indium Scanning
In Crohn's disease there is mucosal leucocyte 
infiltration and also faecal excretion of leucocytes. 
Autologous leucocytes can be labelled with x •‘•Indium and 
when re-injected will accumulate within any part of 
inflammed bowel (Saverymuttu et al., 1983). (See Chapter 5 
of this thesis).
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Ethylenediaminetetraacetate
Twenty-four hour urinary excretion after oral ingestion 
of 5•'•Chromium-labelled ethylenendiaminetetraacetate (EDTA) 
can be used to assess small bowel permeability and hence 
small bowel involvement in patients with Crohn's disease 
(Bjarnson et al., 1983; O'Morain et al., 1986). Results
have shown a higher excretion of 51CrEDTA in patients with 
active small bowel disease. As yet the main use for this 
test lies in screening for Crohn's disease.
Other Laboratory Parameters
Many other laboratory parameters have been used in an 
attempt to define an easy method of assessing disease 
activity : serum amyloid A (Chambers et al., 1987);beta2~ 
microglobulin (Descos et al., 1982); serum lysozyme 
(Peeters et al.', 1976); plasma fibrinopeptide A (Edwards
et al., 1987); post-heparin plasma diamine oxidase 
(D'Agnostica et al., 1988); plasma human leucocyte 
elastase (Adeyemi et al., 1985); leucocyte function 
(Waddell et al., 1982); circulating immune complexes 
(Fiasse et al., 1978); urinary neopterin (Prior et al.,
1986); activated T lymphocytes (Raedler et al., 1985).
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Correlation of Indices
The correlation of many of the clinically based indices, 
involving mainly subjective items, is on the whole good 
(Hodgson, 1982). This is not entirely surprising as most 
of them have evolved from the CDAI and are measuring 
similar variables. Correspondingly the correlation between 
the subjective clinical indices and the more objective, 
laboratory based indices, such as the Al, is weaker. 
However the Italian New CDAI, based on several laboratory 
items, had a reasonably good correlation with the CDAI 
(Prantera et al, 1981).
Several laboratory indices correlate well with the 
clinical indices - in particular the CRP, ESR and alphai- 
acid glycoprotein (Andre et al., 1985). Gomes et al. 
(1986) found poor correlation between the colonoscopic and 
histological findings and other disease activity indices. 
Intestinal protein loss (Karbach et al., 1983) and indium
scanning and excretion (Saverymuttu et al., 1983) show
good correlation with clinical scores and other laboratory 
indices.
Two studies have looked at the relationship between the 
length of the lesion in Crohn's disease and the clinical
and laboratory indices (Prantera et al., 1984; Karbach et
al., 1985). Surprisingly both have found poor correlation.
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Quiescent disease could still show impressive radiological 
changes and normal macroscopic appearances do not exclude 
histological involvement.
Prognostic Indices
The prognostic function of the clinical and laboratory 
scores has not been fully investigated. Brignola et al.
(1986) considered that patients in clinical remission who 
had abnormal laboratory tests might have a greater risk of 
relapse. They used discriminant analysis to derive their 
prognostic index (see earlier in this chapter). The 
accuracy of this index was 88% after 18 months follow up. 
Pinchbeck et al. (1988) used a different statistical 
method to determine their Crohn's Activity Group Scale 
(CAGS). Once the patient's CAGS suggests inactive disease 
there is a 82.1% chance that the patient will remain well 
for the next 12 months. Possibly the prognostic indices 
will become more relevant in future if patients are 
categorised into prognostic groups.
Deficiencies In Indices of Disease Activity
Ideally measuring disease activity in Crohn's disease 
should involve patients with similar disease sites, 
identical surgical complications, in normal nutritional
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state and with active mucosal inflammation (Hodgson, 
1981). The protean nature of Crohn's disease does not 
allow for an ideal index of disease activity. Moreover, 
even using the same clinical data for the same indices, 
there is considerable inter-observer variation (De 
Dombal., 1987).
SECTION II
AIMS AND LAYOUT OF THESIS
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AIMS AND LAYOUT OF THESIS
The principle aims of this thesis were to investigate 
the relationship between nutritional deficiencies and 
disease activity in patients with Crohn's disease, and to 
determine if artificial nutritional support, in particular 
enteral nutrition, could alter disease activity.
Reviews of nutritional problems and methods of 
nutritional support (Chapter 1) and assessment of disease 
activity in Crohn's disease (Chapter 2) provided the 
background for the thesis, supplemented by introductions 
to each study chapter. Methods, results and discussion 
sections formulated the rest of the study chapters. 
Additional information was provided in the appendices.
As there are many methods of assessing activity of 
Crohn's disease, the initial part of the thesis attempted 
to determine the most appropriate tests. Two studies 
looked into this problem : a longitudinal study of
clinical scores and acute phase proteins in both inpatient 
and outpatient groups (Chapter 3); and a study using 
Indium scanning (Chapter 5) . An important aspect of the 
longitudinal study was to assess the best index for 
patients with stomas, whom I had anticipated would appear 
in subsequent clinical studies.
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In Chapter 4, malnourished patients were investigated to 
see if they had an impaired acute phase response which 
could produce false assessment of disease activity. The 
immuno-modulating effect of blood transfusion on disease 
activity was studied in Chapter 6.
The aims of the animal study (Chapter 7) were to compare 
the nutritional efficacy of new modular enteral liquid 
diets, which were to be used in the five later studies 
involving enteral nutritional support.
A major part of the thesis was concerned with the 
application of enteral nutrition in Crohn's disease : to
determine if elemental or polymeric diets are appropriate 
primary therapy for active Crohn's disease (Chapter 8); to 
assess the role of home enteral nutrition in providing 
long-term nutritional support and to document associated 
problems; to identify micronutrient deficiencies in 
patients on home enteral nutrition (Chapters 10, 11); and
to assess home enteral nutrition as a method of correcting 
growth retardation in adolescents with Crohn's disease 
(Chapter 12).
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SECTION III
STUDIES ON SPECIAL PROBLEMS OF CROHN'S DISEASE WITH 
RESPECT TO DISEASE ACTIVITY AND NUTRITION
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CHAPTER 3
THE ROLE OF ACUTE PHASE REACTANTS AND CLINICAL INDICES IN 
THE ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS WITH ACUTE 
AND STABLE CROHN'S DISEASE
INTRODUCTION
Methods of assessing Crohn's disease activity vary from 
simple clinical indices to complex indices involving 
sophisticated laboratory tests, as discussed fully in 
Chapter 2 of this thesis. The majority of studies have not 
performed longitudinal follow-up of these methods nor have 
included patients with intestinal resections resulting in 
stomas. In fact, Van Hees's index (1980) specifically 
excludes such patients.
There is also some doubt as to whether all the clinical 
indices behave similarly in different clinical situations. 
Brignola et al. (1986) showed that the CDAI appeared to 
have a better predictive value for relapse than the AI or 
the new CDAI.
AIMS OF STUDY
The aims of this study were to determine if a simple 
clinical index correlated with more complex indices and 
with other laboratory tests; to check if the indices of 
disease activity had similar correlations in patients
with stable Crohn's disease or with active disease ;and to 
investigate if a modified clinical index gave accurate 
assessment of disease activity in patients with stomas.
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PATIENTS AND METHODS 
Patients
Four groups of patients were investigated : patients
admitted with acute relapses (Group I); patients with 
stomas admitted with acute relapses (Group II); stable 
patients followed up as outpatients (Group III); and 
stable stoma patients followed up as outpatients (Group 
IV) . The clinical and demographic details of the patients 
are shown in Table 3.1 . Eighteen patients appeared in
both the acute and stable groups.
Study Design
All the clinical indices used in this study, except fthe 
modified Crohn's disease index (MOD CDI), have been 
discussed in Chapter 2 of this thesis and appear in full 
in the appendices. The MOD CDI was based on the CDI
(Harvey & Bradshaw, 1980) with an alteration to the 
weighting for stool frequency which allowed it to be used 
for patients with stomas (Appendix 2.7). The stool 
frequency score was changed to 0 = normal stools, 1 = < 3 
liquid stools per day and 2 = > 3 liquid stools per day 
for patients without stomas. For patients with stomas the 
score was 0 = normal stomal output, 1 = slightly increased 
stomal output and 2 = very loose and increased output. The
MOD CDI is similar to the altered CDI suggested by the
Group I Group II Group III Group IV
Number in each 24 3 62 12
group
Gender (M/F) 9/15 1/2 25/37 2/10
Age (years) 34(15-62) 46(28-58) 40(15-68) 44(26-75)
Disease location
small bowel 6 2 22 11
large bowel 6 - 22 -
small and large 12 1 18 1
bowel
Duration of - - 15(0-24) 17(0-27)
follow up 
(months)
Total 24 3 300 70
observations
Number of visits - - 4(1-14) 6(1-12)
per patient
( Key : Age in mean(range) years; duration of follow 
up in median (range) years; number of visits in 
median (range) years)
TABLE 3.1
Patient Clinical and Demographic Details
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OMGE committee (Myren et al., 1984), although this has not 
been validated in a large group of patients.
On admission all patients in Group I had 10 clinical 
indices measured including the Crohn's disease index (CDI) 
(Appendix 2.7), the modified CDI, Sandler's index, Crohn's 
Disease Activity Index (CDAI) (Appendix 2.4), O'Donoghue 
index (Appendix 2.5), Talstad's index (Appendix 2.3, with 
the exception of the result of the barium enema), Cape 
Town index (Appendix 2.11), Oxford index (Appendix 2.10), 
van Hees's index (Appendix 2.8), and the modified AI. 
Seven laboratory tests were performed including the 
haemoglobin, ESR (Westergreen method), C-reactive protein 
(nephelometry), alpha^-acid glycoprotein (radial 
immunodiffusion), protein losing enteropaphy (by CrCl3 
method , van Tongeren & Reichert, 1963), serum albumin and 
platelet count. Group II patients had only 2 clinical 
indices measured, the modified CDI, and the modified AI 
and the same laboratory tests as with the Group I 
patients.
Group III patients had serial measurements of 9 clinical 
indices, the CDI (Appendix 2.7), the modified CDI, 
Sandler's index, the CDAI (Appendix 2.4), O'Donoghue's 
index (Appendix 2.5), Cape Town index (Appendix 2.11), 
Oxford index (Appendix 2.10), the AI (Appendix 2.8), and
80
the modified AI. Talstad's index was not measured as 
several items were not suitable for serial measurements. 
Six laboratory tests were performed (haemoglobin, platelet 
count, ESR, CRP, alpha^-acid glycoprotein, and serum 
albumin). On review of all the results, patients were 
classified as having either active or inactive disease.
The Group IV patients had serial measurements of two 
clinical scores (the MOD CDI, and the MOD AI), the six 
laboratory tests performed on Group III patients, and a 
global assessment of active/inactive disease.
The correlation between all the clinical indices and 
laboratory tests were calculated for each group using the 
Spearman rank correlation coefficient test. Results were 
considered to be significant if the p value was < 0.05.
81
RESULTS 
Group I
There was good correlation between all the clinical 
indices except for both the Cape Town and Oxford indices 
with the AI and the MOD AI (Table 3.2). Interestingly, the 
AI and the MOD AI, two indices considered to be more 
objective as they have a large laboratory weighting, did 
not correlate with the laboratory indices any better than 
the more subjective indices. Most of the clinical scores 
correlated best with the CRP.
The CDAI, AI and MOD AI had significant correlations 
with the protein losing enteropathy test, and the AI and 
MOD AI also had good correlation with the serum albumin. 
This is not unexpected as the serum albumin contributes a 
large part to both indices.
There was generally poor correlation between the 
laboratory indices. In fact the only significant 
correlations were between the CRP and alpha^-acid 
glycoprotein (r = 0.56), PLE and albumin (r = -0.45) and 
albumin and haemoglobin (r = 0.45). The MOD CDI correlated 
well with all the clinical indices and also with the CRP 
(r = 0.42) .
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Group II
Unfortunately due to small numbers in this group the 
significance of these results was difficult to interpret 
(Table 3.3). However there were a few isolated significant 
correlations, including the MOD CDI and CRP, and also the 
MOD AI and ESR. The clinical indices did not appear to 
correlate closely with one another.
Group III
The majority of correlations showed significant values, 
with the clinical scores having the closest correlations 
(Table 3.4). The MOD CDI showed significant correlation 
with all the other indices except alpha^-acid glycoprotein 
and haemoglobin. The Oxford index performed least well. 
Although there were many significant correlations between 
the laboratory indices, most were not particularly good.
Group IV
Although the MOD AI appeared to show more significant 
correlation between the laboratory parameters, the MOD CDI 
was the only index which correlated with the overall 
global assessment of the patients (Table 3.5). There was 
not a significant correlation between the two clinical 
indices.
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DISCUSSION
In both the acute and stable groups, all the clinical 
indices which had a common source (CDAI, Sandler, CDI, MOD 
CDI, Cape Town), correlated extremely well. As expected 
there were weaker correlations between these clinical 
indices and the indices which included more laboratory 
results (Oxford, AI, MOD AI). In particular there was very 
poor correlation between the Cape Town/Oxford indices with 
the AI/MOD AI indices. These results are similar to 
earlier studies (Myren et al., 1984; Wright et al., 1985). 
Correlation was not good between the two clinical indices 
designed for stoma patients. Both are based on different 
indices, the MOD CDI on the CDAI/CDI and the MOD AI on the 
AI which has a large laboratory bias.
There appeared to be different patterns of correlation 
between the clinical indices and the laboratory indices in 
the acute and stable clinical situations. In acute 
patients most of the laboratory indices had poor 
correlation with the clinical indices with the exception 
of CRP and to a lesser extent with PLE and serum albumin. 
In the stable group most of the laboratory indices 
correlated well with the clinical indices, and also the 
global assessment. Most of the previous studies which have 
looked at the correlation of multiple clinical and
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laboratory indices have been performed on stable 
outpatients. The CRP appears the most reliable laboratory 
parameter for both clinical conditions.
There was poor correlation between the MOD AI and the 
MOD CDI in the stoma patient groups despite good 
correlation between these indices in Groups I and II. The 
MOD CDI correlated better than the MOD AI in the overall 
assessment of patients in Group IV, although it had poorer 
correlation with the laboratory indices.
SUMMARY
Multiple clinical and laboratory indices were assessed 
in patients with acute and stable Crohn's disease. In the 
acute clinical situations there was poor correlation 
between the clincal indices and the laboratory indices, 
with the exception of the CRP level. The MOD CDI 
correlated well with the other indices and appeared to be 
suitable for use in most assessments.
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CHAPTER 4
ACUTE PHASE RESPONSE IN MALNOURISHED PATIENTS 
WITH CROHN'S DISEASE
INTRODUCTION
Acute phase proteins have been used in the assessment of 
disease activity of patients with Crohn's disease (Andre 
et al., 1981; Fagan et al., 1982). Alphai-acid 
glycoprotein (orosomucoid) and C-reactive protein are the 
most frequently used acute phase proteins (Andre et al., 
1981; Brignola et al., 1986). In addition to assessing 
disease activity, the acute phase proteins can help in 
predicting relapse (Brignola et al., 1986; Boirvant et 
al., 1988) and in determining the presence of intra­
abdominal abscesses (Pettit et al., 1985).
However there is some evidence to suggest that the acute 
phase response may be altered in malnutrition. Miller & 
John (1970), using isolated perfused rat livers, found 
impaired synthesis of alpha^-acid glycoprotein, fibrinogen 
and haptoglobin in six day fasted rats, with only a small 
increase in synthesis on refeeding, compared with fed 
controls. In another study rats fed a protein free diet
showed an impaired response of alpha2 and beta
glycoproteins when subjected to trauma (Neuhaus et al .,
1963). Malnourished patients with gastric cancer who 
underwent surgery had reduced acute phase response for
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alpha^-antitrypsin and alphai-acid glycoprotein and 
slightly enhanced C-reactive protein and fibrinogen, 
compared with well-nourished gastric cancer patients 
(Domimioni et al., 1983).
The influence of malnutrition on the acute phase 
response in patients with Crohn's disease has not been 
studied despite the increasing use of acute phase proteins 
in the assessment of disease activity and the recognition 
of the high prevalence of malnutrition in patients with 
Crohn's disease (Harries & Heatley, 1983B).
AIM OF STUDY
The aim of this study was to compare the acute phase 
response of well-nourished patients with Crohn's disease 
with malnourished patients.
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PATIENTS AND METHODS 
Patients
Twenty-one consecutive patients requiring inpatient 
treatment for active Crohn's disease were included. 
Patients were considered to be malnourished if their body 
weight was less than 80% of their ideal body weight (IBW), 
as defined by standard tables (Chicago Society of 
Actuaries, 1959). Ten patients were considered to be 
malnourished (Group 1) and 11 patients were well nourished 
(Group 2).
The clinical details of the patients are shown in Table
4.1. The mean age and range (years) of patients in group 1 
was 32 (15-54) and for Group 2, 38 (21-61). Disease
location was assessed using standard radiology and 
colonoscopy either during a recent admission or during the 
study admission. There were slightly more patients with 
colonic disease in Group 2. More patients in Group 1 (70%) 
had previous resections than in Group 2 (27%).
Nutritional Assessment
Full anthropometric and biochemical assessment of /each 
patient's nutritional status was performed as soon as 
possible after each admission and in every case w/thin 2-3 
days. Anthropometric measurements were taken to calculate 
percentage ideal body weight (%IBW), triceps skinfold 
thickness (TST % standard), and mid - arm muscle
Patients Previous
Sex Age Disease Location resections Drugs
1 M 54 SB Colectomy Vit D
2 M 15 SB + LB - -
3 M 36 SB + LB R.Hemi + SB -
4 F 24 SB + LB R.Hemi Mg
5 F 28 SB Colectomy -
6 F 28 SB R.Hemi -
7 M 15 LB - SSZ
8 F 33 TI - -
9 M 28 SB + LB R.Hemi SSZ
10 M 41 SB + LB R.Hemi + SB Mg, Vit
Group 2
11 F 32 SB + LB R.Hemi -
12 M 25 LB - -
13 M 61 SB + LB - -
14 F 33 LB - -
15 F 40 SB - SSZ
16 F 21 SB + LB - -
17 F 60 LB R.Hemi -
18 M 34 SB R.Hemi -
19 F 58 SB + LB R.Hemi + Mg
Sigmoid Colectomy
20 F 51 LB -
21 F 31 SB + LB -
Key: SB = Small Bowel; LB = Large Bowel; TI = Terminal Ileum, R.Hemi = 
Right Hemicolectomy; Vit D = Vitamin D; Mg = Magnesium Supplem ents; SSZ = 
Sulphasalazine
Table 4 .1  - P atients’ Clinical Details
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circumference ( MAMC % standard) (Shenkin & Steele, 1978). 
Percentage weight loss was also calculated for eight 
patients who had previously documented weights. Blood 
samples were taken for analysis of albumin, transferrin, 
calcium, phosphate, magnesium, zinc, copper, iron, 
vitamins A, E, Bi, B2, Bg, B12, red cell folate and 24
hour urine collections for urinary magnesium and zinc 
excretion. Laboratory methods are described in Appendix
4.1.
Disease Activity
A modified clinical scoring system (the Modified Crohn's 
Disease Index MOD CDI) was used (see Chapter 3) . The 
modified index allowed the same clinical score to be used 
for patients with and without stomas. The erythrocyte 
sedimentation rate (ESR) was measured by the Westergreen 
method, C-reactive protein (CRP) by nephelometry (Hyland 
laser Nephelometer) and alphai-acid glycoprotein by radial 
immunodiffusion. Gastro-intestinal protein loss was 
investigated by the CrCl3 method (Van Tongeren & Reichert, 
1966).In addition to the CRP and alphai-acid glycoprotein 
measurements on admission, eight patients in each group 
had previously documented outpatient weights and the rise 
in the acute phase reactants was calculated.
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Statistical Analyses
Most of the indices for disease activity were not 
normally distributed and the Wilcoxon rank sum test was 
used to compare the disease activity between the two 
groups. Comparison of the nutritional assessment between 
the two patient groups was also performed by the Wilcoxon 
rank sum test. All results with p < 0.05 were considered 
to be significant.
RESULTS
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Nutritional assessment
Full nutritional assessment was made on all the patients 
and the results appear in Table 4.2 The percentage IBW 
(mean, sem) for Group 1 was 72 (1)% and Group 2, 95 (3)%. 
The only significant difference in the nutritional status 
between the two groups was for the triceps skinfold 
thickness (percentage standard) : Group 1 v Group 2, 62
(5)% v 87 (6)%. Eight patients in each group also had
previously documented outpatient weights and the 
percentage weight loss calculated : Group 1 patients 14.8 
(1)% and Group 2, 6.8 (0.8)% (p<0.01).
Disease Activity
The results for the indices of disease activity MOD CDI, 
ESR, CRP and alphai-acid glycoprotein, and 
gastrointestinal protein loss are shown in Table 4.3. 
There are no significant differences between the two 
patient groups. Eight patients in each group had previous 
outpatient measurements of the acute phase reactants 
during quiescent periods of their disease. The rise in the 
acute phase reactants was similar in both groups and not 
statistically different.
M e a s u r e m e n t G r o u v 1 G r o u v  2
Weight (%IBW) 72 1) 95 (3)
Percentage weight loss * 14.8 1.0) 6.8 (0.8)
TST (%standard) + 62 5) 80 (7)
MAMC (%standard) 75 4) 87 (6)
Haemoglobin (11.5-15.5 g/dl) 10.6 0.3) 10.5 (0.4)
Albumin (35-50 g/1) 26 2) 29 (2)
Transferrin (2-4 g/1) 1.9 0.2) 1.9 (0.2)
Calcium (2.2-2.6 mmol/1) 2.32 0.18 2.33 (0.15)
Phosphate (0.7-1.4 mmol/1) 1.03 0.11) 1.13 (0.08)
Serum magnesium 0.72 0.03) 0.79 (0.02)
(0.7-1.0 mmol/1)
Urinary magnesium 1.4 0.4) 2.1 (0.3)
(2-11 umol/1)
Serum zinc (12-18 umol/1) 10.0 0.7) 10.7 (0.7)
Urinary zinc 6.8 1.5) 11.5 (2.6)
(4.6-10.6 umol/1)
Copper (15-25 umol/1) 19 1.9) 21 (1.7)
Iron ( 10-30 umol/1) 3.9 0.9) 5.4 (0.6)
Vit A (1-2.8 umol/1) 1.1 0.3) 1.3 (0.1)
" E (14-39 umol/1) 21 4) 24 (3)
" C (11-114 umol/1) 28 5) 32 (5)
1 B1 (<25% activation) 14 3) 17 (4)
" B2 (<60% activation) 27 6) 35 (10)
" B6 (<150% activation) 48 7) 65 (10)
" B12 (150-730 pg/ml) 669 269) 759 (195)
Red cell folate 272 66) 295 (68)
(106-614 pg/ml)
[ Key : IBW = Ideal body weight; TST = Triceps skinfold 
thickness; MAMC = mid arm muscle circumference. All values 
expressed as mean (sem). Normal range in parenthesis.
* p<0.001 + p<0.05 ]
TABLE 4.2
Nutritional Assessment
Activity parameter Grouv 1_________ Grouv 2
MOD CDI (0) 5 / 3-9 6 / 3-10
ESR (<15 mm/h) 49, 22-80 53, 25-102
CRP (<10mg/l) 42, 15-180 40, 11-97
Alphai-acid glycoprotein 
(50-120 mgldl)
288, 156-406 271, 155-416
GI protein loss (<25ml/day) 76, 27-150 61, 11-295
A. CRP (mg/1) 18, 5-80 28, 5-60
[Key : results expressed as median, range. All results 
not significant. Normal values or values indicating 
quiescent disease in parenthesis. CRP = increase in CRP 
from outpatient values in 8 patient in each group ]
TABLE 4.3 
Disease Activity
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DISCUSSION
There is no ideal method of assessing nutritional status 
which involves a combination of clinical examination, 
anthropometric and biological measurements (Shenkin & 
Steele, 1981). My definition of malnutrition as being less 
than 80% ideal body weight could be criticised, but does 
offer a fairly safe criteria which is easy to measure. 
Bistrian (1981) has suggested that percentage weight loss 
is more accurate but many patients in this study did not 
have previous documented weights. Only eight patients in 
each group had a previous weight recorded, but all the 
patients with more than 10% weight loss were in the 
malnourished group.
Dominioni et al. (1983) used serum albumin (less than 32
g/1) as an arbitrary measurement of malnutrition. However 
hypoalbuminaemia can arise from transcapillary flow as 
part of the acute phase response (Fleck et al., 1985) or 
in Crohn's disease from severe protein losing enteropathy, 
rather than from a primary nutritional problem involving 
protein intake, absorption and synthesis. Serum albumin 
was not thought to be suitable as a single parameter of 
nutritional status in this study. The skinfold thickness 
was significantly lower in the malnourished group but not 
the mid arm muscle circumference which can be a less 
accurate measurement. All the biochemical indices except
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for the water soluble vitamins, were lower in the 
malnourished group, but the differences were not 
significant.
There were no significant differences in the disese 
activity as assessed by several indices between the two 
groups. The use of three different methods of assessing 
disese activity (clinical score, acute phase response and 
GI protein loss) should have compensated for any 
deficiency in using only a single method.
This study has shown that the acute phase response of C- 
reactive protein and alpha^-acid glycoprotein in patients 
with Crohn's disease is not impaired in malnourished 
patients. The acute phase response can be used as a marker 
of disease activity in Crohn's disease in patients whose 
nutritional status is unknown.
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CHAPTER 5
ASSESSMENT OF AUTOLOGOUS MIXED LEUCOCYTE INDIUM SCANNING
IN DETERMINING DISEASE ACTIVITY AND EXTENT 
INTRODUCTION
Conventional imaging techniques of the bowel involve 
invasive procedures. Small and large bowel radiology and 
colonoscopy have small but recognised complication rates, 
and may be hazardous, especially in patients who have 
active disease. Radionuclide scanning of the bowel offers 
unrestricted use as it is non-invasive and does not 
require bowel preparation.
^ Gallium Scanning
^Gallium citrate , used during the late 1970s in the 
investigation of occult abcesses and neoplasia, was one of 
the first radionuclides to be used in the investigation of 
Crohn's disease. The results were disapointing, as many 
patients with Crohn's disease had negative scans 
(Goldenberg et al., 1979; Rheingold et al., 1979). 
99MTechnetium diethylenetriamine pentaacetic acid ( ^ mTc- 
DTPA ) has a clearance similar to inulin, which has a 
distribution approximating to the extracellular fluid 
space (Kadir & Strauss, 1979). It was reasoned that 99mTc_ 
DTPA may be useful in Crohn's disease in which a localised 
increase in the extracellular fluid space and an increased 
tissue permeabilty to the radionuclide could occur (Kadir
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& Strauss,1979). Although many patients showed increased 
99mTc-DTPA activity in the diseased bowel, this type of 
scanning never became popular due to the high false 
positive rate.
Indium-Oxine Mixed Leucocyte Scanning
Segal et al. (1976) were the first to use ^-^Indium
labelled white cell scanning for abscesses and
subsequently in patients with Crohn's disease (Segal et
al., 1981). As a heavy neutrophil infiltrate of the lamina
propria is a characteristic microscopic appearance in
Crohn's disease, in addition to the large neutrophil
excretion in the stools, it was presumed that
radiolabelled leucocytes would appear in areas of inflamed
111bowel. Autologous leucocytes, when exposed to Indium, a 
gamma ray emitting radioisotope, and 8-hydroxyquinolone 
(oxine), a chelating agent, are stably labelled with the 
radioisotope (Zakhireth et al.,1979). The lipophillic 
chelating agent facilitates transport of ^^Indium across 
the white cell membrane. The labelled leucocytes are re­
injected and subsequent scanning with a gamma camera 
identifies areas of inflammation. The faecal excretion of 
labelled leucocytes has been found to be higher in 
patients with Crohn's disease, raising the possibility of 
its use as a marker of disease activity (Segal et 
al.,1981) .
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^•^Indium Scanning - Diagnosis of Crohn's Disease
111The application of Indium scanning in patients with 
Crohn's disease includes diagnosis, assessment of disease 
extent, assessment of disease activity and the 
investigation of intra-abdominal abscesses. In a large 
study of 100 consecutive cases of suspected inflammatory 
bowel disease, 33 cases (24 of Crohn's disease) were 
confirmed by conventional tests, including radiology 
colonoscopy, histology and/or surgery (Saverymuttu et al., 
1985A). The scan accuracy was 94% compared with radiology 
of only 79%. The sensitivity of the scan increased to 100% 
when faecal indium excretion was included. Fotherby et al. 
(1986) looked at 40 patients with gastrointestinal 
symptoms and found 2 patients who had inflammatory bowel 
disease, 2 false postive scans and no false negative 
scans.
111J"L-LIndium Scanning - Assessing Extent
A few studies have been performed to assess the accuracy 
111of Indium scanning in estimating the extent of diseased 
bowel. Initial studies found excellent results when 
scanning was compared with radiology or colonoscopy, with 
the exception of small bowel disease (Saverymuttu et al ., 
1982,; Saverymuttu et al., 1983B,; Stein et al., 1983). In 
addition there was good correlation between the scans' 
estimation of extent, and colonoscopic and
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histological assessment (Saverymuttu et al., 1986C). The 
less accurate results with small bowel disease were 
explained by poor imaging due to motility of the small 
bowel loops. While more recent studies have shown good 
correlation with disease extent in small bowel disease 
(Saverymuttu et al., 1983A; Fotherby et al., 1986; Becker
et al., 1986), the scans were less accurate compared with 
scans for colonic disease (Crama-Bohbouth et al., 1988).
Indium Trooonolone Granulocyte Scanning 
There have been several reports indicating that 
1:L1Indium scanning is less accurate than conventional 
techniques, resulting in an underestimation of disease 
extent (Buxton-Thomas et al., 1984; Leddin et al.,1987). 
The poor results of these studies could be explained by 
the scanning technique. Initial studies were carried out 
using a mixed leucocyte preparation, which unavoidably 
labelled lymphocytes and platelets in addition to 
granulocytes (Saverymuttu et al., 1983B; Buxton-Thomas et 
al.,1984). The technique has been modified to replace the 
mixed leucocyte preparation with pure granulocytes 
(Saverymuttu et al.,1983C). This provides better scan 
image by reducing the background to target activity. 
However preparation of pure granulocytes is time-consuming 
and expensive, and remains outwith the armamentarium of 
many nuclear medicine departments (Hesselwood, 1986) .
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There has also been discussion over the ideal chelating
agent. Leucocytes have to be removed from plasma during
labelling with ^-^Indium oxine because of the affinity of
this complex for transferrin (Peters et al.,1983), which
could interfere with the viability of the leucocytes.
Zakhireh et al. (1979) did not find impairment with the i n
111
v i t r o locomotion and bactericidal activity of ■LJ-Indium - 
oxine labelled leucocytes.
In 1983 Peters et al. introduced the chelating agent 
111troponolone for Indium cell labelling, which offered 
the advantage of labelling the leucocytes in plasma and 
thereby reducing any effect on leucocyte function (Peters 
et al., 1983). Since then several studies on the use of 
Indium scanning in Crohn's disease have used troponolone 
as the chelating agent despite its additional cost and the 
need for a high cell concentration. A study by Datz et al. 
(1985) found that leucocytes labelled by either chelating 
agent have similar physiological activity for the 
detection of occult infections. However, an oxine-like 
chelating agent, acetylacetone, performed less well 
compared with troponolone in a large study of patients 
with mixed clinical conditions (Schauwecker et al., 1986). 
Whilst the labelling debate continues, oxine remains the 
agent used for routine scanning.
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Assessing Disease Activity
111Early investigators realised the value of •LJ--LIndium 
scanning in assessing Crohn's disease activity. There are 
two methods : assessment of the intensity of the
radioactivity of the abdominal scans (Ybern et al., 1986) 
or the quantification of the faecal Indium excretion 
(Saverymuttu et al., 1983B). Obviously the assessment of 
the scans is much easier than a four day stool collection, 
which is often incomplete and inaccurate.
Measurement of disease activity in Crohn's disease is
very difficult (Chapter 2) and there is no objective gold
standard. Most studies use a clinical index, most commonly
the Crohn's Disease Activity Index (CDAI) (Best et
al.,1976). Saverymuttu et al. (1982), using this
estimation of disease activity, found that indium scanning
could distinguish between active and inactive Crohn's
colitis. In a later study Saverymuttu etal. (1983C) found
111good correlation with •LXXIndium-tropolone granulocyte 
scanning and the CDAI. Fifteen patients were looked at pre 
and post steroid therapy. Surprisingly 6 out of 12 
patients who had a CDAI <150 (inactive disease) had scan 
scores >1. Other studies have found good correlation 
between scan activity and CDAI (Stein et al., 1983), CDI 
(Ybern et al., 1986), acute phase proteins (Fotherby et 
al., 1986), ESR (Fotherby et al., 1986), colonic histology
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(Saverymuttu et al., 1983D) and colonoscopic assessment 
(Saverymuttu et al.,1983D).
Faecal Indium Excretion
Faecal indium excretion has been more widely used than 
scanning activity for the assessment of disease activity. 
Several studies have found good correlation with the 
CDAI(Saverymuttu et al.,1983b ; Saverymuttu et al., 1983D; 
Buxton-Thomas et al.,1984; Saverymuttu et al.,1986C); the 
Van Hees clinical index (Leddin et al.,1987; Fishbach et 
al., 1987); ESR (Saverymuttu et al., 1983D;,. Fishbach et 
al.,1987); CRP (Saverymuttu et al.,1983D ); alpha^-acid
glycoprotein (Fishbach et al., 1987),;alphai-antitrypsin 
(Fishbach et al.,1987); albumin (Fishbach et al.,1987); 
colonic histology (Saverymutttu et al., 1986C) and
colonoscopic findings (Saverymuttu et al.,1986C).
Although Saverymuttu et al.(.1986C) found good
correlation between faecal indium excretion and 
gastrointestinal protein loss this was not confirmed by 
Fishbach et al. (1986) using alpha^-antitrypsin stool 
concentration and clearance. Leddin et al (1983) found 
that faecal indium excretion had good correlation with the 
van Hees index, but there was a poor correlation with the 
CDAI.Several of their patients were classified by the CDAI
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as having inactive disease.
The fault may lie with the clinical scores : they are 
subjective and rely heavily on stool frequency which could 
be due to other factors. Saverymuttu et al. (1986B) looked 
at 48 patients (71 assessments) who had inactive disease 
as assessed by the CDAI (CDAI < 150) and found that 89% of 
the patients had elevated faecal excretion compared to a 
control group of patients with irritable bowel syndrome.
Other Methods of Scanning
111Because of the difficulty with AXIndium, other methods 
of labelling white cells have been developed.^mTechnetium
111
offers several advantages over AAAIndium : the cell
separation is technically easier and more convenient; it 
is less expensive; better image resolution; and lower 
radiation dose. Attempts have been made to "feed"
leucocytes radiolabelled particles, usually ^ mTechnetium 
colloid (Pullman et al.,1986). The leucocytes are induced 
to phagocytose and thereby activated, producing poor 
results and high false positive rates (Peters et al.,
1986A), and it is not recommend for routine screening.
Locher et al (1986) used anti-granulocyte antibodies 
labelled with 125 j w ith some success. However the
granulocytes are activated as a result of antibody
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attachment and the patients may be immunised. Sucralfate, 
which is known to bind to ulcerated areas throughout the 
gastrointestinal tract, has been labelled with 
99mTechnetium (Dawson et al.,1985).A recent study has 
failed to confirm the initial promising results (George et 
al., 1987). A major disadvantage is the necessity to wash 
out the bowel to recover unbound sucralfate.
Hexamethylpropylene-amineoxine (HMPAO) can form a lipid- 
soluble neutral complex with ^ mTechnetium which is 
rapidly incorporated into leucocytes i n  v i t r o . Initial 
results were impressive, despite evidence of leucocyte' 
activation (Peters et al.,1986B). Bowel excretion of 
technetium makes images taken more than three hours post­
injection difficult to interpret.
Summary of introduction
111Indium white cell scanning is a new non- invasive
method of assessing disease extent and activity in
111patients with Crohn's disease. While Indium-troponolite
labelled pure granulocyte scans appear to give the optimum
results, these scans are outwith the armamentarium of a
111routine nuclear medicine department. Indium-oxine mixed 
leucocyte scanning is the routine method. Other methods of 
radionuclide labelling to leucocytes have not produced 
equivalent results due to leucocyte activation.
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AIMS OF STUDY
The aims of this study were to compare *LIndium-oxine 
mixed leucocyte scanning with other indices of Crohn's 
disease activity and to assess the accuracy of indium 
scanning in determining the location and extent of 
disease.
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PATIENTS AND METHODS 
Patients
Nineteen patients with Crohn's disease (sixteen females, 
three males, mean age 29, range 16-62) who required 
hospital admission with active disease were studied. Four 
patients had two assessments and therefore 23 sets of 
results are available. Conventional radiology and 
colonoscopy were used to assess the extent of disease, 
which was found to be limited to the small bowel in six 
patients, small and large bowel in four, ileocaecal in 
three, large bowel in four and ileocolonic anastomosis in 
two. Two patients had an ileostomy and one a colostomy 
(Table 5.1). Five patients were on sulphasalazine during 
the assessment period, three on both sulphasalazine and 
steroids and four on enteral nutrition.
Indium Scanning
Indium scanning was performed within five days of the 
conventional imaging techniques and before any change in 
drug therapy. Fifty millilitres of venous blood were taken 
from each patient and mixed with 2000 units of heparin and 
8 ml of hetastarch. This mixture was gravity separated for 
one hour. The white cell layer was separated and 
centrifuged and resuspended in 10 ml saline, and incubated
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for 45 minutes with 10-20 MBq 1-L1Indium-oxine. Further 
centrifugation was done to yield the labelled cell button 
which was resuspended in 10 ml saline and reinjected 
intravenously. Gamma camera scans were carried out at four 
hours, anterior images of the abdomen and pelvis being 
obtained using a wide field of view gamma camera 
interfaced to a microcomputer.
The indium scan activity score was calculated by 
dividing the scanned area into five segments : the small
intestine; right colon; transverse colon; descending 
colon; and sigmoid colon/rectum. For each segment an 
activity score of 0 = no activity, 1 < marrow activity, 2 
< liver activity, 3 < splenic activty , and 4 >splenic 
activity was allocated and summated to give a theoretical 
maximum score of 20. Each scan was scored blindly by 
Professor J. McKillop. Examples of the scoring system are 
shown in Plates 5.1 - 5.3.
Disease Activity Indices
Disease activity was assessed by two clinical scores : 
the Crohn's Disease Activity Index (CDAI) (Best et al., 
1976), and a modified Crohn's Disease Index (MOD CDI), 
based on the Bristol simple index (Harvey & Bradshaw, 
1980), to allow for a score to be calculated for patients
PLATE 5.1 Normal indium scan (scan score 0)
PLATE 5.2 Indium scan showing disease of 
descending and sigmoid colon 
(scan score 4)
PLATE 5.3 Indium scan showing total colitis 
(scan score 9)
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with stomas. The scoring for the Bristol Index was changed 
to 0 = normal stools, 1 = < 3 liquid stools per day, 2 = > 
3 liquid stools per day ; for stoma patients 0 = normal 
stomal output, 1 = slightly increased output, 2 = greatly 
increased and very loose output. All patients had their 
erythrocyte sedimentation rate (ESR, Westergreen method), 
C-reactive protein (CRP, by nephelometry) and
C 4
gastrointestinal protein loss measured by the CrCL3 
method (Van Tongeren & Reichert, 1966).
Statistical Analyses
The Spearman rank correlation coefficient (rs) was 
calculated for the indium scan activity scores and the 
other indices of disease activity, and only p < 0.05 
values were considered to be significant.
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RESULTS
All patients had technically satisfactory scans with no 
pooling of leucocytes in the lungs.
Disease Activity
Twenty three sets of results are available (Table 5.1) 
and are summarised in Table 5.2 . Only the MOD CDI was 
calculated for the three stoma patients. There were no 
significant correlations between the indium scan activity 
scores and the other indices of disease activity - CDAI 
(rs=0.25/ p>0.1); MOD CDI (rs=0.27/ p>0.1); ESR (rs=0.4,
p>0.05); CRP (rs=0.2,p>0.1); and CrCl3 GI protein loss 
test (rs=0.04/ p>0.1) (Figures 5.1 to 5.5).
Disease Location
Of the five patients who had negative scans, three had 
extensive disease. Indium scanning showed correct location 
of disease in 58% of patients (Table 5.3).In one patient 
with small and large bowel disease the extent of the 
disease was underestimated. In two patients with small 
bowel disease alone the scans were reported as showing 
small and large bowel disease (patient 2) and only right 
colonic disease in patient 19. Radiology but not
Median__________________Ran ere
CDAI 215 70-440
MOD CDI 4 0-10
ESR 36 10-65
CRP 28 10-93
GI protein loss 60 11-255
Indium scan 2 0-6
(Normal values or values indicating quiescent disease 
CDAI < 150, MOD CDI < 2, ESR < 20 mm/h, CRP < lOmg/1, 
GI protein loss < 25 ml/24h, scan score =0.)
TABLE 5.2
Summary of Disease Activity Assessment
Correct Incorrect
Small bowel (6) 2 2
Small and large 2 1
bowel (4)
anastomosis (2)
TABLE 5.3
Location of Disease by Indium Scan
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FIGURE 5.1
Correlation of Indium Scan Score and CDAI
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Correlation of Indium Scan Score and MOD CDI
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FIGURE 5.3
Correlation of Indium Scan Score and ESR
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FIGURE 5.4
Correlation of Indium Scan Score and C-Reactive Protein
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FIGURE 5.5
Correlation of Indium Scan Score and GI Protein Loss
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colonoscopy had been performed on patient 2 and both 
investigations on the other patient.
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DISCUSSION
1 1 1The results of this study, which compared ■LXAIndium-
oxine labelled mixed leucocyte scanning activity with
other indices of disease activity and its assessment of
disease extent, have failed to confirm previous
encouraging results (Saverymuttu et al.,1982; Saverymuttu
et al., 1983B; Saverymuttu et al., 1983C; Stein et
al.,1983; Saverymuttu et al.,1986C). Buxton-Thomas et al.
(1984) and Leddin et al. (1987) had found poor results
111with ■LJ"LIndium‘-oxine labelled mixed leucocytes. Five 
patients with unequivocally active disease had negative 
scans.
Indium scanning correctly located disease extent in only 
58% of patients. The disease location accuracy was best 
for patients with colonic disease as had been found in 
previous studies (Saverymuttu et al.,1983B; Stein et 
al.,1983). This discrepancy could be explained by two 
reasons : poor scan technique or an actual limitation of 
indium-oxine mixed leucocyte scanning in detecting active 
inflammatory bowel disease.The first reason is unlikely as 
the scans had labelling efficiency of leucocytes of around 
70%, comparable to other groups (Saverymuttu et al.,1983C; 
Saverymuttu et al.,1986A). Several groups have suggested 
that the scan technique can be improved by using a pure 
granulocyte preparation and substituting indium -
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troponolone for indium oxine as the chelating agent 
(Saverymuttu et al.,1983c). Although Datz et al. (1985) 
found similar activities of both sets of leucocytes 
labelled by either indium-oxine or indium-troponolone, 
Fotherby et al. (1986), using Indium-troponolone showed an 
improvement in scan results from their previous study when 
indium-oxine had been used (Buxton-Thomas et al.,1984).
From this study standard indium-oxine mixed leucocyte 
scanning does not offer major advantages over the 
conventional methods of bowel immaging in inflammatory 
bowel disease. It may play a wider role in special 
circumstances, including severely unwell and toxic 
patients, very old and frail patients and in the 
investigation of intra-abdominal abscesses.
SUMMARY
Standard Indium leucocyte scanning was compared with 
other indices of disease activity in 19 patients. There 
was poor correlation with he CDAI, MOD CDI, ESR, CRP and 
GI protein loss. Scanning correctly located disease extent 
in only 58% of patients.
1 1 0
CHAPTER 6
THE EFFECT OF BLOOD TRANSFUSION ON CROHN'S 
DISEASE ACTIVITY
INTRODUCTION
Recurrence After Surgery
The authors of the first reports on Crohn's disease 
(Dalziel, 1913; Crohn et al., 1932) considered that 
surgical resection offered a cure. However, it was not 
long before further studies reported early recurrence 
after resections. (Felger & Schenk, 1940; Van Patter et 
al., 1954). Lennard-Jones & Stalder (1967), who were the 
first to use life-table analysis to investigate recurrence 
after surgery for Crohn's disease, found a cumulative 
recurrence rate of 23% after 5 years and 51% after 10 
years. A recent study (Rutgeerts et al., 1984) found 
endoscopic evidence of recurrence in 72% of patients after 
one year following small bowel resection. Since then many 
other studies have looked at possible factors affecting 
recurrence after surgery : site of disease, with ileocolic 
disease having the highest recurrence (Wheelan et al., 
1985); indications for surgery (Greenstein et a l ., 1988);
and drug therapy after surgery (Wenckert et al., 1978).
Ill
Immunomodulating Effect of Blood Transfusion
Blood transfusion may cause immunosuppression in in the 
recipient : this is considered to be the mechanism of the 
improved graft survival in renal transplant patients 
(Woodruff & Van Rood, 1983) and the higher rate of
recurrence following cancer surgery in patients who
received blood in the perioperative period (Blumberg et 
al., 1986; Creasy et al., 1987). Blood transfusion could 
have a similar immunomodulating effect in Crohn's disease, 
which has been associated with many immunological
abnormalities (Elson, 1988). The only previous study in 
Crohn's disease has been by Tartter et al. (1988) who 
examined the incidence of post-operative septic 
complications in patients who had received blood 
transfusions. They found that blood transfusion in the 
perioperative period was associated with an increased 
incidence of infection, even allowing for other factors 
including extent of disease and previous surgery. However, 
they did not examine if blood transfusion affected the 
disease activity or recurrence rate.
Blood transfusion is one of the oldest forms of 
artificial nutritional support. The potential effect of 
blood transfusion on disease activity in Crohn's patients 
has been ignored, which if present, could alter the 
therapeutic outcome of drug and diet trials.
AIM OF STUDY
The aim of the study was to determine if blood 
transfusion altered the relapse rate following surgical 
resections, and also in patients treated by medical 
methods.
PATIENTS AND METHODS 
Patients
Patients were eligible for this study if they fulfilled 
the following criteria : an established diagnosis of
Crohn's disease had been made by standard clinical, 
radiological, endoscopic and histological methods; they 
had required an admission for treatment of active Crohn's 
disease; they had responded to treatment and/or surgery 
and were off all drugs except maintenance therapy in the 
form of sulphasalazine-like drugs; they had been followed 
up for at least one year post admission. Patients who had 
received a blood transfusion for indications other than 
directly related to Crohn's disease were excluded.
Study Design
Details were recorded of disease activity (haemoglobin, 
C-reactive protein, ESR, albumin), treatment during
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admission, duration of treatment, duration of disease 
remission, blood transfusion requirements, indications for 
blood transfusion, drug therapy before admission and drug 
therapy after admission. Indications for surgery were 
classified as either perforating (acute perforation, 
abscess formation, internal fistula) or non-perforating 
(intestinal obstruction, haemorrhage, failed medical 
therapy, toxic dilatation) (Greenstein et al., 1988).
Definition of Recurrence
Although there may be subtle differences between the * 
terms recurrence, relapse or recrudescence, patients'? 
outcomes are unchanged. For the purpose of this 
study, relapse has been used and is defined strictly as 
the appearance of gastrointestinal symptoms attributable ? 
to active Grohn's disease with objective laboratory, 
radiological and/or endoscopic evidence of active Crohn's 
disease.
Statistical Analyses
Results of patients' ages, distribution of disease, 
disease activity, and blood transfusion requirements were 
expressed as mean (sem). Demographic details of patients 
and results for disease activity were compared by using
the Student t test. Life-table analysis using the Kaplan- 
Meier (1958) method was used to calculate the cumulative 
relapse rate for different groups. Comparison of relapse 
rates between groups and treatment regimes were analysed 
by using the Chi square test. Results with p < 0.05 were 
considered to be significant.
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RESULTS
Patients
207 patients fulfilled the criteria for this study. 151 
(72.9%) patients did not receive a blood transfusion 
during their admission (NBT group), and 56 (27.1%)
received a blood transfusion (BT group). The demographic 
details of the total, NBT and BT groups are shown in Table 
6.1. There were no significant differences in age at the 
time of the study, age at presentation, duration of 
disease, or disease location.
Treatment Regimes
The treatment regimes for patients in the total, NBT and 
BT groups are shown in Table 6.2. Although there were more 
patients treated by surgical resection in the BT group 
(44.7%) compared with the NBT group (24.5%), this 
difference was not significant.
Maintenance Therapy
65.2% of the total group were taking maintenance therapy 
in the form of sulphasalazine (85.9% of patients on 
maintenance therapy) and mesalazine (14.1%). There were no 
significant differences in the number of patients taking
TOTAL NBT BT
GROUP GROUP GROUP
(n=207)_______ (n=151)______ (n=56)
Age at Study 35.2(1.6) 35.7(1.3) 33.9(2.1)
Age at Presentation 32.8(1.6) 33.1(1.2) 32.2(2.1)
Duration of Disease 2.5(0.3) 2.7(0.3) 1.8(0.3)
Gender (M/F) 83[40.1]/ 62(41.4]/ 21(37.5]/
124(59.9] 89(58.9] 35(62.5]
Disease location :
small bowel 53(25.6] 38(25.2] 15(26.7]
large bowel 73(35.3] 57(37.7] 16(28.7]
small and large 81(39.1] 56(37.1] 25(44.6]
(Key : results for age at study, age at presentation, 
duration of disease are expressed as mean(sem). Results 
in [ ] are % of groups)
TABLE 6.1
Patients7 Demographic Details
T O T A L N B T B T
(n=201) (n=151) (n=56)
TREATMENT MEDICAL 145(70) 114(76) 31(55)
SURGICAL 62(30) 37(24) 25(45)
M E D I C A L  T R E A T M E N T T O T A L N B T B T
In=145) (n=114) (n=31)
Oral steroids 89 (61) 65(57) 24(78)
Topical steroids 17(12) 16(14) 1(3)
Nutritional support 14(10) 10(9) 4(13)
Sulphasalazine alone 16(11) 15(13) 1(3)
Sulphasalazine and 6(4) 5(4) 1(3)
enteral nutrition
Sulphasalazine and 1(0.7) 1(0.9) 0
imtravenous nutrition
Mesalazine 2(1.3) 2(2) 0
S U R G I C A L  T R E A T M E N T T O T A L N B T B T
(n=62) (n=37) (n=25)
Right hemicolectomy 41 (66) 27(73) 14(56)
Right hemicolectomy 2(3) 2(5) 0
and small bowel resection
Small bowel resection 14 (23) 6(16) 8(32)
Subtotal colectomy 5(8) 2(5) 3(12)
(Key : results in parentheses are % of group)
TABLE 6.2
Treatment Regimes for Total NBT and BT Groups
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maintenance therapy between the NBT group (67.5%) and the 
BT group (58.9%) (Table 6.3).
Similar percentage of medically treated patients in both
9
NBT and BT groups were taking maintenance therapy ( X = 
1.07, p > 0.05). Although in the surgically treated
patients there were fewer patients in the NBT group taking 
maintenance therapy (21.6%) compared with the BT group 
(40%), this difference was not statistically significant ( 
X2 =2.45, p > 0.05).
Indications for Surgery
Patients in both NBT and BT groups were equally 
distributed between perforating and non-perforating 
indications for surgery (Table 6.4).
Blood Transfusion
In the BT group patients' mean (sem) tranfusion 
requirements were 3.4 (0.3) units. Table 6.5 shows the
distribution of the number of units per patient and the 
ratio of whole blood to packed cells. Indications for 
transfusion were : correction of anaemia (76.8% : all 31 
medical patients, 12 surgical patients); perioperative 
transfusion (8.9% : 5 surgical patients); and post-
SASP & MES SASP MES
Total group (n=207) 135(65) 116(56)
NBT group (n=151) 102(68) 87(58)
BT group (n=56) 33(59) 29(52)
NBT-MED group (n=114) 94(82) 81(71)
BT-MED group (n=31) 23(74) 20(65)
NBT-SURG group (n=37) 8(22) 6(16)
BT-SURG group (n=25) 10(40) 9(36)
(Key : results in parentheses are % of group;
sulphasalazine; MES = raesalazine)
TABLE 6.3
Maintenance Therapy
19 (9) 
15(10) 
4(7)
13(11) 
3(10)
2(5)
1(4)
SASP
PERFORATING NON-PERFORATING
TOTAL (n=62) 20 (32) 42 (68)
NBT (n=37) 10 (27) 27 (73)
BT (n=25) 10 (40) 15 (60)
(Key : numbers in parentheses are % of groups)
TABLE 6.4
Indications for Surgery
B L O O D  T R A N S F U S I O N  P A T I E N T S  P A C K E D  C E L L S
(UNITS)_____________ (n =  56)__________ / W H O L E  B L O O D
1 1 (2) 1 PC
2 22 (38) 20 both PC
1 both WB 
1 PC/WB
3 10 (18) 9 all PC
1 all WB
4 18 (32) 18 all PC
6 1 (2) All PC
8 1 (2) All PC
9 1 (2) 6PC/3WB
10 2 (4) 1 7PC/3WB
1 6PC/4WB
(Key : PC = packed cells; WB = whole blood; figures in 
parentheses are % of group)
TABLE 6.5
Blood Transfusion Requirements
117
operative transfusion (14.3% : 8 surgical patients).
Disease Activity
BT patients in the total group compared with NBT 
patients had significantly more active disease, assessed 
by the ESR (p<0.01) and serum albumin (p<0.01) (Table 
6.6). The C-reactive protein levels were also slightly 
higher in the BT group (p>0.05). As expected the mean 
(sem) haemoglobin level in the BT group was lower than the 
NBT group [8.8 (0.2) v 11.9 (0.1)] (p<0.01). Similar
differences in disease activity between the BT and NBT 
groups were also found in the medically treated patients
(Table 6.7), but not in the surgically treated patients
(Table 6.8).
Follow-Up Relapse Rate
The cumulative relapse rates for all the patients in
both NBT and BT groups were not significantly different 
(X2=0.05, p>0.05) (Figure 6.1). If only medically treated
patients were analysed, there was a significant decrease 
in the relapse rate in the NBT group (X2=5.42, p<0.02)
(Figure 6.2). The opposite result was found in surgically 
treated patients, as the BT patients had a better relapse 
rate than the NBT patients (X2=6.71, P<0.01) (Figure 6.3).
NBT GROUP________BT GROUP
Haemoglobin (g/dl) 11.9(0.1) 8.8(0.2) *
[n=151] [n=56]
C-Reactive Protein 41.4(4.7) 56(10.8)
(mg/1) [n=58] [n=10]
ESR (mm/h) 43.8(1.7) 57(3.8) +
[n = 1 2 2 ] [n = 4 9 ]
Albumin (g/1) 31.1(0.6) 28.1(0.9) +
[n=71] [n=23]
(Key : * = p < 0.001; + = p < 0.01; results are mean(sem); 
figures in [ ] parentheses are numbers of results)
TABLE 6.6
Disease Activity for Total Group
NBT GROUP_______BT GROUP
Haemoglobin (g/dl) 11.8(0.2) 8.1(0.2) *
[n=114] [n=31]
C-Reactive Protein 43.5(5.6) 64.4(14.1)
(mg/1) [n=49] [n=7]
ESR (mm/h) 42.1(2.1) 67.4 (5.5) *
[n=92] [n=28]
Albumin (g/1) 32.5(1.3) 27.6(0.9) +
[n=56] [n=14]
(Key : * = p<0.001; + p<0.01; figures in [ ] are number 
of results; results are expressed as mean(sem))
TABLE 6.7
Disease Activity for Medically Treated Patients
NBT GROUP________BT GROUP
Haemoglobin (g/dl) 11.8(0.3) 9.5(0.3) *
[n=37] [n=25]
C-Reactive Protein 31 (4.1) 27.7(4.9)
(mg/1) [n=9) [n=7]
ESR (mm/h) 43.5(1.8) 45.9(4.9)
[n=30] [n=21]
Albumin (g/1) 31.8(1.2) 28.9(1.7)
[n=18] [ n=9 ]
(Key;* = p<0.001; figures in [ ] are number of results 
results expressed as mean(sem))
TABLE 6.8
Disease Activity for Surgically Treated patients
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DISCUSSION 
Relapse Rates
This study has shown that blood transfusion does not 
affect the overall cumulative relapse rate for Crohn's 
disease. While medically treated patients who did not 
receive a blood transfusion (NBT-MED group) appeared to 
have a better relapse rate than patients who had received 
blood (BT-MED group), and surgically treated patients who 
had received blood (BT-SURG group) had a better relapse 
rate than surgical patients who had not received blood 
(NBT-SURG group), these discrepancies could be explained 
by differences in disease activity and maintenance therapy 
usage.
Disease Activity
The BT-MED group appeared to have more active disease at 
the time of admission (assesssed by ESR, CRP and albumin) 
then the NBT-MED group, which would be in keeping with the 
lower haemoglobin level and the requirement for blood 
transfusion. Although by definition of the criteria for 
entry into the study each patient had to achieve clinical 
remission, it is possible that the disease activity of the 
BT-MED group had not been suppressed completely and hence 
would be more likely to recur. The percentage of patients 
on maintenence therapy in the medically treated groups was
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similar. While all the BT patients in the total group had 
more active disease, the relapse rates were the same for 
both groups.
The BT-SURG group relapse rate was better than the NBT- 
SURG group. Both groups had similar disease activity 
except that the BT group had lower haemoglobin levels. 
Fewer patients in the NBT-SURG group were on maintenance 
therapy compared with the BT-SURG group. Although the 
difference was not significant, it could have altered the 
long-term cumulative relapse rates. Previous studies, 
however, have failed to show any benefit from maintenence 
therapy following surgery (Wenckert et al., 1978; Summers 
et al., 1979).
Immune Mechanisms
The exact immunological mechanisms explaining the 
different outcomes in transfused patients following renal 
transplant and cancer surgery remain unclear. Creasy et 
al.(1987) have suggested that perioperative blood
transfusion may impair the immunological surveillance of 
micro-metastases at the time of surgery. It is likely that 
there are different immune mechanisms affected by blood 
transfusion during transplant or cancer surgery.
Many different immunological abnormalities have been 
described in Crohn's disease (Elson, 1988). If 
immunological abnormalities varied considerably between 
patients with relatively inactive disease and very active 
disease, the immunomodulating effect of blood transfusion 
could depend on the degree of activity. This study has not 
found this as there were no significant differences 
between the NBT and BT patients in the total group, 
despite the BT group having more active disease.
SECTION IV
A S S E S S M E N T  O F  N E W  E N T E R A L  L I Q U I D  D I E T S
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CHAPTER 7
A STUDY OF NITROGEN UTILISATION, WEIGHT GAIN. FAECAL 
RESIDUE.HEPATIC LIPID CONCENTRATION OF RATS FED WITH NEW 
MODULAR ENTERAL LIQUID DIETS
INTRODUCTION
Elemental Diets and Small Bowel Function
The introduction of elemental diets for nutritional 
support was heralded as a significant advance in the 
management of patients with impaired gastrointestinal 
function (Russell, 1975). Elemental diets, composed of 
amino acids, simple sugars with very little lipid, were 
thought to offer advantages over whole protein and peptide 
diets. Nelson et al. (1981) demonstrated improved small 
bowel villus height and decreased crypt to villus ratio in 
rats fed with the elemental diets Vivonex and Flexical, 
and suggested that these changes resulted from improved 
survival of the mature enterocyte. Although the structure 
of the rat small intestine is altered by elemental diets 
(Nelson et al., 1981), small bowel function, assessed by 
water absorption using a perfusion technique, was not 
changed and in fact was worse with Flexical.
Peptide Diets
Potential advantages of elemental diets for patients 
with malabsorption or maldigestion (Russell, 1975) have 
not been demonstrated by subsequent animal and human 
studies. Silk et al. (1979) showed that normal subjects
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absorbed orally administered mixtures of peptides and 
amino acids with equal efficiency. Elemental diets when 
compared with partially hydrolysed diets (a mixture of 
amino-acids and peptides) have been found to produce less 
weight gain and reduced nitrogen utilisation in rats (Main 
et al., 1984; Nelson et al., 1986; Maxton et al., 1987); 
in primates (Albino et al., 1985); and in patients (Meguid 
et al., 1984; Nasrallah et al., 1984).
Polymeric Diets
Young et al. (1980) compared the whole protein diet, 
Ensure, with the elemental diet, Vivonex, and partially 
hydrolysed diet, Flexical, in an isocaloric feeding study 
of rats over two weeks. Ensure-fed rats had greatest 
weight gain. Recognised disadvantages of elemental diets 
include unpalatability, diarrhoea due to hyperosmolality, 
higher costs and tendency to produce fatty livers (Young 
et al., 1981; Nelson et al., 1986). New modular elemental, 
polymeric whole protein, and peptide diets are available 
and offer greater flexibility of nutritional therapy.
AIMS OF STUDY
The aims of this study were to assess : the nutritional 
efficacy (weight gain, nitrogen utilisation) of the new 
modular diets, in particular the elemental diet, Elemental
124
028; the effect on faecal residue; and the development of 
fatty liver during feeding.
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METHODS
Experimental Design
36 male Sprague Dawley rats were housed separately in
matabolic cages, designed to limit coprophagia, and to 
allow separate collection of faeces and urine. Controlled 
feeding of the diet was possible and the animals were 
allowed free access to water. There were six test diets 
:the contol rat chow (Oxoid, Oxoid Limited, Basingstoke,
UK) ; two elemental diets, Vivonex High Nitrogen (Eaton
Laboratories, Woking, UK) and Elemental 028 (Scientific 
Hospital Supplies, Liverpool, UK) ; two peptide diets, 
Pepdite and MCT Pepdite (Scientifc Hospital Supplies, 
Liverpool, UK) ; and a polymeric diet, Enteral 400 
(Scientific Hospital Supplies, Liverpool, UK).
The composition of the diets is shown in Table 7.1 . The 
diets are prepared using nitrogen, energy, vitamin and
mineral " modjuls " from the SHS range. The peptides used 
for the Pepdite and MCT Pepdite diets are derived from 
hydrolysed non-milk protein and have mean chain lengths 
of 7.7 amino acids and molecular weight distribution of 5% 
> 2000, 9% 1000-2000 and 86% < 1000. L-amino acids are
added to ensure a high biological value. The nitrogen 
source in Enteral 400 is whole protein (98%), derived from 
whey protein. Elemental 028 is composed of crystalline 
essential and non-essential amino acids.
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Each of the test diets were fed in isocaloric amounts 
(62 kcal/day) to 6 rats for 28 days. The diets varied in 
their kilocalorie to nitrogen ratio (Table 7.1), and since 
the rats were fed the same number of calories , a small 
ratio for the Oxoid and Vivonex HN diets indicated a 
relatively high nitrogen intake compared with the other 
diets.
Measurements
1. Body weight was measured every day and expressed as 
weight gain over 28 days as a percentage of starting 
weight.
2. Nitrogen balance was measured throughout the 2 8 days of 
the study. It was defined as the difference between 
nitrogen intake and nitrogen excretion measured by the 
micro-Kjeldahl technique (Fleck & Munro, 1965), on 
aliquots of each diet and on the excreta.
3. Nitrogen wastage, an approximate measure of nitrogen 
utilistaion, was defined as nitrogen excretion as a 
percentage of nitrogen intake.
4. Daily faecal residue was collected and dried, and 
weighed.
5. After 28 days of feeding the animals were sacrificed 
and the livers weighed and frozen for estimation of total
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cholesterol (Abell et al.,1952) and lipid (van der Kamer 
et al., 1949).
Statistical Methods
Numerical data are expressed as mean (sem). Statistical 
analyses were performed using the Student t test and only 
results of p < 0.05 were considered to be significant.
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RESULTS 
Weight Gain
Mean weight gain (% of starting weight) ranged from 40
(3.5)% for the MCT Pepdite (MCT) group to 68 (3.4)% for
the Enteral 400 (E) group (Figure 7.1), and was
signicantly less for the peptide diets P and MCT compared 
with Oxoid (0) (p<0.001), Vivonex HN (VHN) (p<0.001),
Enteral 400 (E) (p<0.001) and Elemental 028 (ELE)
(p<0.001) (Table 7.2). This difference in weight gain 
could be partly explained by the reduction in dietary 
intake (% of diet not consumed) (Figure 7.2) in the P and 
MCT groups compared with the O, VHN, E and ELE groups (all 
p<0.05)(Table 7.2). Reduction in the dietary intake was 
found with all the rats in the P and MCT groups.
Nitrogen Utilisation
Nitrogen balance (mmol/24h)(Figure 7.3) of all the test 
diets was signicantly increased compared with the control 
diet (0) (p<0.001) as was VHN compared with E, ELE, P and
MCT (p<0.001). Although the VHN group had the highest 
nitrogen wastage (nitrogen excretion as % of intake) 
(Figure 7.4), this difference was not significant. All 
test liquid diets had significantly reduced nitrogen 
wastage compared with the control diet, O (p<0.001, Table 
7.2) .
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Faecal Residue
All test liquid diets induced low faecal residue (<6% of 
control feed) (Figure 7.5). The faecal residue was 
significantly increased (p<0.001) in the P group compared 
with VHN/E #ELE and MCT (Table 7.2). The faecal residue in 
the VHN group was reduced significantly (p<0.001) compared 
with ELE, P and MCT but not E.
Hepatic Lipid
Hepatic lipid (Figure 7.6) was significantly increased 
(p<0.05) with the elemental diets VHN and ELE, compared
with the polymeric and peptide diets (E and P) . There was
no significant difference between the elemental diets 
(Table 7.2). The hepatic cholesterol (Figure 7.7),
although elevated in the elemental diets, was not
significantly higher than the other groups except MCT.
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Weight Gain
The weight gain of the rats fed the elemental diets, VHN 
(52(3.3)%) and ELE (53(4.9)%) was lower, although not 
significantly, than the polymeric diet group E (68(3.4) 
%) . Other studies have found reduced weight gain with 
elemental diets (Young et al.,1980; Nasrallah et al.,1984; 
Nelson et al., 19.86). Unexpectedly the peptide diet groups, 
P (41(3.5)%) and MCT (40(3.5)%) had significantly reduced 
weight gain compared with 0, VHN, and E groups. The poor 
weight gain with the peptide diets has not been found with 
other studies (Nasrallah et al., 1984; Meguid et al.,1984; 
Albina et al.,1985) and can be explained by the very poor 
intake of the peptide diets by the rats during the study 
period. The presumed poor palatability of the peptide 
diets would be a disadvantage for human consumption.
Nitrogen Wastage
Elemental diets, comprising of only amino acids, in 
particular Vivonex, have been shown to have poor nitrogen 
utilisation, producing elevation in blood urea and 
increased urinary urea nitrogen (Smith et al.,1982; Jones 
et al.,1983; Meguid et al.,1984; Albina et al.,1985). 
Meguid et al. (1984) suggested that the high glutamine 
content of Vivonex stimulated the urea cycle. However in a 
controlled metabolic study using human volunteers, Albina
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et al. (1985) found that glutamine was not responsible for 
the difference in nitrogen utilisation, which may be due 
to other factors in the Vivonex diet. Main et a l . (1984),
using the technique of neutron activation analysis to 
assess whole body nitrogen, found that Vivonex fed rats
had significantly reduced whole body nitrogen compared 
with Flexical and Clinifeed fed rats, but Vivonex HN fed 
rats had improved whole body nitrogen. In this study I 
found that nitrogen balance was significantly increased 
with VHN compared with the other diet groups, mainly due 
to the high nitrogen content of the VHN group. The
nitrogen wastage (an arbitrary assessment of nitrogen 
utilisation) was higher in the VHN group but not
significantly greater than the other test liquid diets.
Faecal Residue
Elemental and other liquid diets contain no indigestable 
fibre and produce very low stool weight (Russell, 1975). 
This study showed that the faecal residue of the VHN diet 
group was significantly reduced compared with the other 
liquid test diets. Elemental 028, the other elemental diet 
tested in this study, produced a mean(sem) faecal residue 
of 304(8) mg/day (similar to the other peptide and
polymeric diets), and significantly higher than VHN 203
(4.6) mg/day. This difference in faecal residue between 
the two elemental diets and the other diets may be due to
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the carbohydrate composition of the diets. Main et al. 
(1984) have shown that bacteria form the main component of 
the faecal residue of liquid diets, and that feeding with 
Vivonex produces the lowest bacterial content. Vivonex's 
carbohydrate source is glucose which is absorbed in the 
proximal small bowel. The other diets, including Elemental 
028, have more complex carbohydrates and the unabsorbed 
carbohydrate can be fermented by colonic bacteria to 
provide energy for bacterial proliferation (Nyman & 
Asp,1982).
Hepatic Lipid
The hepatic lipid was increased significantly in both 
elemental diet groups compared with all the diets. There 
were no significant differences between the elemental 
diets. Although the hepatic cholesterol was higher in the 
VHN and ELE groups, only the MCT group had hepatic 
cholesterol concentration which was significantly lower. 
Young et al. (1981) found that Vivonex but not Vivonex HN 
produced a significant increase in the lipid concentration 
compared with Flexical, Vital and control rat feed. In a 
study by Nelson et al. (1986), rats which were allowed ad 
libitum access to Vivonex and Flexical developed massive 
increase in hepatic lipid, assessed biochemically and 
histologically. Isocaloric feeding, in the same study, 
produced a lower increase in hepatic lipid. The increase
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in the hepatic lipid with the elemental diets have been
attributed to the high content of easily absorbed
carbohydrate and reduced fat content, which is similar to 
fatty liver production during parenteral nutrition (Lee, 
1988). However Elemental 028 has similar carbohydrate 
source ( although in a higher amount) to the other modular 
liquid diets, although the fat content is lower.
CONCLUSION - Overall Nutritional Efficacy
In conclusion, the new Elemental 028 diet does not offer 
any advantages over Vivonex, and may produce slightly
increased faecal residue. The polymeric diet, Enteral 400, 
performed well, producing the highest weight gain and 
satisfactory nitrogen utilisation similar to Elemental 
028. Both elemental diets produce fatty livers, which
raises some concern over their long-term use. The other 
modular diets do not appear to offer any nutritional 
advantages, and the peptide diets may be less palatable 
than the other diets.
SECTION V
C L I N I C A L  A P P L I C A T I O N  O F  E N T E R A L  N U T R I T I O N  I N  
C R O H N ' S  D I S E A S E
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CHAPTER 8
DOUBLE BLIND CONTROLLED TRIAL OF ELEMENTAL AND 
POLYMERIC DIETS AS PRIMARY THERAPY IN 
ACTIVE CROHN'S DISEASE
INTRODUCTION
Elemental Diet As Primary Therapy
Improvement in disease activity of patients with Crohn's 
disease by dietary methods would be an attractive method 
of treatment: not only is diet more natural than drugs;but 
may also avoid potential side effects and improvement of 
the nutritional state of patients would also be expected. 
In the 1970's several reports were published of the 
possible value of elemental diets in Crohn's disease 
(Voitk et al., 1973; Giorgini et al., 1973; Rocchio et 
al., 1974; Goode et al., 1976; Axelsson & Jarnum, 1977).
Voitk et al. (1973) and Rocchio et al. (1973) reported 
individual patients who received elemental diets for 
nutritional support, and in whom the clinical outcome was 
considerably better than expected. This early success in 
treatment led to the concept of the use of elemental diet 
as "primary therapy" in active Crohn's disease (Voitk et 
al., 1973). Giorgini et al (1973) were the first to 
demonstrate radiological improvement following elemental
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diet in a child with disease affecting the terminal ileum.
However many of the publications have been only case 
reports (Cucchiara et al., 1984; Pfeil et al., 1988) or 
uncontrolled studies (Morin et al., 1982). It was not 
until the middle 1980 's that the use of elemental diet in 
active Crohn's disease was investigated by controlled 
trials (O'Morain et al. , 1984; Saverymuttu et a l . , 1985B;
Sanderson et al., 1987). Most publications have found that 
elemental diets with or without antbiotics are as 
successful as steroid therapy in producing remission of 
disease activity. Although Seidman et al. (1986) found 
that Vivonex was as effective as steroid therapy in 
inducing remission after three weeks treatment, most diet 
treated patients relapsed at an early stage.
Mechanisms of Action of Elemental Diets in Crohn's Disease 
Elemental diets are considered to be hypoallergenic and 
may alter the immunological mechanisms and thus the 
disease activity in patients with Crohn's disease. However 
other mechanisms for the improvement in disease activity 
have been prposed including improvement in immune function 
following correction of malnutrition, alteration of bowel 
flora, and the low residue nature of the diets (Russell, 
1975; Rhodes & Rose, 1986).
Non-Elemental Diets in Crohn's Disease
It is possible, however, that other non-elemental liquid 
diets which are at least of equal nutritional efficacy may 
share the same beneficial effect on disease activity. 
Harries et al. (1983A) have shown in a controlled trial of 
polymeric liquid supplements in a group of malnourished 
outpatients with Crohn's disease that the use of 
supplements have beneficial effects on nutritional 
parameters, immunological tests and disease activity.
These findings were not confirmed by Brignola et 
al.(1983) in a smaller study using the diet Precision. 
Imes et al. (1986) found a less encouraging response in a 
group of patients who were given Ensure, as several 
patients were unable to tolerate the diet due to side- 
effects. In a case report, Fernandez-Banares et al (1988) 
found that a 14 year old boy with small and large bowel 
Crohn's disease responded to a polymeric diet, although he 
had also received metronidazole. However Steinhardt et al. 
(1988) found in six patients with stable Crohn's disease 
fed for a week with lactalbumin or its hydrolysate that 
intestinal protein loss was reduced using the diet with 
the hydrolysate as the nitrogen source.
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AIMS OF STUDY
The aims of this study were to investigate whether an 
elemental diet offered any advantages over a polymeric 
diet in active Crohn's disease and to determine the role 
of improvement in nutritional status on activity of 
Crohn's disease.
PATIENTS AND METHODS 
Patients
Fourteen patients with active Crohn's disease were 
entered into the study, randomly allocated to receive 
either the elemental diet (ED) Elemental 028, or the 
polymeric diet (PD), Enteral 400 (Scientific Hospital 
Supplies, Liverpool, UK) . Seven patients were started on 
each dietary regime. The mean (range) in years for the ED 
group was 33 (15-58) which was similar to the PD group 
38(23-62), as was disease location (Table 8.1).
E D  G R O U P P D  G R O U P
AGE (mean, range) 33(15-58) 38(23-62)
GENDER (F/M) 6/1 7/0
DISEASE LOCATION
small bowel 1 1
ileocaecal 0 1
large bowel 2 1
small and large bowel 4 4
DURATION OF DISEASE
[years, mean(sem)] 5.8(2.9) 2.4(1.4)
(Key : ED = elemental diet; PD = polymeric diet;
ED v PD p > 0.05)
TABLE 8.1
Clinical Details of Study Patients
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The diagnosis of Crohn's disease was made by the usual 
clinical, radiological, endoscopic and histopathological 
criteria. All patients had been admitted to hospital with 
active Crohn's disease which for inclusion into this study 
was defined by the modified Crohn's disease index (MOD 
CDI, see Chapter 3 of this thesis) of greater than 2, with 
at least 2 abnormal laboratory indices for disease 
activity, whcih included ESR, CRP, gastrointestinal 
protein loss, and indium scan activity.
Patients were excluded from the study : if they had
evidence of significant intestinal obstruction, clinically 
evident intra-abdominal sepsis, toxic megacolon; if they 
had received systemic steroids or immunosuppressive agents 
in the preceeding six months; or if they were not willing 
to have enteral nutrition for 28 days. Two patients, one 
in each group, were on sulphasalazine on admission, which 
was continued during the trial.
Disease Activity
A clinical scoring system, the modified Crohn's disease 
index (MOD CDI), was used (see Chapter 3 of this thesis). 
Clinical remmision at the end of the trial was defined as 
a MOD CDI of less than 2.
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Laboratory assessment of disease activity was made by 
:the erythrocyte sedimentation rate (ESR - Westergreen 
method); C-reactive protein (CRP), measured by 
nephelometry (Hyland laser nephelometer); gastrointestinal 
protein loss, using the CrCL3 clearance method (Van 
Tongeren & Reichert, 1966); and autologous mixed leucocyte 
scan ( as descibed in Chapter 5 of this thesis) . The MOD 
CDI was calculated and ESR and CRP measured before, weekly 
during the trial, and at the end of the trial. 
Gastrointestinal protein loss and indium scans were 
performed pre- and post-trial.
Nutritional Assessment
Full anthropometric and biochemical assessment of each 
patient's nutritional status was performed before the 
start of the trial, at weekly intervals during the trial 
and at the end. Anthropometric measurements were taken to 
calculate percentage ideal body weight (% IBW), triceps 
skinfold thickness (TST % standard), and mid-arm muscle 
circumference (MAMC % standard) (Shenkin & Steele, 1978). 
Blood samples were taken for analysis of albumin, calcium, 
phosphate, magnesium, zinc, copper, transferrin, iron, 
vitamins A, E, C, B^, B2, Bg, Bi2/ and red cell folate
(See Appendix 4.1 for laboratory methods). Twice weekly 24
141
hour urine collections were taken for urinary magnesium, 
zinc and nitrogen. Nitrogen balance was calculated as the 
difference between daily nitrogen intake and daily 
nitrogen output (urinary nitrogen plus 3g nitrogen to 
cover faecal and other nitrogen losses) (Shenkin Sc Steele, 
1978). A full dietary history was taken on admission 
before the start of the trial.
Enteral Liquid Diets
The composition of both Elemental 028 (ED) and Enteral 
400 (PD) diets (Scientific Hospital Supplies, Liverpool, 
UK) is shown in Table 8.2. ED is an elemental diet 
containing crystalline synthetic amino acids. It is 
considered to be hypoallergenic as it is free from whole 
protein. The polymeric diet, Enteral 400, is a whole 
protein diet (98% whole protein) derived from whey protein 
isolate, and it is therefore not considered to be 
hypoallergenic. Although the fat sources differ between 
the diets, the carbohydrate (maize based), maltodextrin, 
and the mineral and electrolyte compostion of both are 
similar due to the modular nature of the diets.
Each patient was randomised to receive for 28 days 2.4 
litres per day of either the ED or the PD by nasogastric 
tube, controlled by a pump system (Flexiflo II, Abbott
E L E M E N T A L  028_________E N T E R A L  4 0 0
Total Energy (kcal) 2400 2400
Carbohydrate (g) 467 345
Fat (g) - arachis oil 40 71
- M.C.T. oil - 23
Protein (g)
- whey protein isolate - 69
- amino acids 72 -
Osmolality (mosm/kg) 810 349
( Key ; values per 2.4 litres of diet )
TABLE 8.2
Composition of Enteral Liquid Diets
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Laboratories, Maidenhead, UK) . Each patient was scheduled 
to receive 2400 kcal daily whether in the form of ED or PD 
(Table 8.2). The type of diet was known only to the 
dietetic staff. The double blind nature of the trial was 
achieved by the dietetic staff covering the food reservoir 
with a large plastic bag and wrapping tape around the 
giving sets from the pump. The patients were prevented 
from taking other dietary intake during the 28 day trial 
period, except for tea and coffee without milk.
Statistical Analysis
Most of the indices for disease activity were not 
normally distributed and the Wilcoxon Rank Sum Test was 
used to compare the disease activity pre- and post-trial 
between the two groups and also intra-group analyses. 
Comparison of the nutritiional status was made by the 
Student t test. Follow up of the patients and the time to 
relapse was compared by Chi square analysis with Yates 
correction. All results with p < 0.05 were considered to 
be significant.
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RESULTS
Patients
Ten of the fourteen patients completed 28 days of 
feeding. Three patients in the ED group were withdrawn 
from the trial around 2 weeks and one PD group patient 
between 3 and 4 weeks. The 3 ED group patients were still 
included in the 2 week assessment. The reason for 
withdrawal in all patients was continuing disease 
activity. Dietary and nutritional assessments, and 
assessment of disease activity were made in all patients 
weekly until 4 weeks, or additionally at time of 
withdrawal from the study.
Dietary Intake
Patients in each group had a pre-trial assessment by the 
dietary staff of their calorie and protein intake (Table 
8.3). Five patients in the ED group and 3 patients in the 
PD group had less than 90% of recommended daily intake 
(Passmore et al., 1974). During the trial only one patient 
in each group did not receive the recommended daily 
intake. There were no significant differences between the 
two groups with respect to the dietary intake during the 
study (Table 8.3).
E D  G R O U P P D  G R O U P
Pre-trial assessment of total
daily calorie intake (kcal) 1655(203) 2023(817)
Pre-trial % RDA 71(6) 96(18)
Total daily calorie intake 
during trial (kcal) 2266(87) 2289(75)
Total daily nitrogen intake 
during trial (g) 10.9(0.2) 10.5(0.3)
(Key : all results mean (sem); all ED v PD comparisons 
p > 0.05; ED = elemental diet; PD = polymeric diet)
TABLE 8.3
Dietary Intake of Study Patients
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Nutritionl Assessment
Nutritional assessment was performed on all patients 
pre-trial and weekly during the trial. Very few patients 
were significantly malnourished at entry to the study. 
Only 1 ED and 2 PD patients were less than 80% of their 
ideal body weight, and only 1 ED and 3 PD patients had 
serum albumin of less than 25 g/1. Several patients in 
both groups had minor trace metal and vitamin 
abnormalities. In both groups there was an overall 
improvement in nutritional parameters by the end of the 
trial. Only the patients in the PD group, however, showed 
a significant increase in weight during the trial. Most of 
the improvement in nutritional status had occured by the 
third week. There were no significant differences in the 
biochemical nutritional status between the groups, either 
before, during or after feeding (Table 8.4).
Disease Activity
At the start of the trial there were no significant 
differences between the groups in disease activity by both 
clinical scores and laboratory parameters (Table 8.5). The 
results for post-trial CDI score compared to the pre-trial 
assessment (ED v PD all patients, ED v PD only patients 
who completed 28 days feeding and PD intragroup analysis) 
were significantly improved for the PD group. At the end
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of 28 days feeding 5 (71%) of the PD group were in
clinical remission (CDI < 2) compared with only 2 (29%) of 
the ED group. The other 2 ED patients had improved
clinically with reduction in CDI score from 10 to 3 and
from 6 to 3. There were no other significant differences 
in the other disease activity parameters, either comparing 
each group or pre- and post-trial results for each group.
Of the patients in clinical remission at exit from the 
trial the laboratory parameters of disease activity showed 
that 2 ED patients and 3 PD patients were in remission by 
the "simple" criteria of normal ESR and CRP, but that 1 of 
the ED patients still had an elevated GI protein loss of 
36 ml/24 hours and 2 of the PD patients had indium scan 
scores of 1 or greater. Hence at exit from the trial only 
1 of the ED patients and 1 of the PD patients fulfilled
all the criteria of remission by laboratory parameters 
(ESR < 20mm/h; CRP < 10mg/l; GI protein loss < 25 ml 24h; 
Indium scan score < 1).
Of the patients who completed 28 days of feeding 2 ED 
patients required alternative therapy (1 steroid, 1 
surgery), within a few weeks of stopping the trial and 
were not well enough to be discharged from hospital on 
resuming normal diet. Within 1 year the relapse rates for
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the patients (ED v PD) who completed the trial were 100 v 
66% (p > 0.05).
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DISCUSSION
Diet Trial - Induction of Remission
This prospective controlled double-blind study of 
elemental and polymeric diet in active Crohn's disease has 
shown that the polymeric diet (PD) is as effective as the 
elemental diet (ED) in improving clinical and laboratory 
parameters of Crohn's disease. The polymeric and elemental 
diets given to the patients were of equivalent nutritional 
composition. The only differences being in the 
presentation of the protein source, being whole protein in 
the polymeric preparation and pure amino acids in the 
elemental preparaation.
Although this study demonstrated clinical and laboratory 
improvement in most patients in both dietary groups, a 
complete remission of disease, (as defined by CDI < 2, ESR 
< 20 mm/h, CRP < 10mg/l, GI protein loss < 25 ml/24h, and 
Indium scan score < 1), was only achieved in one patient 
in the elemental diet group and one patient in the 
polymeric diet group. Using less rigid criteria, as have 
been used in previous studies (O'Morain et a l ., 1984;
Saverymuttu et al., 1985B; Sanderson et al., 1986),
clinical remission occured in 5 (71%) of the PD group and 
only 2 (29%) of the ED group. It is not clear why the
remission rates were not as good as these previous 
studies. This may be due to slightly smaller groups,
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different study criteria or be an indication of the true 
therapeutic value of these diets.
Nutritional Assessment
Nutritional assessment showed slight improvement in all 
parameters tested, with a significantly greater increase 
in weight for the PD group. This improvement occurred 
steadily during the treatment period. Patients who had to 
be withdrawn from the study due to continuing or worsening 
symptoms also showed evidence of early nutritional 
improvement.
Ideal Diet Trial
Although other studies using elemental diet in active 
Crohn's disease have been controlled (O'Morain et al.> 
1984; Saverymuttu et al., 1985B; Sanderson et a l ., 1986;
Seidman et al., 1986), they have not been double-blind nor 
has the elemental diet been given by naso-gastric tube 
under close supervision in hospital, as in this study.In 
the previous studies, after a period of stabilisation in 
hospital, usually one week, patients were discharged home 
to continue their elemental diet as sole therapy. 
Observation of the patients' "true diet" is extremely 
important and can only be effectively performed on an in­
patient basis. In this study other dietary intake was not
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accessible to the patients. Very few patients are tolerant 
of an elemental diet by mouth and often it has to given by 
naso-gastric tube, which requires effective hospital 
supervision in the short-term. To accurately assess the 
comparative efficacy of elemental and polymeric diets as 
"primary therapy" in active Crohn's disease, it is 
necessary to use a double-blind controlled model and to 
make sure the diets were given as sole therapy to 
patients.
It is also difficult to assess a controlled trial of 
dietary methods in active Crohn's disease because of the 
variable natural history of the disease, the possibility 
of spontaneous improvement and as the disease 
characteristics vary considerably. Some of these factors 
may have interfered with the results. However, this study 
has attempted to achieve controlled status in that both 
groups of patients had similar disease location and 
disease activity at entry to the study. The small number 
of patients who completed the study is somewhat 
disappointing, but reflects the strict entry criteria, in 
particular the exclusion of patients who had received 
steroid therapy, and the demanding patient co-operation 
for the study.
150
Conclusion
In conclusion, a nutritionally equivalent polymeric diet 
appears to be as effective as an elemental diet in 
improving clinical and laboratory evidence of activity in 
Crohn's disease and inducing remission in some patients.
Improvement occurring in Crohn's disease following the 
use of liquid diets may be a reflection of nutritional 
improvement rather than a specific effect of the diet 
itself. If this is so, polymeric diets, which are easier 
to use and cheaper than elemental diets, may be preferable 
to elemental diets.
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CHAPTER 9
PRACTICAL ASPECTS AND THERAPEUTIC EFFICACY OF HOME
ENTERAL NUTRITION
INTRODUCTION
Home enteral nutrition (HEN) for Crohn's patients was 
introduced for correction of nutritional deficiences 
before elective surgery (Goode et al., 1976). Since then 
the indications for HEN have expanded to cover refractory 
malnutrition, management of the short bowel syndrome and 
growth retardation (Main et al., 1980; McIntyre et al., 
1983). However subsequent reports have included! small 
number of patients, have not included results of long-term 
outcome and have avoided discussion of practical problems 
associated with HEN.
AIMS OF STUDY
The aims of this study were : to investigate the
practical aspects of HEN and in particular all technical 
problems; to document the incidence of complications 
related to HEN; to determine patients' compliance of the 
technique and their impression of any change in their 
life-style produced by HEN; to determine the therapeutic 
efficacy of HEN; to assess the use of the new modular 
liquid diets in HEN.
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METHODS
Patients
Sixteen patients (9 males, 7 females) were included in 
this study. The mean age was 21.9 years, (range 13-44). 
The location of Crohn's disease was confined to the small 
bowel (6), small and large bowel (7) and large bowel alone 
(3). Several patients were taking mineral supplements 
including zinc (4), magnesium (2), iron (5), and copper 
(1), and anti-inflammatory drugs which included 
sulphasalazine (8), mesalazine (1), prednisolone (6), and 
azathioprine (1).
Individual Patient Clinical Summaries
Patient 1 13 year old male who was diagnosed as having 
Crohn's colitis at the age of 12. Despite few 
gastrointestinal symptoms and little evidence of disease 
activity he failed to gain weight and although his height 
was within the 25th centile he was pre-pubertal. He was 
anorexic, consuming only 1650 kcals per day. HEN was 
started to to correct his poor oral intake in an attempt 
to stimulate puberty.
Patient 2 17 year old male who presented in 1986 with 
diarrhoea and was found to have Crohn's disease of small 
and large bowel. He had received steroids with some 
improvement in disease activity but remained underweight 
and anorexic. HEN was started for nutritional support.
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Patient 3 40 year old male who had a right hemicolectomy 
for Crohn's disease in 1976. He required a further small 
bowel resection in 1980 for obstructive symptoms. He was 
subsequently found to have extensive small and large 
bowels disease. He presented in June 1986 with severe 
malnutrition and active disease. HEN was started after a 
period of inpatient intravenous nutrition to continue 
nutritional support.
Patient 4 28 year old female who had extensive small 
bowel Crohn's disease and required small bowel resections 
at the age of 24 and 26. She presented in June 1986 with 
severe anorexia and nutritional deficiency.
Patient 5 This 14 year old male presented with delayed 
stature, weight loss and anorexia in February 1984, and 
was found to have Crohn's disease of the distal ileum and 
proximal colon. Despite anti-inflammatory drug therapy he 
failed to gain weight or height and was started on HEN in 
October 1984.
Patient 6 17 year old female was found to have small 
bowel Crohn's disease in 1985, requiring continuous 
steroid therapy. She continued to have mildly active 
disease and gradually lost weight. HEN was started in 
November 1986 for nutritional support.
Patient 7 30 year old male who required a subtotal
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colectomy for Crohn's disease in 1980. He developed 
abdominal pain in 1986 and was found to have disease 
affecting both small and large bowels. His symptoms 
improved with anti-inflammatory therapy but he failed to 
gain weight. HEN was started in November 1986.
Patient 8 26 year old female who was diagnosed as having 
anorexia nervosa at the age of 16. Subsequently she 
required a panproctocolectomy for severe colonic Crohn's 
disease at the age of 21, and a small bowel resection at 
the age of 22. In 1985 small bowel radiology showed 
disease affecting her mid ileum. By August 1985 she was 
malnourished and HEN was commenced.
Patient 9 25 year old female who had required a right 
hemicolectomy at the age of 20. She re-presented in 1986 
with abdominal pain and diarrhoea and was found to have 
recurrence at the anastomosis. Despite anti-inflammatory 
therapy she failed to improve, but she refused sugery. HEN 
was started in June 1987 for nutritional support.
Patient 10 18 year old male who had required a right 
hemi-colectomy for Crohn's disease at the age of 14, 
followed by small bowel resection two years later. He had 
marked growth retardation. In October 1984 HEN was 
commenced in an attempt to reverse the growth retardation.
Patient 11 16 year old female of normal height who
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presented in 1985 with diarrhoea and was found to have 
colonic Crohn's disease.She required continuous steroid 
therapy and by October 1986 had lost considerable amount 
of weight. HEN was commenced for nutritional support.
Patient 12 15 year old male who presented in February 
1986 with diarrhoea and delayed stature. He was found to 
have Crohn's disease of the distal small bowel and large 
bowel. Steroid therapy improved his symptoms but he failed 
to gain weight. HEN was started in May 1986.
Patient 13 16 year old male who developed abdominal pain 
and weight loss and was found to have small and large 
bowel Crohn's disease in 1987. He was growth retarded and 
HEN was commenced in July 1988 in an attempt to reverse 
this.
Patient 14 44 year old male who had a subtotal colectomy 
for Crohn's disease in 1981. He developed recurrence of 
his Crohn's disease in the large bowel with a colo- 
cutaneous fistula. He was malnourished and HEN was started 
in June 1987 in an attempt to improve his malnutrition and 
heal the fistula.
Patient 15 27 year old female who required a right hemi­
colectomy in 1985 for Crohn's disease. She developed 
recurrence of disease in the neo-terminal ileum and colon 
and became malnourished. She failed to improve with
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steroids, and HEN was started in January 1987.
Patient 16 15 year old female who was found to have
Crohn's disease of the distal small bowel and proximal 
colon in 1986. Steroid therapy improved her symptoms but 
she continued to lose weight. HEN was started in February 
1987 in an attempt to reverse the malnutrition.
The primary indications for HEN were nutritional support 
(10), correction of growth retardation (5) and healing of 
fistula (1) (Table 9.1). Several of the 16 patients had a 
history of previous bowel resections, and 4 patients had 
required two or more resections.
Study Design
Each patient completed a dietary diary card before 
starting HEN and on follow-up. Nursing staff skilled in 
methods of nutritional support instructed each patient in 
the techniques of passing a nasogastric tube, the 
preparation of the enteral liquid feeds and the mechanics 
of the feeding pump. A questionnaire covering all 
practical aspects of HEN was completed in addition to a 
simple sleep diary. Most patients were studied in the 
latter stages of their periods of HEN. All patients were 
followed up regularly and anthropometric indices and
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biochemical screens were checked.
All patients used the Flexiflo feeding system (Abbott 
Laboratories, UK), induing the Flexiflo volumetric 
feeding pump. Patients used Vygon paediatric feeding tubes 
(Vygon UK Ltd) and checked position by aspirating gastric 
fluid.
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RESULTS
Patient training
All patients were trained as inpatients and the time 
taken for training ranged from 1-2 days for 13 (81%)
patients to 7 days for 3 (19%) patients.
Therapeutic Efficacy of HEN
Patients received HEN for a median period of 17 months 
(range 4-54) (Table 9.1). All patients, except patient 7, 
have stopped.
Types of Enteral Liquid Diets and Duration of Infusion
All patients fed themselves overnight. 8 patients used 
Ensure (Abbott Laboratories, UK), 4 patients used 
Elemental 028 (Scientific Hospital Supplies, Liverpool, 
UK) 1 patient used Osmolite (Abbott Laboratories, UK), 1 
patient Enteral 400 (Scientific Hospital Supplies, 
Liverpool, UK), 1 patient Triosorbon (E.Merck Ltd, UK) and 
1 patient Reabilan (Roussell, UK) (Table 9.2). The median 
volume of feed infused per night was 1000 mis (range 750 - 
1500), infused over 10-12 hours (Table 9.2).
Preparation time for HEN
Every patient found that the daily preparation of the 
feed was easy to perform. Time to set up the feed and 
position the nasogastric tube ranged from 5 minutes (2), 
10 minutes (6), 15 minutes (7) to 20 minutes (1). Only 2
patients required assistance from a relative.
P A T I E N T D U R A T I O N  O F  
H E N  (months)
I N D I C A T I O N  
F O R  H E N
R E A S O N  F O R  
S T O P P I N G
R E S U L T
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
21
24
14
9
28
4
54
28
4
30
6
16
30
17
12
6
pre-pub
mal, act dis
post IVN 
maintain weight
mal
GR
mal
mal, SB
mal, SB
mal, act dis
GR, act dis
mal, act dis 
GR
GR, act dis 
fist, mal 
mal 
mal
post-pub
well
weight
loss
well
gro norm
well
well
surgery
well 
gro norm
well
gro norm
gro norm
fist healed
well
well
success
success
failure
success
success
success
success
success
failure
success
success
success
success
success
success
success
(Key : pre-pub = pre-pubertal; post-pub = post pubertal 
mal = malnutrition; act dis = active disease; GR = 
growth retardation; gro norm = growth normal; fist = 
fistula; post-IVN = post intravenous nutrition; SB = 
short bowel)
TABLE 9.1
Therapeutic Efficacy of HEN
PATIENT DIET FREQUENCY 
PER WEEK
VOLUME
(mis)
INFUSION
TIME
(hrs)
1 Ensure 5 1000 10
2 Osmolite 5 1000 10
3 Elemental 028 7 1000 10
4 Elemental 028 7 1500 12
5 Triosorbon 5 1000 10
6 Ensure 7 1250 10
7 Ensure 7 1000 10
8 Elemental 028 4 1200 10
9 Ensure 7 750 10
10 Elemental 028 7 1500 12
11 Ensure 7 1250 10
12 Ensure 5 1000 10
13 Ensure 5 1000 10
14 Reabilan 7 1500 12
15 Ensure 7 750 10
16 Enteral 400 7 1200 10
TABLE 9.2
Enteral Liquid Diets and Infusion Times
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Sleep Disturbance During HEN
Six patients complained of disturbed sleep during HEN/ 
usually due to increased nocturnal arousal due to 
urination (4), defaecation (1) and noise of pump (1).
Problems with Equipment
Four patients complained that the Flexiflo pump was 
heavy for portable use. One of the patients also 
complained of the noise of the pump during sleep.
Complications of HEN
No patients experienced symptoms of cough, wheeze, 
dyspnoea, regurgiation or aspiration of feed. No patient 
required treatment for a chest infection during the 
periods of HEN. All patients felt that HEN was completely 
saf e .
Patients/ Assessment of the Efficacy of HEN
Eleven patients (69%) felt better on HEN which had 
improved their life-style (Table 9.3). Most attributed 
this to inproved daily activity and reduction in hospital 
admissions. Four patients (25%) felt no improvement and 1 
patient (6%) felt worse on HEN.
Dietary Intake During HEN
Before starting HEN the dietary intake from the 
patients' daytime diet was very low with a mean (sem) 
intake of only 1240(70) kcals/day. This represented
P A T I E N T S  B E T T E R  L E S S  I M P R O V E D  I M P R O V E D  N O
L I F E  H O S P  S Y M P T O M S  D A I L Y  C H A N G E
___________ S T Y L E  A D M _______________ A C T I V _____
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
( Key : hosp = hospital; adm = admission; activ 
activity)
F A I L U R E
*
TABLE 9.3
Patients' Assessment of the Efficacy of HEN
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approximately 49% of the RDA. During HEN the daytime diet 
increased a little to 1307(85) kcal/day, but this increase 
was not significant (Table 9.4). The mean (sem) intake 
from HEN was 993(65) kcal/day and this represented 43(3)% 
of the total dietary intake. Despite the use of HEN, 2 
patients failed to receive more than 1900 kcals/day.
Anthropometric Results
The anthropometric results are shown in Table 9.5. The 
mean (sem) increase in weight (kg) was 8.5(1.5), in 
skinfold (TST) was 1.3(0.4) mm, and in mid arm muscle 
circumference (MAMC) 1.7(0.4) cm. Weight increase
expressed as % of pre-HEN weight was 25(3).
Therapeutic Goal
Therapeutic goal was achieved in 14 (88%) patients.
Patient 3 did not maintain his weight on HEN and was 
switched over to home intravenous feeding. Although 
patient 5 relapsed on HEN his growth retardation was 
reversed. Patient 9 continued to have severe disease 
activity and failed to gain a significant amount of 
weight. During their period on HEN none of the patients 
received additional therapy for their Crohn's disease. At 
the end of HEN most patients disease activity had improved 
(see Chapter 11 and Table 11.6).
PATIENTS INTAKE FROM INTAKE FROM TOTAL % OF TOTAL
D A Y T I M E  D I E T  
fkcal /d a v )
H E N  
fkcal /dav)
I N T A K E  
fkcal /dav)
I N T A K E  F R O M  
H E N
1 1650 700 2350 30
2 1480 1000 2180 32
3 800 1000 1800 56
4 650 1500 2150 69
5 1440 700 2140 33
6 1300 1250 2550 49
7 1800 1000 2800 36
8 980 1200 2180 55
9 1260 750 2010 37
10 1340 1500 2840 53
11 1460 1250 2710 46
12 1640 700 2340 30
13 1760 700 2460 28
14 1060 1250 2310 54
15 1180 700 1880 37
16 1460 1200 2660 45
TOTAL 1307(85) 993 (65) 2251(94) 43(3)
( Key : total results expressed as mean (sem) )
TABLE 9.4
Intakes from Daytime Diet and Liquid Diet During HEN
P A T  W E I G H T  T S T  M A M C
vre 3DOSt A vre v o s t A vre v o s t A  .
1 45.1
(71)
61.0
(93)
15.9
(22)
4.8
(38)
6.0
(45)
1.2
(7)
19.3
(76)
21.0
(80)
1.7
(4)
2 50.0
(74)
60.3
(89)
10.3
(15)
11.0
(88)
12.0
(96)
1.0
(8)
20.0
(79)
22.0
(87)
2.0
(8)
3 70.0
(95)
61.2
(83)
-8.8
(-7)
11.5
(92)
7.6 ■ 
(61)
-3.9
(-31)
21.6
(85)
18.4 
(73) (
-3.2
-12)
4 37.0
(74)
43.5
(87)
6.5
(13)
8.4
(51)
9.6
(58)
1.2
(7)
14.1
(61)
16.1 
(69)
2.0
(8)
5 29.0
(54)
41.0
(76)
12.0
(22)
6.0
(48)
9.0
(72)
3.0
(24)
14.4
(57)
18.4
(73)
4.0
(16)
6 41.0
(77)
47.0
(89)
6.0
(12)
10.5
(64)
12.0
(73)
1.5
(9)
18.2
(78)
19.2
(83)
1.0
(5)
7 43.0
(62)
52.0
(75)
9.0
(13)
3.5
(28)
7.3
(58)
3.8
(65)
. 16.5 
(65)
19.8
(78)
3.3
(13)
8 40.0
(65)
48.0
(77)
8.0
(12)
10.0
(61)
11.3
(68)
1.3
(7)
16.4
(71)
18.0
(78)
1.6
(7)
9 44.7
(77)
45.7
(79)
1.0
(2)
8.2
(50)
9.0
(54)
0.8
(4)
15.4
(66)
15.5
(66)
0.1
(0)
10 35.0
(53)
49.0
(70)
14.0
(17)
10.5
(84)
11.2
(98)
0.7
(15)
17.7
(69)
20.2
(80)
2.5
(11)
11 41.0
(82)
48.0
(96)
7.0
(14)
10.1 
(61)
12.0
(73)
1.9
(12)
16.0
(69)
18.0
(78)
2.0
(9)
12 37.0
(56)
52.0
(79)
15.0
(23)
6.0
(48)
10.0
(80)
4.0
(32)
17.6
(69)
20.1
(79)
3.5
(10)
13 29.0
(44)
43.0
(65)
14.0
(21)
5.5
(44)
7.0
(56)
1.5
(12)
16.4
(65)
19.0
(75)
2.6
(10)
14 46.5
(68)
58.0
(86)
11.5
(18)
4.4
(38)
6.1
(49)
1.7
(11)
20.9
(83)
22.4
(89)
1.5
(6)
15 43.0
(80)
47.0
(88)
4.0
(8)
8.0
(48)
7.8 • 
(47)
-0.2
(-1)
18.5
(80)
18.2
(80)
-0.3
(0)
16 30.0
(56)
40.5
(75)
10.5
(19)
4.2
(25)
6.0
(48)
1.8
(23)
15.0
(65)
17.1
(74)
2.1
(9)
[ Key : TST = triceps skinfold thickness; MAMC = mid arm 
muscle circumference; figures in parenthesis are the % of 
IBW or % standard results ].
TABLE 9.5 Anthropometric Details of Individual Patients
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DISCUSSION
This study has shown that the techniques of HEN can be 
easily taught to patients with Crohn's disease. Most of 
the patients mastered the technique within 1-2 days. 
Berezin et al. (1988) have shown similar results in a
group of paediatric patients who were in fact instructed 
at home. Most of the patients did not encounter any major 
practical problems and they all remained complication-free 
during their period of HEN.
The success of HEN can be estimated by both the
patients' assessment of the technique and if the 
therapeutic goals have been achieved. Eleven (69%) 
patients felt better on HEN and only 1 (6%) patient felt
worse. Fourteen (88%) patients were considered to have 
attained their pre-HEN therapeutic goal. In particular, on 
HEN patients gained 25(3)% (mean, sem) of their ideal body 
weight (IBW) compared with their pre-HEN weight and post- 
HEN 50% of patients' weights were > 80% of their IBW
compared with only 19% of patients pre-HEN. Interestingly 
without additional treatment for their Crohn's disease,
most of the patients disease activity improved.
In summary, HEN offers a method of long-term nutritional 
support which does not require extensive training, is
acceptable to patients who require little assistance, and
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is free from complications. The main advantage of HEN 
compared with home intravenous feeding is the ease of 
administration and lack of complications.
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CHAPTER 10
MAGNESIUM DEFICIENCY IN PATIENTS ON HOME 
ENTERAL NUTRITION
INTRODUCTION 
Magnesium and Nutrition
Multiple nutritional deficiencies are frequently found 
in Crohn's disease (Beekan, 1975; Harries & Heatley, 
1983B) . As it is less common for a single deficiency to 
arise, the clinical manifestations from a particular 
deficiency can be masked by other deficiencies and also by 
underlying disease activity. However, the clinical aspects 
of pure magnesium deficiency have been studied using 
metabolic studies on human volunteers (Dunn & Walser,1966; 
Shils, 1969), and include irritability, lethargy, tetany 
and tremor. Cardiac arrhythmias can also arise (Iseri et
al., 1975). The symptoms and clinical signs of magnesium
deficiency can be reversed within hours of repletion
(Shils, 1969).
Magnesium, an essential mineral, is required as co­
factor in at least 300 enzyme systems involved in
intermediary metabolism, including adenosine
triphosphatase (ATP) (Shils, 1988). Only 1% of the total 
body magnesium is in extracellular fluid, the majority is 
distributed in bone (65%), muscle (27%) and other cells 
(7%). Magnesium is absorbed throughout the small bowel.
164
Approximately 30-50% of the ingested magnesium is absorbed 
and subsequently excreted in the urine (Graham et al., 
1960) .
Prevalence of Magnesium Deficiency in Crohn's Disease.
As magnesium is abundant in food magnesium deficiency in 
patients with Crohn's disease is usually seen in 
conditions producing high faecal outputs including severe 
diarrhoea, fistulas and short bowel syndrome. Booth et al. 
(1963) were the first to describe hypomagnesaemia in seven 
patients following small bowel resections, and further 
reports appeared later (Heaton & Fourman, 1965; Gerach et 
al., 1970). Nine of 63 patients (14%) with Crohn's disease 
had low serum magnesium (Beekin, 1975). Main et al. (1981) 
reported that 6 out 17 patients with severe Crohn's 
disease requiring intravenous nutrition had low serum 
magnesium, and 15 patients (88%) had low urinary 
magnesium. In this study magnesium deficiency was severe 
enough to produce symptoms in two patients.
Urinary magnesium excretion was below the normal range 
for Swedish adults in 32% of Crohn's patients who had 
undergone a small bowel resection (Hessov et al., 1983). 
Sjogren et al. (1988), using muscle biopsy intracellular 
analysis and intravenous magnesium infusions, found 
reduced magnesium stores in 30 patients with relatively
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mild disease who were not particularly malnourished.
Assessing Magnesium Status
The variable prevalence rates for magnesium deficiency 
arise due to different patient populations and different 
methods of assessing magnesium status. In human volunteers 
who were made magnesium deficient, urinary magnesium fell 
within seven days of starting a magnesium deplete diet and 
stayed at a low level till repletion (Shils, 1969). Plasma 
magnesium fell more slowly. It is argued that as magnesium 
is an intracellular ion, low plasma levels may 
underestimate the frequency of magnesium deficiency (Lim & 
Jacobs, 1972). Several authors have suggested that tissue 
magnesium levels should be used. However studies have 
shown conflicting results. Abraham et al. (1986) have 
advocated the use of red blood cell and mononuclear cell 
magnesium levels. In another study, Sjogren et al.(1988) 
found that red blood cell magnesium levels of Crohn's 
disease patients who were magnesium deficient did not 
correlate with the other tissue levels including muscle, 
and were the same as normal controls. Only one out of ten 
chronic alcoholics with magnesium deficiency had a low red 
blood cell magnesium (Lim & Jacobs, 1972).
Pure magnesium deficiency in human volunteers is 
associated with normal muscle magnesium levels and Dunn &
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Walser (1966) concluded that the lost magnesium must have 
arisen from bone. This finding was not confirmed by Lim & 
Jacobs study (1972) of ten chronic alcoholics who had low 
muscle magnesium levels but normal bone levels. Alfrey et 
al. (1974) found that muscle magnesium was directly 
related to muscle potassium level and may reflect changes 
in total body potassium rather than an accurate measure of 
total body magnesium.
More recently Holm et al. (1987) and Sjogren et al. 
(1988) have advocated the use of the magnesium load test, 
measuring the muscle magnesium level after an intravenousi 
infusion of magnesium. This test is potentially dangerous 
as it involves an intravenous infusion of magnesium, in 
addition to being time-consuming and complicated. It is 
interesting to note from the study by Sjogren et al. j 
(1988) that the basal urinary magnesium levels were 
statistically lower than the control group. A combination 
of plasma and urinary magnesium levels appears to be 
sufficient to assess magnesium depletion.
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AIMS OF STUDY
The aims of this study were to investigate the magnesium 
intake of patients on home enteral nutrition (HEN), the 
contribution of the magnesium intake from HEN, and their 
magnesium status.
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PATIENTS AND METHODS 
Patients
Nine patients were investigated. There were 5 females 
and 4 males with a mean age of 26 years (range 16-40). The 
extent of their Crohn's disease was confined to the small 
bowel (5), small and large bowel (3), and large bowel 
alone (1). Two of the younger patients had short bowel 
syndrome with high faecal output and had growth 
retardation. All the patients were on overnight feeding, 
receiving between 650-1200 mis over 8-12 hours.
The patients received HEN for a median of 7 months 
(range 2-17 months). The types of enteral liquid diets 
used were Ensure (4 patients) (Abbott
Laboratories,Maidenhead, U.K.), Elemental 028 (4 patients) 
(Scientific Hospital Supplies, Liverpool, U.K.) and 
Triosorbon (1 patient) (E. Merck Ltd, Alton, U.K.).
Assessing Magnesium Intakes and Deficiency
Total calorie and magnesium intakes were calculated from 
dietary assessment of daytime food intake (using the 
Salford University "Microdiet" Computer System), magnesium 
supplements and enteral liquid diets. A 10 ml blood sample 
was taken for serum magnesium and a 24h urine collection 
for urinary magnesium excretion, measured by atomic 
absorption spectrometry. Magnesium deficiency was defined 
as serum magnesium < 0.7 mmol/1 and/or urinary magnesium <
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2 mmol/24h. Magnesium status was determined before 
starting HEN and at follow-up, when magnesium deficient 
patients were allocated to Group 1 and magnesium replete 
patients to Group 2.
Statistical Analyses
Statistical analyses of the differences between both 
groups were performed using the Student t test, and p 
values < 0.05 were considered to be significant.
RESULTS
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Magnesium Status
There were no significant differences in the magnesium 
status of the total patient group between the pre- feeding 
and follow-up assessments (Table 10.1). However, at
follow-up, 4 patients (Group 1) were found to be
biochemically magnesium deficient, although no patient had 
clinical magnesium deficiency (Table 10.2). Two patients 
in Group 1, both with short bowel syndrome and high faecal 
output, had been magnesium deficient before starting HEN. 
Five patients had normal magnesium status (Group 2).The 
diets used for HEN and the magnesium content of the diets
are summarised in Table 10.3.
Dietary Intakes
There were no significant differences in the total 
calorie intake (kcal/day) between group 1 2850(300) (mean, 
sem) and Group 2 3150(400) and in the percentage of total 
calories derived from HEN 34(6) compared with 37(5)%.Total 
daily magnesium intake did not differ significantly 
between Group 1, 19.5(2.6) mmol/24h and group 2, 20.1
(2.1) mmol/24h. However, patients in group 1 had a 
significantly smaller percentage of total magnesium intake 
derived from HEN 32(4)% compared with Group 2 patients 47 
(5)% (p<0.05) (Table 10.4). One patient in Group 1 was
taking magnesium supplements (Maalox, Rorer
P r e  H E N  F o l l o w - u p
S e r u m  M g  U r i n a r y  M g  S e r u m  M g  U r i n a r y  M g
(m m o l  /I ) (m m o l  / 24h ) (mmol / I ) (mmol /2 4 h  )
Total 0.79(0.04) 2.5 (0.3) 0.76(0.03) 2.4 (0.6)
group
Group 1 0.73(0.04) 1.8 (0.2) 0.68(0.04) 1.1 (0.3)
Group 2 0.84(0.06) 2.9 (0.4) 0.82(0.02) 3.4 (0.8)
[ Key : all results mean(sem) ]
TABLE 10.1
Magnesium Status of Study Patients
P r e  H E N  F o l l o w - u p
S e r u m  M g  U r i n a r y  M g  S e r u m  M g  U r i n a r y  M g
___________(mmol / l )_________(m m o l / 2 4 h  ) (mmol /l) (m m o l / 2 4 h  )_
Patients
Group 1
1 0.68 1.3 0.64 1.6
2 0.75 2.0 0.72 0.6
3 0.72 2.1 0.62 0.5
4 0.76 1.8 0.75 1.6
Group 2
5 0.91 3.2 0.88 3.4
6 0.76 4.5 0.79 6.3
7 0.80 2.2 0.79 2.6
8 0.81 2.4 0.78 2.6
9 0.93 2.6 0.87 2.1
TABLE 10.2
Magnesium Status of Individual Patients
G r o u p  1 G r o u p  2 M g  c o n t e n t  o f  d i e t
__________________________ (mmol p e r  1 0 0 0  k c a l )
Ensure (Abbott) 1 3 8.5
Elemental 028 3 1 6.7
(SHS)
Triosorbon - 1 7.5
(Merck)
TABLE 10.3
Enteral Liquid Diets
wao
pHPh Cm
r i O M l O  
CO CM CO
CM r—I i—I CO CD 
^  ^  CD CO IO
0
■a
3 -
M p  bD^ cm
cfl
+->o
H
CD lO 05 CM
CO CO CM 00 
CM CM 1—1 -i—I
t» 00 O  O  CM 
• • * • •
t> in ^  "cf os
H C M H N r t
’S ^o ^
O CM cm
>> O
P  s
0 g
Q  3
CM 05 CO 
• • ♦ ♦
CD 00 t>- CO
cm cm in o  m  
o  in id cd oo
0
•rH
»'d
a.20 0 
V  O' 
03 P Ph
oo oo oo
CM CM CM
o  o  o
r-H r-H 0 0 0
&&£& SP H W W H
U v,—/ s—'Ph
O  CO ^  00 05
P o 
p
Ph 
O 
0 
O
a  *pH
ft Ph
CM
00
CM
O
*0+->
P
0a
0
P Eh W W W W
y  w  v— / *
r* °  ^HO  m  o  i>  h  h
P
CM
£  a
W  g 
ffi w
rtf CD CD
in cd
CD t>
in • m  o  • 
. o  • • o
l>  H  00 OO H
a
■S
0
a)
£
bl
0
0
V  ^  P _0
S CM
0 
r H  ^
ft 2 
ft §p am  w
i i I 00 I I I I I
p
0
Eh
171
Pharmaceuticals, Eastbourne, U.K.)-
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DISCUSSION
Magnesium Deficient Patients
Four patients (44%) on long-term home enteral nutrition 
were found to have biochemical evidence of magnesium 
deficiency, although no patient had signs of magnesium 
deficiency. Two patients in group 1 who were magnesium 
deficient before starting HEN (patients 1 and 4) had short 
bowel syndrome with high faecal output. Only one of these 
patients (patient 4) had been taking magnesium 
supplements. Dietary intake of magnesium is usually well 
above the recommended daily allowance (RDA) (Mineral 
Elements, 1977) of 15 mmol per day. However this study has 
shown that some patients with Crohn's disease who require 
nutritional support have an inadequate magnesium intake 
from their diet. Five of the 9 patients (56%) had 
magnesium dietary intakes of 10 mmol/day or less. The 
inadequate oral intake was corrected by HEN and magnesium 
supplements in 3 of the 5 patients.
Magnesium Intakes
There were no significant differences in the total 
magnesium intakes between the two groups. However the 
percentage of the total magnesium intake from HEN was 
significantly less in Group 1. This may be partly
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explained by the frequent use of Elemental 028 in Group 1 
patients which has a lower magnesium content than the 
other liquid diets. Most patients starting HEN will have a 
precarious nutritional balance. It is important to check 
their magnesium status on a regular basis as the provision 
of HEN may not protect them from magnesium deficiency. 
Many patients on HEN may also require magnesium 
supplements.
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CHAPTER 11
VITAMIN STATUS OF PATIENTS WITH CROHN'S DISEASE 
ON HOME ENTERAL NUTRITION
INTRODUCTION
Vitamin A Deficiency
Vitamin deficiencies can occur in Crohn's disease. 
Vitamin A deficiency has been reported in a few patients 
with Crohn's disease (Russell et al., 1973; Main et al., 
1983), and has attracted some attention due to the effect 
of vitamin A on epithelial cells and the possible 
protective function on gut permeability (Dvorak, 1980). 
The previous studies have mainly involved outpatients with 
relatively inactive disease. Imes et al. (1987) found that 
serum retinal measurements were normal in 13 7 outpatients 
with Crohn's disease, despite 34% of patients taking less 
than the recommended daily allowance for vitamin A. 
Factors commonly found in vitamin A deficient patients 
were extensive small bowel disease and weight < 80% of 
ideal (Main et al., 1983).
Other Vitamin Deficiencies
Other heterogeneous groups of patients with Crohn's 
disease have been found to have deficiencies of folate,
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vitamin B12 / an^ vitamin D (Rosenberg & Bowman, 1983). 
There is little information on complete assessments of 
multiple vitamin deficiencies in Crohn's disease, 
especially in patients with nutritional deficiencies who 
may require long-term enteral nutrition.
Vitamin Content of Liquid Diets
Fortunately the vitamin content of most commercial 
liquid diets used for HEN is much higher than the 
recommended dietary allowances (Shenkin, 1988). Berner et 
al. (1989) concluded that the high vitamin content of the 
commercial diets explained the near normal plasma vitamin 
levels in a group of patients with neoplasias who were 
totally dependent on HEN. It is unknown if the high 
vitamin content of the commercial diets would compensate 
for potential vitamin malabsorption in patients with 
Crohn' disease who are on long-term HEN.
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AIMS OF STUDY
The aims of this study were to assess the vitamin status 
of patients with Crohn's disease before starting HEN, and 
on completion of HEN when they would be expected to be 
nutritionally replete.
PATIENTS AND METHODS 
Patients
Sixteen patients (9 males, 7 females) with mean (range) 
age of 21.9 (13-44) years, were investigated. Full
descriptions of the patients' clinical histories can be 
found in Chapter 9 of this thesis. The site of disease was 
small bowel (6), small and large bowel (7) and large bowel 
alone (3) .
All patients were assessed before starting HEN and at 
the end of their course. Patient 7 was on continuous HEN 
at the time of his follow-up assessment. The mean (range) 
duration of HEN was 21.6 (4-54) months.
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Patients' Diets During HEN
Eight patients were taking Ensure (Abbott Laboratories, 
Maidenhead, UK) as their liquid diet, one patient Osmolite 
(Abbott Laboratories), four patients Elemental 028 
(Scientific Hospital Supplies, Liverpool, UK), one patient 
Enteral 400 (Scientific Hospital Supplies), one patient 
Reabilan (Roussell Laboratories, Uxbridge, UK), and one 
patient Triosorbon (E. Merck Ltd, Alton, UK).
Assessment of Dietary Intakes
Pre- and post-HEN assessments of calorie and vitamin 
intakes were made from the patients' daytime diets using 
the Salford University "Microdiet" Computer System. The 
calorie and vitamin intakes from HEN and from vitamin 
supplements were recorded. Intakes were compared with the 
Recommended Dietary Allowances (Passmore et al., 1974).
Nutritional Assessments
20 mis of blood was taken for measurement of vitamin A, 
E, C, Bi, B2, Bg, B^2/ an^ red cell folate using 
laboratory methods which are summarised in Appendix 4.1. 
Most of the water soluble vitamins were measured using 
enzyme activation analysis (Shenkin, 1988). Serum albumin 
and transferrin were also measured.
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Disease Activity Assessment
Disease activity pre- and during HEN was measured using 
the modified Crohn's disease index (MOD CDI) and the C- 
reactive protein level.
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RESULTS
Assessment of Dietary Intakes
The pre-HEN daytime dietary calorie was low at 1240(70) 
kcal/day [mean(sem)]; which represented 49(4) % of the RDA 
(Table 11.1). During HEN the daytime dietary intake 
increased slightly to 1307(85) kcal/day. The total intake 
on HEN increased significantly to 2251(94) kcal/day (p > 
0.05), which was 90(7)% of the RDA. The mean(sem) 
percentage contribution from HEN was 43(3)%.
Assessment of Vitamin Intakes
Three patients (study numbers 6, 7, 8) were receiving
monthly vitamin B^2 injections and two patients were on 
folate supplements (patients 8, 10). These patients were
excluded from the group analyses of the vitamin B^2 an(  ^
folate levels. The vitamin contents of each enteral liquid 
diets are shown in Table 11.2. The estimated pre- and 
post-HEN vitamin intakes (% of RDA) are shown for 
individual patients in Table 11.3, and summarised for the 
whole group in Table 11.4
Patients 1 and 4 had acceptable pre-HEN vitamin intakes, 
having deficient intakes of only two vitamins (vitamins E 
and Bg). All the other patients in the group took < 90% of
P R E  - H E N D U R I N G  H E N
Calorie intake from 
daytime diet 1240(70) 1307(85)
Calorie intake from 
daytime diet as % RDA
Calorie intake from HEN
Total calorie intake
49 (4)
1240(70)
52 (5) 
993 (65) 
2251(94)
Total calorie intake 
as % RDA
of total diet from HEN
49 (4) 90(7)
43(3)
( Key : results expressed as mean(sem) kcal/day; RDA 
recommended daily allowance )
TABLE 11.1
Daily Calorie Intakes
DIETS
A B C D E F
Calories
(kcal) 1000 1000 1000 1000 1000 1000
Protein
(g) 35 42 30 32 29 40
Fat (g) 35 35 16 39 39 40
Vit A 107 147 107 107 107 67
Vit E 230 320 201 150 210 50
Vit C 510 440 234 333 237 150
Vit B 1 125 133 125 125 125 58
Vit B2 94 100 83 83 83 44
Vit B6 111 122 106 111 106 61
Vit B12 300 340 225 100 225 75
Folic
acid 100 220 104 125 104 100
( Key : Diet A = Ensure; B = Osraolite; C = Elemental 028 
D = Reabilan; E = Enteral 400; F = Triosorbon; all 
values per 1000 ml of diet; vitamin content as 
% RDA)
TABLE 11.2
Nutrient Content of Commercial Liquid Diets
PATIENTS VITAMIN A VITAMIN E
PRE HEN DURING HEN PRE HEN DURING HEN
___________________ Diet HEN Total__________ Diet HEN Total
1 90 M 75
2 64 55 103
3 8 13 107
4 101 106 160
5 84 77 67.
6 40 47 133
7 11 73 106
8 53 53 80
9 40 40 80
10 73 81 160
11 66 80 133
12 60 15 75
13 56 50 75
14 24 20 160
15 36 40 75
16 48 56 128
( Key : results expressed a
underlined )
159 74 10 160 240
158 54 50 224 274
120 10. 2 210 212
266 49 11 300 351
144 32 34 140 174
180 10 11 290 305
179 42 11 230 268
133 13 16 140 156
120 H 32 160 192
241 45 41 300 443
213 13 22 180 302
140 36 30 160 190
125 35 18 160 198
180 10 14 225 239
115 16. 11 160 178
184 30 34 128 166
% RDA; results < 90% RDA are
TABLE 11.3
Vitamin Intakes of Individual Patients
PATIENTS VITAMIN C VITAMIN B}
PRE-HEN DURING HEN PRE-HEN DURING HEN
_________________  Diet HEN Total_________ Diet HEN Total
1 800 960 357
2 460 520 308
3 1240 866 234
4 630 650 350
5 496 530 106
6 660 33 633
7 8 12 506
8 50 63. 280
9 100 113 380
10 363 403 350
11 36. 31 593
12 360 325 357
13 130 125 357
14 20 26 500
15 260 310 357
16 380 415 284
( Key : results expressed as 
underlined )
1317 110 95 88 183
828 80 70 93 163
1100 142 150 125 275
1000 158 142 192 334
636 75 67 42 109
666 75 71 158 229
518 42 50 125 175
343 92 108 92 200
493 25 33 92 125
753 130 142 197 333
630 42 33 158 191
682 76. 84 88 172
482 64 52 88 140
526 33 40 188 228
667 56. 48 M 136
699 82 M 150 234
% RDA; results < 90 % RDA. are
TABLE 11.3 (Continued)
Vitamin Intakes of Individual Patients
PATIENTS VITAMIN B2 VITAMIN B6
PRE-HEN DURING HEN PRE-HEN DURING HEN
___________________ Diet HEN Total___________ Diet HEN Total
1 110 120 66 186 60 45 78 123
2 60 74 70 144 38 46 85 131
3 31 50 13 133 55 45 98 143
4 261 211 122 333 100 75 143 218
5 150 161 31 192 55 70 65 135
6 50 47 118 165 5 8 125 133
7 50 53 94 147 30 40 100 140
8 117 128 16 194 35 40 65 105
9 12 11 71 82 30 35 75 110
10 166 180 128 307 105 120 140 260
11 94 89 118 207 20 20 125 145
12 84 105 66 171 34 44 78 122
13 120 136 66 202 46 30 78 108
14 16. 10 125 135 8 12 167 179
15 66 54 66 110 24 20 78 98
16 84 74 100 174 44 33 127 160
( Key : Results expres sed as % RDA; results < 90 % RDA
are underlined)
TABLE 11.3 (continued)
Vitamin Intakes of Individual Patients
PATIENTS VITAMIN B 12 FOLIC ACID
PRE-HEN DURING HEN PRE-HEN DURING HEN
___________________ Diet HEN Total___________ Diet HEN Total
1 364 320 210 530 108 104 70 174
2 216 182 238 410 M 96 154 250
3 16 10 225 235 126 105 104 201
4 440 380 335 715 171 160 156 316
5 265 275 55 330 65 70. 70 140
6 170 170 375 545 54 55 125 180
7 135 155 300 455 54 60. 100 160
8 145 126 160 286 41 45 73 118
9 8 10 225 235 44 40 75 115
10 295 270 280 550 138 115 156 271
11 120 120 375 495 37 42 125 167
12 180 264 210 474 53 62 70 132
13 235 265 210 475 76 82 70 157
14 21 45 150 195 28. 34 188 222
15 125 118 210 328 36 49 70 119
16 164 185 270 455 56 74 125 198
( Key : Results expressed as % RDA; Results < 90% RDA are 
underlined )
TABLE 11.3 (continued)
Vitamin Intakes of Individual Patients
V I T A M I N S P R E - H E N  D U R I N G  H E N
___________ D a v t i m e  D i e t____ H E N _____ T o t a l
Vitamin A 57(6)
[88]
59 (6) 
[94]
107 (8) 
[50]
166 (9) 
[0]
Vitamin E 32 (5) 
[100]
40 (5) 
[100]
203(15) 
[0 ]
243 (20) 
[0]
Vitamin C 375(85)
[25]
292 (76) 
[25]
378(41)
[0]
670(69)
[0]
Vitamin 80(10)
[69]
80(10) 
[69]
122(12) 
[31]
202(17)
[0]
Vitamin B2 92 (16) 
[56]
93(15) 
[56]
87 (7) 
[56]
180(16)
[6]
Vitamin Bg 43(7)
[87]
42 (7) 
[93]
102 (8) 
[50]
144 (11) 
[0 ]
Vitamin B 12 182(30) 
[19]
181 (27) 
[19]
239 (21) 
[6]
420(35)
[0]
Folic acid 73(10) 
[75]
75(9)
[69]
108(10)
[44]
183(15) 
[0]
( Key : intakes expressed as mean(sem) % RDA; results 
in [ ] parentheses are % of total group with 
intake < 90% RDA )
TABLE 11.4
Daily Intake of Vitamins for Total Group
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the RDA of three or more vitamins. The poorest intakes 
were for vitamins A, E, Bj_, Bg, and folate, in particular 
vitamins A and E (none of the group had normal vitamin E 
intakes) . Intakes for vitamins B12 and C from the daytime 
diet were well within the RDA.
The vitamin intakes from HEN alone were above the RDA 
for vitamins C and E for the whole group, and for vitamin 
B12 in 15 patients. Patient 5 had a low vitamin B12 intake 
from HEN as the liquid diet he was on (Triosorbon) has a
low vitamin B^2 content. On HEN the vitamin intakes for
all the patients were normal, and in most cases much 
higher than the RDA, except for one patient who had a low
intake (82% of RDA) for vitamin Bi2 *
Assessment of Vitamin Status
The pre- and post-HEN vitamin status of individual 
patients is shown in Table 11.5, and summarised in Table 
11.6. Pre-HEN, patients had low levels for only vitamins 
A, E and C. This was partly due to poor dietary intakes 
for these vitamins (Table 11.4), but the correlation 
coefficient for vitamin intakes and status was rs=0.44 ( p 
> 0.05) .
HEN corrected the deficiencies in all but two patients -
PATIENTS VITAMIN A VITAMIN E VITAMIN C
(1.0-2.8 umol/1) (14-39 umol/1) (11-114 umol/1)
P r e P o s t P r e P o s t P r e P o s t
1 1.0 1.1 17 20 73 50
2 2.1 1.8 29 40 20 82
3 1.2 0.5 11 4 10 10
4 0.9 3.1 26 65 45 82
5 1.2 1.3 22 24 36 21
6 1.4 2.7 25 51 85 29
7 0.6 2.0 6 22 10 46
8 0.4 1.7 1 4 80 40
9 1.6 1.7 29 28 50 30
10 0.6 1.1 20 21 26 26
11
00o 1.4 12 19 38 42
12 0^9 1.7 36 30 29 71
13 0.9 1.3 40 32 15 63
14 0.6 1.4 23 16 46 54
15 0.8 2.0 22 42 17 30
16 0.9 1.1 34 30 37 45
( Key : normal values in parentheses; results under­
lined represent deficient values )
TABLE 11.5
Vitamin Status for Individual Patients
PATIENTS VITAMIN B± VITAMIN B2 VITAMIN B6
(<25% act) (<60% act) (<150% act)
P r e P o s t P r e P o s t P r e P o s t
1 <2 8 14 9 60 97
2 3 4 9 2 14 29
3 36 8 23 23 47 13
4 3 10 15 8 30 35
5 8 12 8 28 63 52
6 12 2 19 2 65 32
7 6 5 32 27 42 32
8 13 6 12 ■ 15 17 36
9 6 2 32 11 42 21
10 16 8 46 30 32 33
11 12 10 44 30 60 34
12 7 10 8 16 58 38
13 4 3 36 12 80 46
14 2 14 30 9 57 45
15 9 15 40 15 98 101
16 19 15 21 18 72 60
( Key : normal values in parentheses )
TABLE 11.5 (continued)
Vitamin Status for Individual Patients
PATIENTS V I T A M I N  B 12 
( 1 5 0 - 7 3 0  p g / m l )  
P r e P o s t
R E D  C E L L  F O L A T E  
( 1 0 6 - 6 1 4  p g / m l ) 
P r e_______P o s t
1 412 459 164 195
2 427 550 401 384
3 198 330 154 273
4 158 695 447 410
5 364 316 270 240
6 * 1008 900 299 285
7 * 730 672 265 335
00 * + 2238 2460 >1000 >1000
9 730 425 265 260
10 + 180 400 >1000 >1000
11 346 285 500 460
12 312 243 351 266
13 509 680 249 449
14 392 172 316 345
15 534 407 604 368
16 240 305 240 300
( Key : normal values in parentheses; * = patient on 
Vitamin B12 supplements; + = patient on folate 
supplements )
TABLE 11.5 ( continued )
Vitamin Status for Individual Patients
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patient number 3 who failed on HEN and required
intravenous feeding, and patient 8 who remained low in 
vitamin E. While the intakes of the other vitamins (B^,
B2/ Bg, B 12/ anc  ^ folate) were low before starting HEN,
all the patients had normal plasma vitamin levels.
For the whole group only the pre-HEN vitamin A level 
[mean(sem)] was low [0.9(0.1) umol/1]. The post-HEN
vitamin A level [1.6(0.2)] is significantly increased (p < 
0.001). Similarly the pre-HEN serum albumin [31.6(0.9) 
g/1 ] and transferrin [ 1.9(0 .1)g/1 ] levels were
significantly reduced compared with the post-HEN results, 
38.2(1.5) (p<0.001) and 2.7(0.2) (p<0.001) respectively
(Table 11.6) .
Disease Activity
The mean(sem) pre-HEN and post-HEN CRP levels were 
31.3(6.0) mg/1 and 16(3.3) mg/1 respectively (Table 11.6). 
Similarly the median(range) MOD CDI scores were 4(0-7) and 
0(0-4). Both CRP and the MOD CDI scores indicated 
significant improvement whilst on HEN.
P R E  ~ H E N P O S T  ~ H E N
Vitamin A
(1.0-2.8 umol/1)
Vitamin E
(14-39 umol/1)
Vitamin C
(11-114 umol/1)
Vitamin
(< 25% activation)
Vitamin B2
(< 60% activation)
Vitamin Bg
(< 150% activation)
Vitamin B 12
(150-730 pg/ml)
Red cell folate 
(106-614 pg/ml)
Serum albumin 
(40-52 g/1)
Serum transferrin 
(2-4 g/1)
C-reactive protein 
(< 10 mg/1)
MOD CDI 
(0)
0.9 (0.1) 
[63]
22.2 (2 .6) 
[25]
38.6 (5.9) 
[13]
9.9 (2.2) 
[0]
24.3 (3.3) 
[0]
52.3 (5.6) 
[0]
375 (60) 
[0]
333 (30) 
[0]
31.6 (0.9)
1.9 (0.1)
31.3 (6)
4 (0-7)
1.6
28
45.1
8.3
15.9
44
415
336
38.2
2.7
16
0.2)
6 ]
0.2)
13]
5.3) 
6 ]
1.1)
0 ]
2.3) 
0]
6.1)
0]
54)
0 ]
20)
0 ]
1.5)
0.2)
3.3)
0-4)
( Key : All results are mean(sem), except median(range) 
for MOD CDI; figures in [ ] parentheses represent 
% of total group with subnormal levels; results 
pre and post HEN * = p<0.01; + = p<0.001 )
TABLE 11.6
Pre and Post HEN Results for Vitamin Status and Disease
Activity for Total Group
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Correlation Between Vitamin A and Disease Activity
There was poor correlation between the pre-HEN vitamin A 
levels and pre-HEN serum albumin (rs=-0.12/ p=0.68), serum 
transferrin (rs=0.2/ p=0.52)/ CRP (rs=0.21/ p=0.56), and
the MOD CDI (rs=0.28/ p=0.29). The correlation was equally 
poor between vitamin A and the disease activity indices in 
the post-HEN period - serum albumin (rs=-0.05, p=0.86)/
serum transferrin (rs=0.19/ p=0.51), CRP (rs=-0.49,
p=0.053), and MOD CDI (rs=-0.33, p=0.21).
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DISCUSSION
Vitamin Intakes
Most of the patients in this study had low intakes of 
vitamin A, E and folate in the period before starting HEN. 
After supplementation with HEN, the vitamin intakes 
increased considerably and were above the RDA except for 
one patient who continued to have a low vitamin Bg intake.
Vitamin Status
Despite the low dietary intake of vitamins before HEN, 
the plasma vitamin levels were remarkably normal except 
for vitamins A, E and C. There were significant increases 
in the plasma levels for vitamins A and B2 after HEN. 63% 
of patients had low vitamin A levels before starting HEN. 
Although the low vitamin A levels could be partly 
explained by reduced retinal binding protein levels (which 
were not measured in this study), secondary to the acute 
phase response of active Crohn's disease (Shenkin, 1988), 
there was not a strong correlation between the vitamin A 
levels and serum albumin, transferrin and indices of 
disease activity. It is likely that some of the patients 
had true vitamin A deficiency.
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Vitamin Content of Liquid Diets
The marked improvement in vitamin intake during HEN was 
due to the high vitamin content of the enteral liquid 
diets (Table 11.2). The vitamin contents of even 1000 ml 
of most of the diets are much higher than the RDA : with 
the exception of most of the vitamins in Triosorbon, the 
B2 levels in Elemental 028, Enteral 400 and Reabilan.
SUMMARY
Vitamin status was assessed for 16 patients on HEN. 
Despite low intakes of most vitamins especially A, E and 
folate, plasma vitamin levels were generally within the 
normal range. The pre-HEN plasma vitamin levels for 
vitamin A and B2 were low and improved with HEN. Home 
enteral nutrition is an effective method of correcting 
poor dietary vitamin intakes.
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CHAPTER 12
RESPONSE OF GROWTH RETARDED ADOLESCENTS WITH CROHN'S 
DISEASE TO HOME ENTERAL NUTRITION
INTRODUCTION
Prevalence of Growth Retardation in Crohn' s Disease
Crohn's disease in childhood and adolescence can be 
complicated by growth retardation and delayed puberty. 
Although this problem was recognised in early reports of 
Crohn's disease (Tanner, 1939), it is only recently that 
studies have found the prevalence to be as high as 17-33% 
(McCaffrey et al., 1970; Gryboski & Spiro, 1978; Puntis et 
al., 1984). The clinical significance of growth 
retardation in Crohn's disease is emphasised by the 
inclusion of a section of assessing growth in Lloyd- 
Still 's index for disease activity in children (Lloyd- 
Still et al., 1979 : see Appendix 2.6).
Aetiology of Growth Retardation
While McCaffrey et al. (1970) found abnormalities in 
growth hormone secretion, later studies have failed to 
demonstrate significant abnormalities (Gotlin & Dubois, 
1973; Layden et al., 1976; Tenore et al., 1977; Kelts et 
al., 1979; Kirschner et al., 1981A), and if present are
thought to be unrelated to the under-lying disease 
activity (Farthing et al., 1981).
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The use of steroids has been implicated as a cause of 
growth retardation. However Layden et al. (1976) found 
that several children treated on long- term steroids had 
normal growth, and Block et al. (1977) commented that 
many growth retarded children had never been treated with 
steroids.
Malnutrition is now regarded to be the prime cause for 
the growth retardation (Kirschner et al., 1981A). Although 
children with Crohn's disease have been found to have 
absorptive defects (Kirschner et al., 1978), poor oral 
intake is the main reason for the malnutrition (Layden et 
al., 1976; Kelts et al., 1979; Kirschner et al., 1981A).
There have been recent reports on the reversal of growth 
retardation in children with Crohn's disease treated by 
improved oral diet (Werlin, 1981; Kirschner et al., 
1981A); short course of elemental diet (Morin et al., 
1980); and intermittent elemental diet for one year (Belli 
et al., 1988).
AIMS OF STUDY
The aims of this study were to determine the efficacy of 
HEN in reversing the growth retardation in adolescents 
with Crohn's disease, and to assess if polymeric diets 
were as successful as elemental diets.
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PATIENTS AND METHODS 
Patients
Five male adolescent patients with Crohn's disease were 
recruited into this follow-up study. Their demographic 
details are described fully in chapter 9 (patients 1, 5,
10, 12, 13) . Their mean age was 15.2 years (range 13-18),
and disease was confined to small bowel (1), small and 
large bowel (3) and large bowel alone (1) (Table 12.1). 
Two patients were taking steroids, three were on 
sulphasazine or mesalazine and two were on iron and other 
mineral supplements. All had been taking medical therapy 
for at least 4 months.
All patients had significant growth failure with 
evidence of linear growth arrest or reduced linear growth 
(<4 cm/year), and/or bone age delay of greater than two 
years.
Nutritional Assessment
Previous heights and weights were recorded, and at 
clinic visits anthropometric measurements and assessments 
of pubertal development were made (Tanner et al., 1975). 
An X-ray of the left wrist was taken at the start of the 
feeding to assess the bone age. A full dietary history was 
assessed and a dietary card completed over three days 
before starting HEN.
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Nutritional Support
All patients received inpatient instruction, and within 
1-2 days were able to self intubate using a fine bore 
nasogastric tube (Vygon UK Ltd) and able to set up the 
pump with feed reservoir for overnight feeding. The 
enteral liquid diets were Ensure (3) (Abbott Laboratories, 
Maidenhead, UK), Elemental 028 (1) (Scientific Hospital
Supplies, Liverpool, UK), and Triosorbon (1) (E. Merck
Ltd, Alton, UK). (Table 12.1) The type of diet was 
determined by individual preference. Patients were 
followed up for at least 6 months post HEN.
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RESULTS
Nutritional Support
The patients were on HEN for a mean (range) duration of 
25 (16-30) months. Before starting HEN the mean (sem)
daily dietary intake was 1526 (99) kcals, which
represented only 56.6 (2.8) % of the recommended dietary 
allowance. Whilst on HEN the supplemented intake was 860 
(160) kcal/day (Table 12.1), although most of the 
patients took around 7 00 kcal/night. The intake from HEN 
was 34.8 (4.6) % of the patients' total daily intake of 
2426 (115) kcals, which represented 87(3.3) % of the
recommended daily allowance (Passmore et al., 1974).
Reversal of Growth Retardation
The changes in weight, height and pubertal development 
are shown in Table 12.2. Patient l's main indications for 
HEN were to correct his malnutrition and to reverse the 
delayed puberty. His growth velocity for the previous year 
had been slightly low at 4 cm/year, but on starting HEN he 
was at the 97th percentile for height (Figure 12.1). 
During his period on HEN he grew a further 9 cms. Although 
during HEN he gained 18 kg in weight over 2 years, he 
remained at the 75th percentile (Figure 12.2). His 
pubertal development progressed from 2+ to 5.
Patient 5 was markedly underweight , with short stature.
PATIENTS 10 12 13
S+L
1
16
12
0.5
1760
61
Site of Disease L S+L S
Duration of 1 0.5 4
disease (years)
Chronological age 13 14 18
(years)
Bone age (years) 11 11 14
Pre-HEN growth 4 0 0
velocity (cra/yr)
Pre-HEN daytime 1650 1440 1340
diet (kcal/day)
Pre-HEN daytime 63 55 47
diet as % of RDA
Liquid diet Ensure Triosorbon E028
Calorie intake 700
from HEN (kcal/day)
Total calorie 2350
intake during HEN 
(kcal/day)
% of total intake 30 
from HEN
Total diet as 
of RDA
89
700
2140
33
81
1500
2840
53
99
S+L
0.3
15
12.5
1
1640
57
Ensure Ensure 
700 700
2340
30
81
2460
28
85
(Key : L = large bowel; S - small bowel; E028 = Elemental 
028; RDA = Recommended Dietary Allowance)
TABLE 12.1
Patients' Demographic Details and Dietary Intakes
P A T I E N T S 1 5 10 12 13
HEIGHT
Pre-HEN 165 (97) 138(<3) 144(<3) 149(<3) 153(<3)
6 months 169(90) 142(<3) 148(<3) 151(<3) 161(<3)
12 months 170(90) 144(<3) 150(<3) 153(<3) 166(10)
18 months 171(90) 146(<3) 154(<3) 156(<3) 168(10)
24 months 172(75) 149(<3) 160(<3) - 169 (25)
30 months - 150(<3) 163(3) - 173(25)
6 months 
post HEN
174(75) 154(<3) 165(10) 160(3) 175(50)
WEIGHT
Pre-HEN 45.1(75) 2 9 (<3) 3 5 (<3) 37 (<3) 2 9 (<3)
6 months 50(75) 3 7 (<3) 44(<3) 41 (<3) 40.5(<3)
12 months 53.7(75) 39(<3) 44.5(<3) 47 (<3) 4 0 (<3)
18 months 60(75) 41(<3) 46 (<3) 52(10) 41(<3)
24 months 61(75) 42(<3) 50.5(3) - 41 (<3)
30 months - 4 1 (<3) 49(<3) - 4 3 (<3)
6 months 63(75) 
post HEN
PUBERTY RATINGS
48(3) 52 (3) 54(10) 46 (<3)
Pre-HEN 2+ 2 3 2 2
6 months 2+ 2 3 2 2
12 months 3 2 4 3 3
18 months 4 3 5 4 3
24 months 5 4 5 - 4
30 months - 4 5 - 4
6 months 
post HEN
5 5 5 4 4
(Key : numbers in 
cm; weight in
parentheses 
kg.)
are percentiles; height in
TABLE 12.2
Height Weight and Puberty Ratings
cm
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FIGURE 12.1
Height and Pubertal Development Chart for Patient 1
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FIGURE 12.2
Weight Chart for Patient 1
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He increased his height by 12 cm whilst on HEN for 30 
months (Figure 12.3), although still remaining below the 
3rd percentile. His weight initially increased on HEN but 
then plateaued at around 40-41 kg (Figure 12.4). At the
latter stages of his period on HEN he developed
obstructive symptoms and required a right hemicolectomy. 
Following this resection he gained a further 7 kg in 
weight, with an increase in height. His pubertal 
development was delayed until his weight had climbed to 
around 40 kg. Even following his resection his height 
remained below the 3rd percentile, despite a growth
velocity of 5-7 cm/ year. He refused further HEN at that
stage. Fortunately during the 18 months post resection he 
had achieved catch up height and had reached the 10th 
percentile.
Patients 10, 12 and 13 were all similar with pre-HEN
heights and weights below the 3rd percentile. After a 
period of HEN all managed to undergo reversal of their 
growth retardation, and were within their 3rd and 10th 
percentile for age. Patient 13's weight continued to be 
below the 3rd percentile despite an increase of 14 kg. The 
improvement in growth continued after HEN was stopped 
(Figures 12.5 to 12.10).
The summaries for the changes in weights, heights and 
pubertal developments are shown in Table 12.3. The mean
PATIENTS_________1__________ 5_________10_________12
Increase in 7
height (cm)
Increase in 17.9 
weight (kg)
Growth vel 4
before HEN 
(cm/yr)
Growth vel 3.5
on HEN (cm/yr)
Change in +3
pubertal score
(Key : vel = velocity)
16 19 7
19 17 15
0 0 1
6.4 7.6 4.7
+3 +2 +2
TABLE 12.3
Increase in Height. Weight and Pubertal Development 
During HEN
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Weight Chart for Patient 5
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Height and Pubertal Development Chart for Patient 10
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(sera) increase in height was 13.8 (2.9) era, and in weight 
was 16.6 (0.9) kg. Patients on HEN had a growth velocity
of 6.1 (0.9) cm/year, compared with the pre-HEN growth
velocity of 1.1 (0.7) cm/year. The pubertal development
progressed by 2.4 (0.3).
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DISCUSSION
Reversal of Growth Retardation
This study has shown that growth retardation and delayed 
puberty in patients with Crohn's disease can be reversed 
with additional dietary intake using HEN. All patients 
before starting HEN had very low mean (sem) dietary 
intakes of only 1526 (99) kcal/day, which represented 56.6 
(2 .8)% of their recommended intakes for age and height 
(Passmore et al., 1974). Using a modest increase in 
dietary intake at 860 (160) kcals/day from HEN , the mean 
(sem) total dietary intake rose to 87(3.3)% of the 
recommended intake.
The total calorie intake in this study was lower than 
reported by Kelts et al. (1979), who fed their patients 75 
kcal/kg/day by a combination of oral diet and intravenous 
feeding (mean intake of 136% of expected dietary intake), 
and by Werlin (1981), who gave 3000 kcal/day via enteral 
nutrition to two patients. Kirschner et al. (1981A), using 
supplemented oral diets, increased their patients' dietary 
intakes from 56% of the recommended intake to 91 % ( a n  
increase from 1535 to 2493 kcal/day) and found a good 
response. The dietary intakes from the study by Kirschner 
et al. (1981A) were similar to my results. It is unlikely 
that many patients would be able to tolerate more than 
3000 kcals/day using oral diets and supplemented HEN.
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Catch-Up Growth
Of the four patients who had marked growth retardation, 
only one patient (patient 13) managed to attain an 
increase in height to the 50th percentile. The other 
patients remained in the 3rd-10th percentiles. There has 
been concern over the possible inability of therapeutic 
modalities, including surgery (Homer et al., 1977) and HEN 
(Werlin, 1981), to correct for the "catch-up" growth in 
growth retarded Crohn's patients, especially following 
puberty.Patient 5 in this study remained below the 3rd 
percentile after stopping HEN and also following surgery, 
but within the next eighteen months his height had reached 
the 10th percentile. Kirschner et al. (1981A) also found 
that several patients were able to reach their pre-illness 
height percentile.
It is unlikely that the improved growth in this study 
arose from the onset of puberty, as the reversal of growth 
retardation occurred at an earlier stage compared with the 
pubertal development.
In the 1970's surgical resection was considered to be 
the best form of treatment for growth retardation in 
Crohn's disease (Block et al., 1977). Later, when evidence 
that poor calorie intake was the main factor in the 
aetiology of growth retardation, intravenous feeding was
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attempted with success (Layden et al., 1976; Kelts et al., 
1979). Subsequent studies (Werlin, 1981; Kirschner et al., 
1981A) and this study, have shown that additional calorie 
intake in the form of HEN can produce equally good 
results. Belli et al. (1988) have also shown that
intermittent HEN therapy (1 month out of 4 months) using 
elemental diets can improve growth retardation.
Polymeric Diets
Although several studies have used elemental diets 
(Kirschner et al., 1981A; Belli et al., 1988) for reversal 
of growth retardation, this study and others (Werlin, 
1981; Kirschner et al., 1981A) have shown comparable
results with polymeric diets, which are generally easier 
to tolerate and are less expensive. The most important
factor to correct growth retardation and delayed puberty 
in adolescents with Crohn's disease appears to be the
requirement to rectify reduced calorie intakes.
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SUMMARY
Five male adolescents with Crohn's disease, complicated 
by short stature and delayed puberty, received HEN for a 
mean period of 25 months, in an attempt to correct poor 
oral dietary intakes. All responded to HEN although three 
patients demonstrated poor "catch-up" growth and remained 
below the 10th percentile for height.
SECTION VI
C O N C L U S I O N
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CONCLUSION
The principle aims of the thesis have been achieved : 
links between Crohn's disease activity and nutritional 
problems were studied; in particular malnourished patients 
were found to be able to mount an appropriate acute phase 
response; and enteral nutrition improved disease activity, 
both in the short term and also during periods of long­
term home enteral nutrition.
It was not my intention at the start of these studies to 
identify the ideal, "gold standard" method of assessing 
Crohn's disease activity : this task may be completely
impractical and even inappropriate for Crohn's disease, 
which has so many heterogeneous features. Further, while I 
had not planned to create a new index for assessing 
disease activity, I was interested in determining which of 
the present routine indices and tests were suitable for 
use in diet trials, and for patients with stomas.
The modified Crohn's disease index (MOD CDI), appeared 
to be the most flexible index for my studies, and should 
provide an accurate assessment for all types of patients 
and in different clinical conditions. This index, in 
addition to the CRP level should be able to provide an 
adequate assessment of disease activity.
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I found that the standard indium-oxine mixed leucocyte 
scanning provided very little additional information and 
feel that it has a limited role in the assessment of 
disease activity. At the start of these studies I was 
unable to include faecal indium excretion as a method of 
disease activity assessment. While Saverymuttu et al. 
(1986C) have suggested that faecal indium excretion may be 
the "best" method of assessing bowel inflammation, its use 
is limited by the complicated technique, difficulty of 
stool collection and inability to perform serial 
estimations.
I was disappointed with the small number of patients in 
the diet trial, which is a recognised problem with such a 
trial. Both polymeric and elemental diets appeared to 
improve disease activity, with Enteral 400 having a better 
overall remission rate. However, I suspect that several 
patients had not entered full remission , which led to 
early relapse.
The results of the long-term home enteral nutrition 
studies were more encouraging, in that most patients 
showed an improvement in disease activity and reduction in 
the rate of hospital admissions whilst on HEN without 
additional therapy. This improvement seemed to persist for 
6 months or longer in most cases. As the improvement was
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more marked with patients on long-term enteral nutrition, 
it is likely that the main effect was due to an improved 
nutritional state, which would not have been so marked 
with the shorter diet trial. Future diet trials may have 
to concentrate on longer term feeding.
Nutritional problems and Crohn's disease are so 
inextricably linked that every patient with Crohn's 
disease should be considered at risk and nutritional 
support, in its simplest form, commenced at an early stage 
and maintained for a long period. Hopefully easier 
management of Crohn's disease patients would result, and 
emaciated patients with Crohn's disease would become 
rarities.
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APPENDIX 2.1
WILLOUGHBY INDEX
CLINICAL FEATURES 
Lassitude 
Nausea
Abdominal pain 
Rectal bleeding 
Wound sepsis 
Fistula 
Anal disease 
Arthropathy 
Skin rash 
Mouth ulcers 
Ocular inflammation 
(graded 0-3 where 0 = absent; 1 = mild, no limitation of 
activities; 2 = moderate, some limitations of activities; 
3 = severe, considerable limitation of activities )
STOOL FREQUENCY 
Graded 0 - 2
LABORATORY PARAMETERS
Haemoglobin < 12 g/dl (males)
< 11.5 g/dl (females)
ESR > 20 mm/h
Albumin < 3.5 g/100 ml.
(one point for each of the abnormal parameter.Theoretical 
maximum score of 38)
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LOCAL FEATURES
Bowel actions 
Pain
Rectal bleeding
SYSTEMIC FEATURES 
Pulse rate 
Temperature 
Haemoglobin 
Weight loss
APPENDIX 2.2
De DOMBAL INDEX
Mild Attack Severe Attack
2-3 /day 
occasional/mild 
negligible
6 or more/day
continuous/severe
macroscopic 
blood in stools
< 90/min
< 99°F 
> 80 %
< 1/2 stone
> 100/min
> 100°F 
< 70 %
> 1 stone
(Attacks intermediate in severity graded as moderate )
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APPENDIX 2.3
TALSTAD INDEX
SCORE
DISEASE ACTIVITY PARAMETER_______1_________ 2________ 3________ 4
Diarrhoea (motions / day) 3-5 6-10
Fever (°C) 38-39 > 39
Tachycardia - >100/mi
Abdominal pain slight ' mod
Weight loss 5-10 kg >10 kg
Fistula - present
X-ray of colon slight mod
Proctoscopy slight severe
ESR (mm/h) 10-30 > 30
Hb (g/lOOml) 10-11.8 < 10
Leucocyte count (10000/ul) — > 1
Thrombocyte count (100000/ul) - > 4
Total protein ( g/lOOml) <6.5 < 5.5
Albumin (g/lOOml) <3.3 < 2.5
Serum iron (ug/lOOml) < 70 < 50
TIBC (ug/lOOml) <270 <200
Schilling test - < 10%
Serum folic acid (mg/ml) <3.0 -
>10
severe
sev toxic
(maximum score of 38. Mod = moderate; sev = severe)
APPENDIX 2.4
ITEM
CROHN7S DISEASE ACTIVITY INDEX (INDEX)
MULTIPLIED BY
Number of liquid/soft stools 
per week
Sum of 7 daily ratings of 
abdominal pain (0=none/ 3=severe)
Sum of 7 daily ratings of well
being (0=generally well, 4=terrible)
Number of associated problems
- arthritis/arthralgia
- iritis/uveitis
- erythema nodosum/aphthous stomatitis
- anal fissure/fistulas/abscesses
- other fistula
- fever over 100°F during last week
20
Taking opiate antidiarrhoeal 30
(0=no/ 1= yes)
Abdominal mass 10
(0= none, 5=definite)
Haematocrit deficeit 6
(males: 47-HCT females:42-HCT)
Body weight (% below standard) 1
Add (underweight) or subtract (overweight)
TOTAL SCORE
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APPENDIX 2.5
O 'DONOGHUE INDEX
SYMPTOMS
Well being 
Abdominal pain 
Bowel frequency 
Rectal bleeding
PHYSICAL SIGNS
Recent weight loss 
Pyrexia
Abdominal mass 
Abdominal tenderness 
Anal lesion 
Fistulas
Joint, eye or mucocutaneous lesion
(all scores = absent (0); mild with no limitation of 
activities (1); moderate with some limitation 
ofactivities (2) ; severe, with considerable limitation of 
activities (3).Abdominal mass scored 0=absent, l=present)
LABORATORY TESTS
Haemoglobin 
White blood count 
ESR
Serum albumin 
(all scored 0-2)
Theoretical maximum score of 39
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APPENDIX 2.6
LLOYD-STILL INDEX
General activity (10)
10 normal school attendance
bowel motions < 3 per day
5 lacks endurance
bowel motions 3-5 per day 
misses < 4 weeks school/year
1 fever, home tutor
bowel motions > 5 per day 
severely restricted activity
Physical examination and complications (30) 
Abdomen 10 normal
5 
1
Proctoscopy/perianal
mass
distension, tenderness
10 normal, no fissures 
5 friability, 1 fissure 
1 ulcers, pseudopolyps, 
bleeding, multiple 
fissures, fistulas.
Arthritis
Skin/stomatitis/eyes
5 nil
3 one joint/arthralgia 
1 multiple joints
5 normal
3 mild stomatitis 
1 erythena nodosum, 
pyoderma, severe 
stomatitis, uveitis
Nutrition (20)
Height 10 
5 
1
> 2 ins/year 
< optimal % 
no growth
Weight 10 
5 
1
normal 
no gain 
weight loss
X-Rays (15)
15 normal
10 ileitis, colitis to splenic flexure 
5 total colon or ileocolonic involvement 
1 toxic megacolon, obstruction
APPENDIX 2.6 contd
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Laboratory (25)
Haematocrit 5 > 4 0  ESR 5 normal
3 25-35 3 20-40
1 < 25 1 > 40
White blood count Albumin
5 normal 10 normal
3 < 20,000 5 3.0 g/1
1 > 20,000 1 < 2.5 g/1
APPENDIX 2.7
CROHN'S DISEASE INDEX (CPI)
General well being (0 = very well - 5 = terrible)
Abdominal pain ( 0 = none - 3 = terrible)
Number of liquid stools / day
Abdominal mass ( 0 = none - 3 = definite and tender )
Complications - arthralgia, uveitis, erythema nodosum,
aphthous ulcers, pyoderma gangrenosum, 
anal fissure, new fistula, abscess 
(score 1 per item)
APPENDIX 2.8
ACTIVITY INDEX (AI)
ITEM MULTIPLY BY
Serum albumin - 5.48
ESR 0.29
Quetelet index - 0.22
Abdominal mass 7.83
(1 = none - 5 = diameter > 12 cm )
Sex ( 1 = male, 2 = female ) - 12.3
Temperature °C 16.4
Stool consistency 8.46
( 1 = well formed - 3 = watery )
Resection - 9.17
( 1 = no, 2 = yes )
Extraintestinal lesion 10.7
(1 = no, 2 = yes )
Constant - 209 
TOTAL =
APPENDIX 2.9 
NEW CROHN'S DISEASE ACTIVITY INDEX (NCDAI)
ITEM MULTIPLY
Average daily number of liquid 4
or very soft stools over the past 
week ( 3-5 stools = 1, over 5 = 2 )
Average daily temperature over the 5
past week ( 38-39°C = 1, > 39 = 2)
Anal fistula or anorectal abscess ( =2 ) 2.5
Serum iron 1.5
[0.1 x (150 - serum iron) ]
C-reactive protein 4
Alpha2“ globulin 1.5
Seromucoids 1
APPENDIX 2.10
OXFORD INDEX
Pain present
Bowels > 6/day or blood and mucus
Perianal complications
Fistula
Other complications 
Mass present 
Waisting/ emaciation 
Temperature above 38 C 
Abdominal tenderness 
Haemoglobin below 10 g/dl
score 1 for each feature, where present)
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APPENDIX 2.11
CAPE TOWN INDEX
ITEM
Diarrhoea 
Abdominal pain 
Well being 
Local complications
Systemic complications
Temperature °C
Weight compared with last 
weight.
Abdominal mass 
Abdominal tenderness
Haemoglobin (g/dl)
SCORE
0 = none - 3 = > 6/day
0 = none - 3 = severe
0 = normal - 3 = terrible
1 = skin tag, 2 = sinus
3 = fistula.
1 = stomatitis, 2=arthralgia 
3 = arthritis, uveitis, rash
0 = < 37,1 = < 38, 2 = < 39,
3 = > 39
2 = < 95%, 3 = < 90%
2 = indefinite, 3 = certain
1 = mild, 2 = moderate,
3 = severe 
0 > 12, 1 = < 12, 2 = < 11,
3 = < 10
APPENDIX 2.12
WRIGHT SIMPLE INDEX
CLINICAL PARAMETERS
Diarrhoea
Pain
Systemic manifestations 
general well-being
GRADES 1 = well
2 = mild symptoms
3 = moderate symptoms
4 = severe symptoms
5 = acutely ill
6 = fulminating attack
APPENDIX 2.13
CROHN'S ACTIVITY GROUP SCALE
VARIABLE COEFFICIENT
Haemoglobin (g/dl)
Serum carotene (ug/dl) 
Prednisolone (tablets/day) 
Serum iron (ug/dl)
Weight (kg)
Age (year)
Mean red cell volume (fl)
% ideal weight 
Sex (1 = male, 2 = female ) 
Serum phosphorus (mg/dl) 
Triceps skinfold thickness 
Serum calcium (mg/dl) 
Duration (years)
Serum vitamin C (umol/1) 
Total lymphocytes 
(Constant)
(mm)
0.3255 
0.0112 
-0.2594 
0.0050 
0.0930 
-0.0406 
0.0415 
-0.0296 
1.6653 
-0.4870 
-0.0396 
0.3418 
0.0274 
-0.0051 
- 0.0001 
-14.2213
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APPENDIX 4.1 
LABORATORY METHODS FOR MEASURING PROTEINS 
AND MICRONUTRIENTS
Albumin, calcium, phosphate 
Magnesium, zinc, copper
Transferrin
Iron
Vitamins A, E and C
Vitamins B^, B2 and B2
Vitamin B^2 an(3- red cell folate 
Urinary nitrogen
SMAC analyser
Atominc absorption 
spectrometry (Perkin- 
Elmer model 3030)
Immunoturbometric
method
Colourimetric method 
(Hitachi 704)
Spectrophotometry 
(Perkin-Elmer MPS 32)
Red cell enzyme 
activation
Radioimmunoassay
Micro-Kjeldahl method
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